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Summary 
Background - The internal elements of the Influenza-A virus, exhibit high levels 
of conservation and offer a more consistent target for the immune system amidst the 
diversity of potential strains. T-cell responses to these proteins have been shown to 
correlate with protection and deceased symptom severity during infection. Yet the 
epitopes and T-cell receptor (TCR) repertoires that underpin these important responses 
have not been analysed in detail at the molecular level.  
 
Results - These responses were analysed by the development of an HLA-DR1 
restricted epitope mapping platform in chapter 3, followed by its application in finding 
DR1-restricted epitopes within the three internal proteins in chapter 4.  Two of these 
epitopes were analysed by X-ray crystallography to understand their presentation and 
complement HLA-binding algorithm data.  
 Identification of epitopes that gave robust and reproducible responses allowed 
analysis of responding T-cell populations by HLA-multimer staining on flow cytometry 
and subsequent clonotypic analysis of TCR repertoires in chapter 5. The clonotypic 
repertoire data was interpreted and then information in response to a single epitope was 
aligned with structural data in chapter 6 to further understand the molecular interactions 
that shape these responses. 
 
Conclusions - This work generated several novel HLA-DR1 restricted epitopes, 
crystal structures and TCR repertoire information that both expands existing knowledge 
of CD4+ T-cell responses, and confirms the potential of the conserved influenza proteins 
as targets in future vaccination research. 
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1 Introduction 
1.1 Understanding the Immune System 
In order to protect against disease, the immune system recognises and 
eliminates threats that have the potential to damage the body. This involves 
distinguishing between self-antigens and those antigens which indicate the presence of 
non-self or malignant entities like bacteria, viruses or cancer. Following recognition of a 
threat, the immune system acts to neutralise and eliminate its source without causing 
extensive damage to the host. 
The primary theme of this project centres on how specific cells of the immune 
system can mediate recognition of a rapidly evolving pathogen, and the extent to which 
these recognition mechanisms are conserved across the human population. By 
understanding the mechanistic basis of protection at the molecular level, it is possible 
gain fundamental knowledge that might be applied in the prevention and treatment of 
disease. 
1.1.1 Innate Immunity 
The cells and mechanisms of the immune system are divided into two arms: 
innate and adaptive immunity. Innate immunity provides broad protection against many 
pathogens utilising fixed mechanisms that do not change in response to evolving threats. 
Barriers (skin and antimicrobial peptides), molecular pathways (complement), receptors 
and cells (phagocytic, lytic and cytotoxic) fall under this definition1. 
Bacteria, viruses and parasites are detected by their pathogen associated 
molecular patterns (PAMPs) such as lipopolysaccharides (LPS) and double stranded 
RNA. PAMPs activate pathogen recognition receptors (PRRs) such as toll-like and NOD-
like receptors that initiate the process of inflammation. Immune cells and coagulation 
factors are drawn to the site of injury and infection by inflammatory cytokines and 
chemoattractant molecules in order to neutralise and limit the spread of invading threats. 
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Neutrophils, macrophages, dendritic cells and basophils can uptake and destroy 
pathogens by phagocytosis, while natural killer (NK) cells and complement exert 
cytotoxic effects that can clear infected or damaged cells. Several innate functions such 
as antigen uptake and presentation on macrophages and dendritic cells, complement 
activation and NK cell cytotoxicity work in tandem with adaptive functions to target 
pathogens. 
1.1.2 Adaptive Immunity 
Innate mechanisms are broad, and cannot focus responses towards unique 
features expressed by a specific pathogen or malignancy. The direction of vast immune 
resources at these specific features or “epitopes” is the most effective method to 
neutralise and eliminate the causative agents of disease. When recognition of epitopes 
is encoded into a rapidly accessible pool of cells, i.e. memory, then reinfection should no 
longer pose a threat. This is the role of adaptive immunity. 
Adaptive immunity is mediated primarily by T-cells and B-cells, which recognise 
antigens through the T-cell receptor (TCR), B-cell receptor (BCR) and its soluble form 
(Antibody). These receptors exhibit high levels of sequence variation, with a single 
sequence having the potential to bind a protein, peptide or chemical antigen in an 
extremely specific manner. 
The epitope is defined as the exact recognition site, and may be only a few amino 
acids in length or a single molecule. The TCR and BCR recognise protein epitopes by 
distinct mechanisms. These mechanisms result in different forms of recognition target 
and resulting effector function, which define the roles of T- and B-cells in response to 
disease. 
1.1.2.1 BCR and Antibody Recognition 
Recognition of conformational or intact protein antigens is achieved by the BCR 
and antibody. Soluble proteins, free in solution or present at the cell surface can be 
bound at any sterically accessible site (Fig. 1.1A). The solvent face of an intact protein 
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presents a unique surface that allows for highly specific receptor binding and adaptive 
immune targeting.  
Yet this surface is dependent on protein stability, and once inside a cell it is 
protected from BCR recognition and therefore no longer active as a marker of infection 
or malignancy. Although the epitope can consist of less than ten amino acids, these 
residues may be distant in terms of linear sequence, and only come together in correctly 
folded conformations2,3. 
1.1.2.2 TCR Recognition and HLA Proteins 
In order to maintain adaptive recognition of pathogens or malignancy in the 
absence of extracellular material and independent of protein conformation, T-cells are 
essential. They can respond to linear sequences of amino acids derived predominantly 
from the cytosol (class-I) or the extracellular space and membrane (class-II) presented 
by the human leukocyte antigen (HLA) proteins4 (Fig. 1.1B).  
The epitope recognised by the TCR is defined by both the peptide and HLA 
protein that presents it. This is due to the unique solvent exposed surface formed by the 
rigidly orientated peptide and surrounding HLA amino acids, both components contact 
the TCR during binding5.  
Antigen presentation and TCR recognition will be discussed, in further detail, in 
later sections. Here, the important point is that T- and B-cells together can exert 
extensive coverage of antigens at the conformational and linear level. Such vast 
antigenic coverage will require a large receptor repertoire to take advantage of the many 
possible epitope-signatures of disease.  
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Figure 1.1 Adaptive mechanisms of protein recognition. 
(A) Antibodies can recognise non-linear or “conformational” epitopes at the surface of 
folded protein. In the denatured or linear state such epitopes may not be present, as the 
amino acids that constitute them are in distant sequence positions. (B) HLA molecules 
hold linear stretches of amino acids in an extended conformation derived from digested 
extracellular or cytosolic material. Recognition of linear epitopes is independent of the 
conformation of the parent protein, and solely related to properties of the amino acid 
sequence.  
= Amino Acid
HLA 
Molecule
Linear 
Epitope
TCR
Folded Protein
Antibody
A
B
Conformational 
Epitope
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1.1.3 Generation of Receptor Diversity 
The protein structures of T-cell and B-cell receptors are composed of 
immunoglobulin (Ig) domains, which consist of two stable antiparallel β-sheets in a folded 
conformation covalently linked by a disulphide bond (the Immunoglobulin “fold”). 
The TCR is an α:β heterodimer of two chains each composed of two Ig domains. 
Diversity is concentrated in the α1 β1 “variable” region that facilitates antigen recognition, 
while the “constant” α2 β2 region is membrane proximal, preceding a transmembrane 
sequence that anchors that TCR to the cell surface (Fig. 1.2A). 
The BCR and soluble form are homodimers (Fig. 1.2B), with each monomer 
consisting of a two Ig-domain light chain (L) disulphide bonded to a four-domain heavy 
chain (H). Like the TCR, diversity is focused in the variable region (VH and VL), while the 
remaining light chain domain and three heavy chain domains constitute the constant 
region (CL, CH1, CH2, CH3), which is membrane anchored in the BCR but soluble as an 
antibody. 
Figure 1.2. Schematic 
representation of (A) TCR 
and (B) BCR protein 
structures (representative of 
an IgG isotype). Each 
immunoglobulin domain is 
represented by an oval, with 
CDRs shown at the ends of 
each variable domain (TCR 
- α1, β1, BCR – VL, VH). 
Inter-chain disulphide bonds 
are represented by red lines.  
Cell Membrane
β1
β2
α1
α2
VL
CL
VH
CH1
CH2
CH3
TCR
BCR
A
Transmembrane Domains
B
Complementarity 
determining regions
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Complementarity determining regions (CDRs) are amino acid loops of variable 
length which form the contact interface of TCR and BCR interactions with cognate 
antigen. Each chain has three regions, CDR1, CDR2 and CDR3, the amino acids of 
which form key contacts with antigen that determine the receptor binding specificity. 
The TCRα and BCR light chain sequences are generated from variable and 
junctional genes, while TCRβ and BCR heavy chain sequences are derived from 
variable, junctional and an additional diversity gene. Many different V, D and J genes are 
encoded in the human genome, but only one of each is incorporated in a specific chain 
sequence6.  
During the development of T- and B-cells, V(D)J segments are recombined to 
give a single exon that may encode a functional variable sequence7 (Fig. 1.3). The term 
“recombination” is used specifically, as gene segments are not simply joined, but 
undergo nucleotide sequence alterations at V-J and V-D-J junctions catalysed by the 
recombinase complex. These involve palindromic (P) and non-templated-encoded (N) 
nucleotide sequence additions to the ends of gene segments, which occurs before 
pairing and ligation of V(D)J strands8. Additionally, exonuclease activity can delete 
terminal nucleotides in extensive numbers, eliminating germline or P/N incorporated 
sequences. These mechanisms are random, and result in somatically encoded amino 
acids and highly diverse V(D)J joining regions that comprise the hypervariable CDR3 
loop of each chain. 
Therefore, chain sequence diversity arises from both the number of potential V, 
D and J gene combinations, and junctional variation created by random nucleotide 
addition and deletion during recombination (Fig. 1.3). Receptor diversity is further 
increased through pairing of α and β, or heavy and light chains, as well as somatic hyper 
mutation in B-cells which will not be discussed here. 
The total number of unique receptors that could arise from these processes has 
been estimated as 5 x 1013 for the BCR (not including somatic hyper mutation) and 1018 
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for the TCR. This theoretical immune diversity has helped us to evolve alongside the 
vast diversity of potentially encountered pathogens.    
As T-cells are the focus of this project, they shall be described in more detail in 
the following sections.  
  
8 
 
 
 
Figure 1.3. Schematic of V(D)J recombination at the TCR locus.  
(A) TCR α-chain (B) TCR β-chain. V genes are in blue, J genes in yellow, D genes in 
green and constant genes in white. Red lines represent junctional diversity introduced 
by the recombinase enzymes during joining of genes. Following rearrangement and 
splicing one of each gene is incorporated into the final mRNA coding for each chain. 
Diversity arises from both the different combinations of V(D)J genes as well as the 
variation in nucleotide additions and deletions at the joining regions.  
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1.1.4 Thymic Selection 
A fundamental property of the immune system is its ability to eliminate disease 
whilst limiting damage to the host tissues and organs. The process of thymic selection 
generates a T-cell TCR repertoire that recognises peptide-HLA (pHLA) but does not 
respond aggressively to self, referred to as “tolerance”. 
T-cell precursors migrate from the bone marrow to the thymus where they 
undergo several stages of development (Fig. 1.4). Commitment to the T-cell lineage is 
followed by active rearrangement of the TCR β-chain, expression of both CD4 and CD8 
co-receptors and rearrangement of the TCR α-chain resulting in a double positive (DP) 
thymocyte. Upon the generation of a functional αβ TCR, DP thymocytes that exhibit 
avidity for self-pHLA molecules on the surface of cortical thymic epithelial cells (cTECs) 
receive activation and survival signals. Those cells which fail to recognise self-pHLA die 
by neglect. Activated DP cells increase TCR expression and lose expression of one co-
receptor, becoming single positive CD8+ or CD4+ T-cells specific to either HLA class-I, 
or class-II, respectively. 
Recognition of self-peptide on HLA has been shown to facilitate “tonic” signalling 
of T-cells in the periphery, maintaining a low level of TCR signalling that can be quantified 
by CD5 expression9,10. Yet if this self-recognition is too efficient it may stimulate effector 
functions outside of the desired setting, destroying healthy host tissues and leading to 
pathogenic autoimmunity. In order to mitigate this threat, CD8+ T-cells with too high an 
avidity for self-antigen receive apoptotic signals and die by negative selection11–13. 
Expression of many tissue-specific antigens on thymic epithelial cells (that would not 
otherwise be present in one body location) is driven by the AIRE (autoimmune regulator) 
transcription factor14,15. 
For high avidity CD4+ T-cells, negative selection may occur, but additionally 
these cells may be driven down the suppressive or regulatory pathway by expression of 
FOXP316–18. Such cells, termed “thymic” T-regs (tTREG) do not respond to cognate pHLA 
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by inflammatory processes, but instead release suppressive cytokines or employ other 
regulatory mechanisms that negatively regulate surrounding immune cells. 
The exact mechanisms of tTREG generation, specifically in relation to TCR avidity 
thresholds that distinguish negative selection and onset of a regulatory lineage are the 
subject of many hypotheses19,20. Recent work analysing the epigenetic changes at the 
FOXP3 locus and super-enhancers21,22 has shed light on this relationship, but 
biophysical and structural evidence for tTREG mediated tolerance mechanisms has yet to 
be uncovered. 
The resulting thymic output is balanced in its ability to recognise pHLA and exert 
tolerance in response to self-antigen. Disruptions in this balance result in either impaired 
immune responses or breaking of tolerance and the onset of disease. 
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Figure 1.4. Schematic representation of the major events in thymic selection. 
(A) Haematopoietic stem cells (HSC) enter the thymus from the bone marrow. (B) 
Rearrangement and transcription of the TCR β-chain which pairs with a surrogate pre-α 
chain to allow surface expression in the “double negative” thymocyte (DN). (C) 
Rearrangement and transcription of the TCR α-chain is followed by expression of both 
CD4 and CD8 co-receptors in the “double positive” thymocyte (DP). (D) DP thymocytes 
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are positively selected if they can bind cognate HLA molecules expressed on thymic 
cortical epithelial cells. Binding stimulates the T-cell through the TCR and triggers 
proliferation and survival signals. (E) Positively selected thymocytes lose the redundant 
co-receptor to become single positive (SP). (F) SP thymocytes which are exposed to 
diverse repertoires of self-antigen presented by cortical epithelial cells can be negatively 
selected if they show too high an affinity for self-antigen. (G) Those CD4+ T-cells which 
are hypothesised to express a slightly higher affinity for cell antigen are thought to 
become thymically derived T-regulatory cells (tTREG). This results in a thymic output of T-
cells which have an optimum affinity for only pHLA, but do not express too high an affinity 
for self-antigen. 
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1.1.5 The HLA-Restriction Paradox 
The process of thymic selection creates an effective T-cell repertoire, which is 
somewhat paradoxical in nature. Put simply, how does this highly diverse population of 
TCRs, exhibit such limited specificity for only pHLA molecules and not the many other 
potential ligands that could possibly be recognised? Is this exceptional restriction 
imposed by the thymus, or does it arise before, in the genes that underlie these 
receptors? 
Two models have been proposed to explain this paradox, yet neither is 
unanimously accepted and new publications present evidence in support of (and 
opposition to) either theory.  
1.1.5.1 Germline-Encoded Model 
This model, championed by Arrack, Kappler and Garcia23, states that the 
germline contacts between the TCR and the HLA have been “evolutionarily refined” in 
order to enhance the probability of a successful interaction. In this model, the notion that 
CDR1 and CDR2 contacts are “opportunistic bystanders” to the CDR3 binding event is 
rejected. Instead they serve to orientate the TCR complex and allow for a highly specific 
mode of recognition. The concept is tackled from a structural perspective, arguing that 
TCR recognition is so focused that it must have evolved, rather than being externally 
imposed in the thymus, somewhat discounting the other interactions that take place at 
the immune synapse. 
Work in support of this hypothesis involves identification of a germline interaction 
“codon” that mediates a conserved binding motif by the TRBV8.2 gene24–26 in many 
different systems. 
1.1.5.2 Co-receptor Selection Model 
The co-receptor model was first proposed by Alfred Singer in 200727. It 
rationalises the breadth of TCR diversity and its potential to see non-HLA ligands by 
postulating that HLA restriction is externally imposed by the CD4 and CD8 co-receptors. 
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As co-receptor engagement is necessary for signalling, this disables T-cell recognition 
of non-HLA ligands and gives the thymically generated repertoire its paradoxical 
specificity28. 
The paradox is dealt with by focusing on the cellular interaction of two 
membranes to facilitate recognition and TCR based signalling. This could be viewed as 
detracting from the unique structural importance of the TCR in recognition, negating the 
countless other contact-mediated cellular interactions that do not exhibit the 
diversity/specificity paradox. The primary piece of work in support of this theory came in 
the 2007 publication by Van Laetham et al. where knockout of the co-receptors (and HLA 
molecules) from transgenic mice resulted in widespread recognition of non-HLA ligands 
by the thymic emigrants27. 
Recent evidence involves germline CDR randomised mouse models29 and further 
analysis of the Singer knockout repertoires30. Other structural evidence is more in 
opposition to germline selection, rather than in favour of the co-receptor model, by 
documenting non-canonical binding modes in T-cell recogniton31,32. Such systems were 
very low affinity, in comparison to well-characterised TCR-pHLA interactions, and could 
possibly be regarded as the exceptions rather than the rule.  
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1.1.6 T-cell Activation 
After leaving the thymus, T-cells migrate to the periphery where exposure to non-
self, or malignant-self antigens may occur. This is mediated by professional antigen 
presenting cells (pAPCs) such as B-cells, dendritic cells and macrophages which 
endocytose pathogens and drain to the lymphatics for antigen presentation to the naïve 
and memory T-cell repertoires. In addition to classical adhesion molecules, pAPCs 
express both pHLA and costimulatory molecules at the cell surface. These are defined 
as “signal-1” (Fig 1.5A) and “signal-2” (Fig 1.5B) respectively, and are necessary for 
activation and proliferation to occur. A third event “signal-3” (Fig 1.5C), can determine 
the differentiation pathway taken by a naïve cell in order to generate functionally distinct 
CD4+ T-cell subsets.  
Once “primed,” a T-cell can respond to antigen through TCR and co-receptor 
recognition alone (Fig. 1.5A). The receptor complex includes two transmembrane CD3 
molecules, and localisation of intracellular TCR-ζ chains, both of which possess 
immunoreceptor tyrosine based activation motifs (ITAMs) that are readily 
phosphorylated33. The intracellular domains of CD4 and CD8 co-receptors bind the src-
kinase Lck34–36, which can catalyse ITAM phosphorylation when in close proximity37. The 
activation event centres on αβ TCR and co-receptor binding to cognate pHLA with 
sufficient avidity to allow for phosphorylation of ITAMs to occur. This initiates signalling 
cascades that result in gene transcription and effector functions38,39. 
Either a sufficient TCR to pHLA “dwell time”40, the rapid induction of multiple 
binding events41 or the segregation of large inhibitory molecules such as CD4542 at the 
immune synapse43–45, are hypothesised to facilitate co-receptor mediated Lck 
phosphorylation of the intracellular TCR:CD3 complex. These models of T-cell activation 
are not necessarily exclusive. What is important is that they explain the balance between 
TCR avidity and cognate pHLA abundance that result in a vast range of dynamic 
recognition states. 
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Figure 1.5.A. Events in T-cell activation, “Signal-1,” schematic diagram specific 
for CD4+ T-cells. Full legend on page 19.  
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Figure 1.5.B. Events in T-cell activation, “Signal-2,” costimulatory and inhibitory 
molecules at the immune synapse. Full legend on page 19. 
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Figure 1.5.C. Events in T-cell activation, “Signal-3,” the roles of polarising 
cytokines in CD4+ T-cell subset differentiation. 
During T-cell activation, the release of cytokine from other activated T-cells and APCs 
can influence the terminal differentiation of effectors into various CD4+ T-cell subsets.  
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Figure 1.5.A. Events in T-cell activation, “Signal-1,” schematic diagram specific 
for CD4+ T-cells. (i) TCRs bind to HLA class-II on the surface of an antigen presenting 
cell. (ii) Binding of the TCR facilitates localisation of the CD4 co-receptor which binds to 
a site on HLA class-II. (iii) Localisation of CD4 brings the cytosolic tail carrying Lck kinase 
into close proximity with the CD3 cytoplasmic tail and the TCR-zeta chain, both of which 
are enriched for ITAMs (immunoreceptor tyrosine –based activation motif). These are 
phosphorylated by the action of Lck. (iv) ITAM phosphorylation facilitates binding of 
further kinases (ZAP-70) and the initiation of signalling cascades. (v) Signalling ultimately 
results in activation of transcription factors and elicitation of effector functions. 
(Adhesion molecules insert) The molecules ICAM-1 and LFA-1 facilitate cell-to-cell 
contact, loosely forming a zone of the immune synapse between the inner pHLA-TCR 
interaction zone and outer exclusion zone of the inhibitory CD45 molecule (Zones of the 
immune synapse insert). 
 
Figure 1.5.B. Events in T-cell activation, “Signal-2,” costimulatory and inhibitory 
molecules at the immune synapse. (i) CD28 on the surface of T-cells is bound by 
either CD80 (B7.1) or CD86 (B7.2) on the surface of antigen presenting cells. This 
interaction occurs alongside the TCR-pHLA interaction and is referred to as 
“costimulation” or “signal-2.” It is essential for activation of naïve precursors to become 
activated effectors. Additional examples of costimulatory molecules are ICOS and its 
ligand ICOS-L (ii), an interaction important in activation and development of TH2 CD4+ 
T-cells. Inhibition of T-cell activation, is facilitated by upregulation of inhibitory molecules 
on the T-cell surface. (iii) CTLA-4 directly competes with CD28 for binding of CD80 and 
CD86, thus blocking costimulation and inhibiting activation. (iv) PD-1 is upregulated on 
exhausted T-cells and binds to its APC ligand PDL1, this is thought to deliver inhibitory 
signals to the T-cell and regulates further activation following TCR-pHLA engagement. 
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1.1.7 CD8+ T-cells 
Following priming, T-cell activation results in proliferation and effector function. 
Generally, these effector functions involve release of cytokines that may act on 
surrounding tissues or other immune cells, as well as the direct induction of cell death. 
Effector functions, in addition to surface molecules and transcription factors are used to 
group T-cells into distinct subsets. The primary division exists between CD4+ and CD8+ 
T-cells. 
CD8+ T-cells are generally cytotoxic and recognise pathogen infected or 
malignant cells through cytosolic epitopes presented by HLA class-I. The release of 
perforin and granzyme, or expression of Fas ligand (FasL) can induce apoptosis, killing 
the compromised target cell46,47. Cytotoxic CD8+ T-cells are essential in clearance of 
viral infections and cancers, exhibiting many correlations with protection and recovery 
from disease48–50 as well as being successfully used in novel cancer immunotherapies51–
53. When compared to CD4+ T-cells, they are relatively simple in terms of effector 
function and subset distribution. This simplicity, and the availability of HLA class-I 
multimer reagents and crystal structures, means they are better understood at the 
molecular level. 
1.1.8 Chemical and Lipid Mediated T-cell Recognition 
As this project deals with protein antigens, two additional classes of T-cells will 
not feature in this introduction: γδ T-cells and unconventional or invariant T-cells such as 
mucosal associated invariant T-cells and invariant natural killer T-cells54. These cells 
have the ability to see chemical and lipid molecules presented by unique HLA-like 
molecules that are essential for immunity to many types of pathogens55. Some of these 
cells can also recognise peptides, but it is their unconventional recognition that sets them 
apart from standard αβ T-cells, making them an attractive target for novel structural and 
biophysical research. 
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1.2 CD4+ T-cells: Conductors of the Immune Response 
CD4+ T-cells respond to HLA class-II peptides derived from exogenous material 
by antigen presenting cells. They do not act on the pathogen or malignancy directly 
(except as a rare cytotoxic subset) but instead elicit effector functions through 
macrophages, dendritic cells, B-cells and CD8+ T-cells. In addition to provoking 
inflammatory responses, they also act on these same cells to induce suppression, thus 
limiting inflammation and preventing immunopathology.  
1.2.1 CD4+ Subsets: Protection and Disease 
CD4+ T-cell subsets are defined by the cytokines they release and the groups of 
cells they act on. These subsets are hypothesised to arise from polarising cytokines56, 
distinct antigen presenting cell subsets57,58 and the quantity of antigen encounter during 
priming59,60. Each subset is linked to a specific aspect of protection as well as pathology, 
thus exhibiting the complex balance that CD4+ T-cells must maintain in a healthy 
immune system (Fig. 1.6). 
1.2.1.1 TH1 
TH1 cells (CD4+, TBX21+) are central to responses against viruses and 
malignancy. Interactions with dendritic cells can increase antigen presentation and 
licence APCs61 for priming of cytotoxic CD8+ T-cells. TH1 stimulation of macrophages 
can cause destruction of pathogens contained with intracellular vesicles, and further 
stimulate presentation62.  
In the viral setting, secretion of the inflammatory cytokines interferon-γ (IFN-γ) 
and tumour necrosis factor-α (TNF-α) can drive the localisation of CD8+ tissue resident 
effectors to sites of infection63, as well as stimulate tissues to maintain an antiviral like 
state and the involvement of innate cells64. Action of IFN-γ on TFH cells stimulates the 
generation of an antibody response to further control free pathogen in the extracellular 
space. The TH1 subset is associated with effective clearance of viral infections and was 
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one of the first defined subsets65. If uncontrolled, these cells are primarily responsible for 
an IFN-γ, TNF-α “cytokine storm” and immunopathology associated with systemic 
infections66–68. 
1.2.1.2 TFH 
The TFH (CD4+, BCL6+) subset, polarised by IL-6 and IL-21, is essential for the 
generation of an effective antibody response69,70. Following recognition of B-cell 
presented antigen (cross-presentation), TFH cells release IL-4 and IL-21 to stimulate 
class-switching and somatic hyper mutation of the BCR, which is subsequently released 
by plasma cells as antibody. Antibody recognition facilitates antibody-dependant cell-
mediated cytotoxicity (ADCC), α-toxin neutralisation, macrophage mediated 
phagocytosis, complement activation, opsonisation of free pathogen and prevention of 
viral entry into host cells. Generation of such TFH responses is essential for viral 
immunity71,72 and the primary goal of many vaccines73–75. Unregulated, TFH responses to 
self-antigens in systemic lupus erythematosus76 and other antigens can drive 
autoimmunity. 
1.2.1.3 TH2 
TH2 (CD4+, GATA3+) cells are polarised by IL-4 in the absence of IFN-γ, and are 
likely to have evolved in response to helminth infection77,78. In the absence of helminth 
exposure these cells have pathogenic roles in allergy and delayed type hypersensitivity, 
releasing IL-4, IL-5, IL-13 and IL-6 in response to innocuous antigens79–81.  
1.2.1.4 TH17 
First recognised in 200682, TH17 cells (CD4+, RORC+)83 are generally 
characterised by the release of IL17 and IL-22. They are able to strongly activate and 
recruit neutrophils to sites of inflammation, and are associated with protective 
antimicrobial and antifungal specificity84,85. They also have a close developmental 
relationship to suppressive CD4+ subsets86–88 which may be linked to their function. 
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Pathological roles for this subtype are found in gut inflammation89, colon cancer90–92 and 
rheumatoid arthritis93–95. Whether they are a symptom or driving factor of pathology is 
yet to be fully understood. 
1.2.1.5 Cytotoxic CD4 T-cells 
When attempting to rationalise the highly effective antiviral properties of some 
CD4+ T-cell subsets, populations able to directly kill infected cells were identified both in 
vitro96 and in vivo97 (2001 and 2008). Cytotoxic (T-Bet+ EOMES+) CD4+ cells98,99 are 
treated with some scepticism due to the inconsistency in how these cells direct their 
killing activity in the absence of widespread HLA class-II expression. 
Work suggests that these are important in cancer and in viral infections, where 
class-II is upregulated on tumours100 and respiratory epithelia respectively101. In the 
absence of class-II expression, such cells may induce cell death indirectly through 
contact mediated macrophage activation in the presence of IFN-γ100. 
1.2.1.6 Regulatory T-cells 
TREG cells (CD4+, CD25HI, FOXP3+) are essential in the maintenance of 
peripheral tolerance and prevention of autoimmunity. Although identified as 
“suppressors” in 1998102,103, the transcriptional basis of suppression, FOXP3, was only 
identified in 200318. 
  They are polarised through IL-2 and TGF-β104,105 and can be further divided into 
thymic and peripheral groups depending on where the regulatory phenotype was 
induced. The mechanistic basis of suppression is highly complex and still to be fully 
understood. Examples include sequestering of IL-2 by CD25106, inhibition of DC antigen 
presentation by CTLA-4107, direct killing of effector cells108, release of IL-10109 and other 
interactions at the immune synapse. 
Although protective against autoimmunity, these cells are enriched at tumour 
sites and may correlate with tumour growth and inhibition of an effective anti-cancer 
immune response110–114. 
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Figure 1.6. The roles of CD4+ subsets in the inflammatory immune response.   
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Figure 1.6. The roles of CD4+ subsets in the immune response. 
(A) TH1 cells stimulate activation of CD8+ T-cells through the release of IFN-γ and TNF-
α. (B) Cytotoxic CD4+ T-cells can directly kill virally infected cells (and tumour cells) 
through recognition of class-II expressed at the cell surface by release of granzyme B 
and perforin. (C) Interactions with antigen presenting cells stimulate antigen uptake and 
presentation. (D) In addition, they release innate inflammatory cytokines and 
chemokines that can maintain an antiviral state and aid innate functions, as well as cause 
upregulation of class-II expression on epithelial cells. (E) An antibody response is 
stimulated by the action of TH2 and TFH cells which respond to B-cell presented class-II 
epitopes and release of IL-4. These cells are central to germinal centre formation and 
driving the processes of antibody class switching and somatic hypermutation. (F) TH17 
cells release IL-17 and IL-22 which increase neutrophil migration to the site of 
inflammation as well as promoting other inflammatory pathways. (G) In response to 
release of self-antigen in an inflammatory environment, regulatory T-cells can suppress 
immune responses by acting on antigen presenting cells and surrounding B- and T-cells 
through the release of IL-10 and other mechanisms.  
The actions of these T-cell subsets have both positive and negative outcomes in different 
disease settings. They are both essential for protection from disease, but simultaneously 
may lead to pathology, unwanted immune suppression, hypersensitivity and 
autoimmunity. 
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1.2.2 Plasticity 
The definitions of T helper subsets are not absolute. There are expanding 
numbers of recently discovered subsets such as TR186, TH9115,116, TH22117 and TH3118 (not 
detailed here), as well as examples of subset interchange86,119,120 in both mice and 
humans. Recent findings suggest that lineage differentiation may be reversible under 
certain conditions, with certain cell surface markers identified that may indicate the 
former phenotype121.  
This phenotypic “plasticity” may be a powerful mechanism by which the immune 
system maintains balance and homeostasis in response to dynamic threats.  
1.2.3 Understanding CD4+ T-cells 
The complexity of CD4+ subsets is paralleled by their protective, detrimental or 
unassigned roles in many common diseases. Their widespread absence in HIV due to 
viral targeting, untreated, leads to fatal compromise of the immune system by infections 
that are controllable in healthy persons. Yet their presence is linked to nearly every 
serious autoimmune disorder, as well as the failure of immune systems to rid the body 
of rapidly growing tumours. 
In order to understand these cells, investigation at the molecular and genetic level 
is necessary to uncover the fundamental basis of each immune response. The first step 
is to look at the peptides they see, and the way in which they are presented. Following 
this, epitope-specific understanding and the molecular basis of immunity can be probed. 
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1.3 HLA Class-II  
The unifying feature of highly diverse CD4+ T-cell subsets is that they recognise 
and respond to pHLA class-II through their TCR. Therefore, an understanding of the 
unique features of class-II mediated antigen processing and presentation is relevant to 
the elicitation of a variety of immune effector functions.  
1.3.1 HLA Structure 
In HLA class-I and class-II molecules, peptides are bound between two α helices 
above a β pleated sheet. This holds the peptide in an elongated conformation that allows 
linear sequence recognition by the TCR. 
Class-I is asymmetric in composition, with a three-domain α chain, of which α1 
and α2 form the binding groove, while the α3 domain is membrane proximal and includes 
a transmembrane region. A monomorphic β2-microglobulin associates with the α3 
subunit to complete the structure122,123. 
Class-II is comparatively symmetric in composition, with individual α and β 
chains, each divided into two domains (Fig. 1.7). The α1 and β1 domains form the binding 
groove, while α2 and β2 associate with the membrane via their respective 
transmembrane regions124. 
Class-I binds peptides between eight and fourteen amino acids in length in a 
closed groove, accommodating two peptide “anchor” residues within binding pockets. 
Longer peptides form a peaked or bulged conformation125 with the majority of HLA 
interactions at the termini. Class-I molecules are shown to be highly unstable in the 
absence of peptide126. 
HLA class-II molecules present peptides greater than nine amino acids in length 
in a flat conformation, with up to four anchor residues and significant backbone 
interactions that stabilise binding5,127. The binding groove is open so there is no known 
structural limit on peptide length128. 
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Figure 1.7. Characteristics of HLA Class-II (specific to HLA-DR1) 
(A) Secondary structural representation of HLA class-II with two α-helices over a β-
pleated sheet form the peptide binding grove. (B) Surface representation in the absence 
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of peptide with the empty binding groove clearly visible. (C) HLA-DR1 peptide binding 
groove viewed from the top down. Labels correspond to the peptide amino acids or 
“anchor residues” whose side chains sit within each pocket. (D) Peptide within HLA-DR1, 
anchor residues are coloured red. Arrows indicate that the groove is open and there is 
no limit on length of peptide which can be bound. (E) Definition of peptide flanking 
residues. Amino acids at the N- and C- termini beyond the first and last anchor residues 
(marked by red arrows pointing down) are coloured yellow. Amino acids within these 
regions are referred to as the flanks.  
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1.3.2 Class-II Expression and Antigen Processing 
HLA Class-II expression is mainly limited to professional antigen presenting cells 
such as B-cells, macrophages and dendritic cells, but it has been shown to be 
upregulated in the epithelia129 and certain cancers130,131. 
Class-II peptides are generally, but not exclusively, derived from membrane 
bound and extracellular sources132. Antigenic material captured by endocytosis and 
denatured through endosomal acidification, pH induced proteolytic cleavage, and 
disulphide reductase activity. These endosomes fuse with the antigen processing or 
“MIIC” compartment where they encounter HLA class-II133,134. 
Class-II molecules are synthesised from the endoplasmic reticulum with an 
invariant chain “CLIP” (Ii) bound to the peptide-binding groove that signals for trafficking 
to the MIIC compartment via the plasma membrane135. HLA-DM catalyses the release of 
CLIP to allow antigenic peptides to bind and be presented at the cell surface136. 
Components of this pathway, such as the mode of endocytosis137, the types of 
proteolytic enzymes138,139 and the expression of HLA-DM140 vary between APC subsets. 
This means they can give rise to distinct peptide repertoires depending on cell type, 
tissue location and inflammatory state141; this may contribute to the diversity of CD4+ T-
cell subsets. 
 
1.3.3 Cross-Presentation 
A linear view of class-II antigen presentation raises conceptual problems of how 
extensively CD4+ T-cells mediate the response to antigens that are not prevalent in the 
extracellular space. If presentation is exclusive to the exogenous pathway, are virally 
infected cells, or intact tumour cells incapable of stimulating an immune response 
through HLA class-II? 
A body of evidence142–144 and mechanistic theory pioneered by Laurence 
Eisenlohr145,146 has addressed this question. In 2005 it was shown that viral class-II 
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restricted epitopes can be completely dependent on the proteasome and TAP (key 
elements of the cytosolic pathway) for presentation147. This was followed by a 2015 
publication where infection of APCs with the influenza virus was essential to account for 
the full cohort of CD4+ T-cell antigen specificity observed in response to live attenuated 
virus148 
While cross presentation is a relatively old observation (1976)149 and widely 
accepted concept in respect to CD8+ T-cells150, it requires further scrutiny in CD4+ T-
cells where understanding is limited to a few examples. 
1.3.4 HLA-DM and HLA-DO 
HLA-DM was first identified as a positive regulator of class-II peptide presentation 
in a series of publications between 1994-1995136,151–154. It was not until three years later 
that HLA-DO was identified as a negative regulator of class-II presentation155,156. 
Crystal structures of HLA-DM alone157,158, with HLA-DR159 and with HLA-DO160 
have helped uncover the molecular basis of their function as well as demonstrate their 
close structural morphology when compared side by side127. 
HLA-DM facilitates release of the invariant chain from virgin class-II molecules by 
associating with the class-II α-chain close to the peptide N-terminal face and inducing a 
conformational change that destabilises the P1 binding pocket to open the binding 
groove159. DM stabilises this open or “peptide receptive” conformation through several 
hydrogen bonds and salt bridge interactions. Upon the release of CLIP, antigenic 
peptides can freely associate and dissociate with the class-II binding groove in an 
exchange equilibrium (Fig. 1.8). 
Adhering to thermodynamic principles, this equilibrium will tend towards the 
lowest energy state, i.e. binding of peptides that exhibit the strongest molecular 
interactions with HLA class-II. As a result, the most stable peptide and class-II 
combinations will predominate141 and ultimately be trafficked to the surface of cells from 
the MIIC compartment for presentation. 
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HLA-DM is upregulated by APCs in response to the TH1 cytokine IFN-γ, therefore 
driving presentation of high affinity pathogenic (and self) peptides in the inflammatory 
state161. Peptide loading in the absence of HLA-DM may also occur (Fig. 1.9). This takes 
place in the “recycling pathway,” where a peptide receptive conformation is induced by 
acidification in endosomes close to the cell surface162,163. 
In the non-inflammatory state HLA-DO inhibits the activity of DM by binding at the 
same site as used to bind class-II, thus competing for occupancy160. This competitive 
inhibition can be overcome by an increase in the expression of DM, triggered by IFN-
γ161, altering the peptide repertoire in the inflammatory state164. 
As DM and DO are differentially expressed in macrophages and specific subsets 
of dendritic cells140, the DM:DO ratio has been used to explain the differences in antigen 
presentation by distinct populations of APCs140. The outcome of this interplay is to tightly 
regulate the potential peptide agonists of highly diverse CD4+ T-cell subsets, thus 
influencing the resulting immune response.  
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Figure 1.8. The endosomal class-II presentation pathway and HLA-DM peptide 
selection. 
(A) Antigen gets endocytosed from the extracellular space into an acidified endosome. 
(B) Endosomes are trafficked to the MIIC compartment which is enriched for HLA class-
II, molecular chaperones and proteolytic enzymes such as cathepsins. (C) Protein 
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antigen is digested into peptide fragments which can bind to HLA class-II when in the 
peptide receptive conformation, reliant on the binding of HLA-DM. (D) The action of DM 
facilitates rapid peptide exchange within the class-II binding groove which reaches 
equilibrium with complementary peptides. Strongest binding peptides will show 
increased occupancy of the groove. (E) HLA-DO competitively inhibits the action of HLA-
DM by binding at the class-II site and holding the DM in an inactive form. (F) Upon 
release of HLA-DM, the stable form of HLA class-II is trafficked to the cell surface for 
presentation to T-cells. 
  
35 
 
 
 
Figure 1.9. Loading of peptides onto HLA class-II in the absence of HLA-DM.  
(A) Protein that is not intact, or fully folded can be endocytosed with HLA class-II at the 
cell surface. (B) Endosomes fuse to form the “recycling endosome” which contains both 
protein material and HLA class-II. As this compartment is acidified it facilitates opening 
of the class-II binding groove and release and binding of peptide. (C) This class-II can 
traffic back to the cell surface without having been exposed to DM mediated peptide 
selection. This is relevant where cells are exposed to partially digested extracellular 
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material or excess of synthetic peptide, and also where knockout cell lines do not express 
HLA-DM. 
1.3.5 Class-II Peptide Presentation 
Following processing; peptides are accommodated within the open-ended class-
II groove with no known restrictions on maximum presentable length165 (the minimum 
being nine residues). This makes the definition of a class-II epitope more complex, as 
there is no clear point at which amino acids beyond the first (P1) and last (P9) anchors, 
no longer contribute to either TCR binding or pHLA complex stability. These amino acids 
are referred to as peptide flanking residues (PFRs). 
Crystallographic166,167 and biophysical168 studies have highlighted interactions 
between the flanks and cognate TCRs to occur at position P-1 (minus one) and P11 
amino acids, but investigation into highly extended flanks has not been carried out. The 
natural peptide repertoire presented by HLA class-II does not provide insight into either 
the necessity or superfluity of flanking residues.  
Acidic elution of peptides from class-II molecules on the surfaces of antigen 
presenting cells has identified diverse “nested sets” of peptides that differ in length but 
contain a common nine amino acid core encompassing the four anchor residues (P1, 
P4, P6 & P9)169,170.  
This suggests that antigen processing and presentation does not produce a 
strictly controlled length of peptide, unlike HLA class-I, and the resulting contribution of 
these length variations to pHLA stability, T-cell activation and repertoire selection is 
largely unknown.  
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1.4 The Influenza Virus 
Influenza is an acute viral infection that can vary in severity from mild illness to 
hospitalisation and death, representing a continual burden to healthcare and society. The 
hallmark of Influenza is its highly infectious nature, coupled with strain diversity, the 
capacity for rapid viral evolution and existence of zoonotic reservoirs that harbour 
sleeping threats. 
1.4.1 Seasonal 
Circulating strains of the virus are defined as “seasonal flu.” They are variable 
and in a state of continual evolution driven by immune selection pressure. The majority 
of the human population is thought to encounter these on a frequent basis, and have 
some pre-existing immunity, the efficacy of which varies markedly from person to 
person171. Peak incidence of infection occurs during winter, and necessitates the 
provision of an annual flu vaccine to mitigate the impact on healthcare and vulnerable 
patients. 
In the UK between week 40 of 2015 and week 17 of 2016, “flu season,” there 
were 2,462 influenza confirmed hospital admissions and 209 deaths172. Each year the 
virus is responsible for between 250,000 to 500,000 global deaths173 and is particularly 
dangerous to those who are immunocompromised. 
1.4.2 Pandemic 
Pandemic strains of the virus are those to which a lack of pre-existing immunity 
results in geographically widespread infection and disease. These strains do not circulate 
in society and are likely to originate in zoonotic reservoirs, of which wild fowl, domestic 
poultry and swine are documented to have crossed the species barrier into humans174. 
Crossing the species barrier requires close contact with the animal or carcass, 
the probability of which is increased by intensive farming practices. After infection has 
occurred, airborne transmission between humans is essential for a pandemic to be 
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possible. This catastrophic step is held in check until a zoonotic virus is able to mutate 
its entry protein and facilitate easy transmission via human respiratory epithelium175. In 
zoonotic reservoirs, the virus is an infection of the gut, and thus enters cells by a different 
sialic acid moiety174. 
Between April 2009 and August 2010, the swine flu pandemic was estimated to 
have caused 284,500 deaths, only 20 % of which were in individuals over 65 years old176. 
In comparison, 35 % of  hospitalisations in 2015/2016 associated with seasonal flu in the 
UK concerned those over 65 years old172. 
1.4.3 Strain Classification 
The term, Influenza, specifically refers to three distinct genera of the 
Orthomyxoviridae family: Influenza-A, -B and -C. Influenza-B is isolated to humans and 
can cause seasonal epidemics (13.8 % of UK hospitalisations 2015/2016), while 
Influenza-C results in mild infection and is not deemed necessary to vaccinate against. 
Neither -B nor -C is associated with pandemics, or has the rapid evolutionary capacity 
and seasonal impact of -A (86.2 % of UK hospitalisations 2015/2016). 
Influenza-A is highly variable and further divided into subtypes based on the 
surface antigens haemagglutinin and neuraminidase. The subtype (p)H1N1 was 
responsible for the 1918 Spanish flu and 2009 swine flu pandemics, while H3N2 was 
responsible for the 1968 Hong Kong outbreak. Currently H1N1, pH1N1 and H3N2 are 
widely circulating in society and account for seasonal infections172,173. 
“Avian flu” strains including H5N1177 and H7N9178 have been tipped as sources 
of the next global pandemic, having been responsible for sporadic outbreaks of 
extremely high mortality179,180. So far, human-to-human transmission of these strains is 
yet to be observed in more than a few isolated cases181 
  
39 
 
 
1.4.4 Viral Structure 
The influenza virion is composed of eleven proteins encoded on eight strands of 
negative sense viral RNA. Three external proteins: Haemagglutinin (HA), neuraminidase 
(NA) and the matrix-2 ion channel (M2) mediate viral entry, exit and pH mediated 
breakdown of the virion, respectively182.  
The eight remaining influenza proteins are internal. These consist of 
nucleoprotein (NP), matrix-1 (M1), the polymerase complex (PA, PB-1, PB-2, PB1-F2) 
and non-structural proteins (NS1 and NS2). 
NP binds viral RNA in a deep groove lined with basic amino acids, forming an 
extended oligomeric ribonucleoprotein structure183,184. The purpose is to pack the RNA 
into a higher order structure, facilitate exit from the host cell nucleus (following 
transcription) and form interactions with the polymerase complex185. 
The M1 protein is essential to virion structure, forming a polymeric helical inner 
coat or “net” that associates with HA and NA cytoplasmic tails186 and the 
ribonucleoprotein complex in the cytoplasm187. This helps to form a stable network of 
interactions and is hypothesised to facilitate budding and virion formation188.  
The first crystal structure of a fully assembled influenza-A polymerase (PA, PB-
1, PB-2 and RNA promoter) was obtained in 2014189,190. The polymerase complex can 
synthesise both positive sense mRNA for translation, and negative sense RNA for 
genome replication191,192. 
NS1 is a virulence factor, involved in disrupting pathways of innate immunity, but 
it is not present in the virion193. NS2 is present and interacts with the ribonucleoprotein 
complex to facilitate import and export from the nucleus of the host cell194 
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Figure 1.10. The Influenza-A virion and mechanisms of viral evolution.  
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Figure 1.10. The Influenza-A virion and mechanisms of viral evolution.  
(A) Overview of the important components of the influenza virus in this study. Non-
structural protein is not detailed. (B) Schematic representation of antigenic drift, the 
process which results in the incidence of seasonal epidemics of flu. Surface proteins HA 
and NA gradually mutate to maintain or increase viral fitness in response to immune and 
replicative selection pressures. (C) Antigenic shift requires coinfection of multiple strains 
in a single host in order to allow swapping of RNA strands and the expression of new 
combinations of previously unseen viral subtypes. This event can lead to pandemic 
strains of influenza under certain circumstances.  
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1.4.5 Life Cycle 
The virus enters host cells by HA mediated binding of sialic acid and the initiation 
of endosomal uptake. Acidification of the endosome causes the release of virion contents 
and the synthesis of positive sense RNA from the viral negative sense genome by the 
accompanying polymerase. Hijacking of host machinery results in translation of viral 
proteins and replication of the viral genome. These components are assembled at lipid 
rafts in the cell membrane where newly formed virions can leave the cell in a process 
known as “budding,” which involves cleavage of bound sialic acid by NA182,195. 
The external proteins HA, NA and M2 serve as antibody targets for the immune 
system. An effective antibody repertoire can prevent HA-mediated entry to the cell, and 
opsonise free virus in the periphery thus neutralising its infectious capacity and 
facilitating phagocytic destruction196. Breaching of this serological protection is the first 
step in a pathological infection. 
Serological specificity to HA and NA is responsible for the commonly used viral 
nomenclature. These proteins were grouped according to the antibodies by which they 
were recognised, for example H1, H2, H3 and N1, N2, N3. Within the H1 group there 
may be thousands of sequence variants, but these were historically seen by the same 
“H1 antibodies.” Today genetic sequencing provides a much more complex, but 
accurate, picture of influenza phylogeny. 
1.4.6 Antigenic Drift 
Antigenic drift describes the minor mutations of viral proteins that accumulate 
over successive replication events and person-to-person transmission. Mutations that 
increase viral fitness in response to pre-existing immune selection pressures are 
positively selected and become prevalent in the gene pool (Fig. 10B). This advantageous 
phenomenon is possible because of polymerase infidelity, which imparts a coding error 
every ten thousand nucleotides197. 
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Antigenic drift is largely responsible for the persistence of seasonal influenza in 
the population, and the limited effectiveness of predictive based vaccine design by the 
WHO198,199. Although all proteins should be equally impacted, it has been shown that 
some proteins are much more prone to mutation than others200. These include the 
external proteins HA and NA, which are under the greatest antibody-based selection 
pressure, and are perhaps more tolerant to mutation due to their singular roles. 
As the internal proteins are not subject to the antibody response, this may explain 
their conservation. In addition, many of these proteins exhibit poly-functional and 
interdependent roles. The combined importance of M1, NP and the polymerase complex 
to virion structure, organisation, stabilisation and replication of the viral genome as well 
as virion assembly prior to budding may limit their mutational tolerance, even under T-
cell based selection pressures. 
1.4.7 Antigenic Shift 
Pandemic events are primarily associated with a drastic change in viral protein 
expression that abrogates the pre-existing antibody response. This is known as antigenic 
shift and occurs when different Influenza-A subtypes (potentially interspecies) co-infect 
the same host and assimilate complete strands of each other’s genetic material201, 
termed reassortment (Fig. 1.10C).  
This can give rise to novel antigenic combinations that are not recognised by the 
human population. If the new strain exhibits transmission and infectivity rates that are 
comparable to seasonal strains, then global pandemic may ensue.  
This was the mechanism hypothesised to explain the origin of swine flu in 2009, 
where up to three strains were thought to have recombined in the domesticated pig 
population202,203.  The origin of the virus was subject to well publicised debate204,205, and 
generated a global outcry for monitoring of influenza in swine populations.  
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1.4.8 Original Antigenic Sin 
One of the most fascinating immunological observations is the concept of original 
antigenic sin. First described in 1953 by Thomas Francis Jr206, the concept states that 
when an individual is first exposed to influenza-A, they produce a balanced antibody 
response to viral antigens. When infected later in life with virus that has undergone 
antigenic drift or shift, the immune response is fundamentally unbalanced, with antibody 
skewed towards the epitopes first recognised during primary infection.  
Most significant is that if a third variant of virus infects the same individual, their 
immune response is still unbalanced in favour of the epitopes of primary infection. 
Epitopes encountered in the secondary infection still do not appear to be evenly adopted 
into the immune response. Hence, human immune systems appear forever “tainted” by 
their first encounter, and the analogy of original sin becomes clear. Several recent 
studies have found evidence that both supports207  as well as refutes this concept208.  
Although associated with humoral immunity, observations of original antigenic sin 
in T-cells are prevalent209,210. Yet distinguishing the molecular basis of antigenic sin from 
that of T-cell cross-reactivity211,212 is an experimental and conceptual challenge. 
Harvesting the benefits of the latter, while negating the wastefulness of the former could 
be a goal in forthcoming T-cell vaccination research. 
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1.5 Aims and Hypothesis of the Thesis 
The interplay between the immune system and the influenza virus is a fascinating 
topic in immunology and disease. The periodic incidence and pandemic potential 
discussed in previous sections are made possible by the viral evolution mechanisms that 
evade the immune response. Seasonal vaccination is largely successful at preventing 
epidemics, but offers little protection against novel pandemic strains or in situations 
where the vaccine strains have been incorrectly matched to the environmental strain (for 
example in 2015/2016). 
The internal elements of the virus, discussed in section 1.4.4, exhibit high levels 
of conservation and offer a more consistent target for the immune system amidst the 
diversity of potential strains. T-cell responses to these proteins have been shown to 
correlate with protection and deceased symptom severity during infection48,213. Yet the 
epitopes and T-cell receptor repertoires that underpin these important responses have 
not been analysed in detail at the molecular level.  
CD4+ T-cell recognition and responses to three of these internal proteins, M1, 
NP and PB-1 are the subject of this thesis. The questions driving this investigation have 
focused on how many robust and reproducible HLA-restricted epitopes were contained 
within these proteins, and to what extent they were recognised in multiple individuals of 
the same HLA-type? Following this, what did the magnitude and clonotypic architecture 
of responding cell populations look like, and given their importance in protection were 
such response characteristics shared across the population? 
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Hypothesis: 
CD4+ T-cell responses to the internal proteins of the Influenza virus will be detectable in 
multiple individuals and generate strong cellular and genetic signatures shared across 
the population.  
 
 
Specific aims: 
1) To isolate HLA-restricted CD4+ T-cell responses to the conserved internal 
proteins and characterise these to the epitope level. 
2) To examine the nature of responses to these epitopes in multiple individuals 
sharing a common HLA allele. 
3) To analyse the underlying clonotypic characteristics of these responses in order 
to understand the genes and amino acids that mediate CD4+ T-cell immunity and 
assess whether these are shared across the population. 
4) To align clonotypic data with structural data to explain the conserved features 
observed in epitope-specific repertoires. 
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2 Methods 
2.1 Generation of DR1.APCs 
2.1.1 List of General Reagents 
A5 media: RPMI 1640 (Gibco), 5 % human AB serum (heat inactivated, acquired from 
Cardiff University Hospital Wales), 2 mM L-glutamine, 100 IU/mL penicillin, 100 μg/mL 
streptomycin 
R10 media: RPMI 1640 (Gibco), 10 % FCS (heat inactivated, Gibco), 2 mM L-glutamine, 
100 IU/mL penicillin, 100 μg/mL streptomycin 
R5 media: same as above with 5 % FCS (Gibco) 
R0 media: same as above in the absence of FCS 
D10 media (HEK293T cells only): Dulbecco's Modified Eagle Medium (DMEM; Gibco), 
10% FCS, 2 mM L-glutamine, 100 IU/mL penicillin, 100 μg/mL streptomycin 
CD4+ T-cell media: RPMI 1640 media, 40 IU/mL IL-2 (human recombinant, Proleukin), 
10 % FCS, 2 mM L-glutamine, 100 IU/mL penicillin & 100 μg/mL streptomycin, 0.02 M 
HEPES, 1mM non-essential amino acids, 1mM sodium pyruvate 
All above reagents acquired from Life Technologies unless stated 
 
FACS buffer: PBS, 2 % FCS 
TE Buffer: 10 mM Tris, 1mM EDTA, pH 8.0  
HEPES buffer: 2.5 mM HEPES, pH 7.3  
Calcium chloride solution: 2.5 M CaCl2 
HEPES buffered saline: 280 mM NaCl, 50 mM HEPES, 1.5 mM Na2HPO4, pH 7.0 
ELISpot plate: Millipore multiscreen filter plate MSIPS4510 
IFN-γ ELISpot kit: Mabtech basic kit, IFN-γ capture mAb (1-D1K), biotinylated detection 
mAb (7-B6-1), Streptavidin-ALP 
Anti-HLA-DR antibody: L243 (0.05 mg/ml, Biolegend) 
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2.1.2 Cell Culture 
Human (Epstein-Barr virus transformed) B Lymphoblastoid cell lines (B-LCL), T2 
and 721.174 (full description and origin detailed in Chapter 3) were cultured in R10 media 
at 37 °C, 5 % CO2 and replenished with fresh media regularly (3-5 days, split 70 %). T-
cell clones were cultured in CD4+ T-cell media (3-5 days, split 50 %). PBMC lines were 
cultured in A5 media, controlled for human AB serum batch. Lines were only exposed to 
a single batch of AB serum, mixing of batches, or culture in different batches of serum 
was strictly avoided. 
2.1.3 DR1 Construct and Lentivirus Production 
HLA-DR1 gene construct was ordered from Genewiz. The construct contained 
HLA-DR1 α and β domains detailed in section 2.3.2, separated by a P2A self-cleavage 
site, and Age1 and Sal1 restriction sites. This construct was cloned into the 
pRRLSIN.cPPT.PGK-GFP.WPRE transfer vector (2nd generation), before calcium 
chloride transfection with the packaging vectors pMD2.G and pCMV-dR8.74 (obtained 
from Dr. Bruno Laugel of Cardiff University) into human embryonic kidney 293T cells.  
Virus was packaged using 2 million 293T cells in 20 mL D10 medium (estimated 
at 60-80% confluency assessed 4 hours before transfection).  550 μL TE buffer was 
combined with pMD2.G (13 μg), pCMV-dR8.74 (24 μg) and HLA-DR1 transfer vector 
(18.75 μg) and 190 μL CaCl2. 1.9 mL of HEPES buffered saline was added dropwise 
with agitation (vortex) and incubated (15 - 25 min, RT) to facilitate precipitate formation. 
Virus solution was added to 293T cells dropwise under agitation, and cells were 
incubated overnight (37 °C, 5 % CO2). Media was replaced (17 ml split) at 16 h then 
supernatant collected 24 hours and 48 hours later. Viral containing supernatants were 
filtered (0.45 μm), 24 and 48-hour fractions pooled and concentrated by 
ultracentrifugation at 150,000 g (2 hours, 4 °C) in sterilised ultra-clear ultracentrifuge 
tubes (Beckman Coulter). The lentivirus pellet was resuspended in 1 mL of R10. 
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Lentivirus preparations were aliquoted (100 μL), snap frozen and stored in lentiviral 
designated freezer location. 
2.1.4 Assessment of DR1 Expression by Flow Cytometry 
All flow cytometry was carried out on a BD Sciences FACS Canto. Cells were 
stained with primary mouse anti-HLA DR antibody L243 (0.05 mg/ml, Biolegend) for 20 
min on ice in FACS buffer. Cells were washed twice (FACS buffer, 400 g, 5 min) before 
incubation with a secondary goat anti-mouse PE (0.02 mg/ml, BD Pharmingen) for 20 
min on ice followed by two washes. 
2.1.5 Infection of “Naked” Cell Lines with DR1 Lentivirus 
The cell lines 721.174 and T2 (174 x CEM.T2) were kindly provided by Prof Awen 
Gallimore and Dr Garry Dolton respectively. 5 million of these cells were incubated with 
100 μL of DR1 lentivirus in a 24 well plate overnight. Media was removed at 16 hours 
and replaced with fresh R10 (to minimise exposure to virus). DR1 expression was 
assessed after one week, as described in section 2.1.4. 
Populations were then enriched for DR1 expressing cells by magnetic activated 
cell sorting (MACS, Miltenyl Biotech) using the L243 antibody, goat anti-mouse FITC (BD 
Pharmingen) and anti-FITC micro beads (Miltenyl Biotech) following manufacturers 
protocol. Clones were obtained by limiting dilution of the DR1 enriched populations. 
2.1.6 IFN-γ ELISpot with CD4+ T-cell Clones 
The T-cell clones DCD10 (specific to a DR1-restricted influenza epitope HA306-
318) and GD.D104 (specific to a DR1-restricted cancer epitope 5T4xxx-xxx peptide 
sequence not disclosed)214 were “rested” (24 hours, 37 °C, 5 % CO2) prior to the assay 
in R-5 media.  Peptide pulsing consisted of incubation (2 hours, 37 °C, 5 % CO2) at 
chosen peptide concentrations in assay media. Cells were then washed in either R0 or 
PBS four times in order to remove unbound peptide from the media, thus limiting T-cell 
to T-cell presentation.  
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Per ELISpot well 50,000 peptide-pulsed APCs were used. T-cell numbers (200 – 
400 per well) and peptide concentrations were varied in order to optimise assay 
conditions. Overnight incubation was carried out on an ELISpot plate coated with the 
IFN-γ capture antibody using the Mabtech IFN-γ ELISpot kit. Development of plates was 
carried out following manufacturer’s protocol and spot forming cells are counted using 
the AID GmbH plate reader and software. For later assays a more advanced plate reader 
was used (see section 2.2.7). 
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2.2 Screening of Donor PBMC against Peptide Libraries  
2.2.1 Peptide Libraries 
Peptide libraries were obtained from GL Biochem (Shanghai) Ltd as 20-mers in 
the crude form. Peptide sequences overlapped 10 amino acids (for full library details see 
appendix section 8.1). Original sources of the sequences are as follows:  
Matrix Influenza A virus (A/Wilson-Smith/1933(H1N1) 252 amino acids), 24 overlapping 
peptides. 
Nucleoprotein Influenza A virus (A/Ck/HK/96.1/02 (H5N1) 401 amino acids), 39 
overlapping peptides. 
PB1 Influenza A virus (A/Puerto Rico/8/1934(H1N1) 757 amino acids), 74 overlapping 
peptides. 
2.2.2 Peptide Pools 
Lyophilised peptides were re-suspended in DMSO (stock concentration of 20 
mg/mL). 1 μL of the designated peptides were added to PBS to make a final volume of 
40 μL. Individual peptides were always at a concentration of 0.5 mg/mL, whether alone 
or in a pool. 2 μL of PBS stock was added to give a working concentration of 10 μg/mL 
(estimated as 5 μM for a 20-mer). 
2.2.3 Processing of PBMC 
PBMC were obtained from local donors, anonymous donor coding and consent 
taken and recorded. Assays were carried out in order to ensure each screen (per protein) 
is carried out on a different bleed. No PBMC from before 2014 was tested.  
20-50 ml of fresh blood taken by venepuncture (done by a trained phlebotomist), 
was transferred into a Falcon tube containing heparin (LEO Laboratories Ltd) at 100 IU/ 
ml of blood. The blood was separated by careful suspension over an equal volume of 
Ficoll (Lymphoprep, Axis-Shield) and density gradient centrifugation (20 min at 1200 g, 
brake off). The PBMC layer (at the plasma interface) was gently aspirated and washed 
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once in R0 (10 min at 700 g, brake on) before being treated with 5-10 ml of RBC lysis 
buffer (10 min, 37 °C). Cells were washed in R0 to remove lysate (6 min at 300 g) before 
resuspension in A5 media. 
2.2.4 Generation of Lines through Culture of PBMC with Peptide Pools 
At day-0 three wells of 200,000 PBMC per condition (from frozen or fresh blood) 
in 100 μL of A5 media was cultured with peptide or peptide pool at 10 μg/mL (1 μg in 100 
μL) in a 96 well plate, with sterile water in the surrounding wells (37 °C, 5 % CO2). 10 μL 
of Cell-Kine (Helvetica Healthcare) was added per well at day-3. 100 μL of A5 + IL-2 (40 
IU per μL) was added at day-6. 100 μL of media was replaced at day-9. Cells were 
“rested” until day-14, following which cells were assayed up to day-21. Prior to assay, 
cells were washed 3 times in PBS before resuspension in A5 media. 
2.2.5 Pulsing of B-LCL 174.DR1 Transduced APCs 
For assays detailed in chapter 3 and 4, 174.DR1 APCs were pulsed in a 96 well 
plate at a concentration of 200,000 cells per 100 μL with peptide or peptide pool at 10 
μg/mL (1 μg / 100 μL) for a minimum of 2 hours (37 °C, 5 % CO2) in R0 media. Pulsing 
concentration and cell numbers replicate those conditions at which cultured cells were 
expanded (section 2.2.4.) Following pulsing, cells were washed in PBS (150 μL) 3 times 
to remove unbound peptides before resuspension in A5 media. APCs that were not 
pulsed with peptide (negative control for ELISpot) were incubated and washed alongside 
pulsed cells. 
2.2.6 IFN-γ ELISpot with PBMC Lines 
75,000 PBMC (number based on the initial PBMC line set up) were cultured on 
anti-IFN-γ coated ELISpot plate (MSIPS4510) coated with anti-IFN-γ capture antibody 
(1-D1K, Mabtech) with relevant 50,000 peptide pulsed APC in a total volume of 150 μL 
for 16 hours (37 °C, 5 % CO2). Plate was washed 5 times in PBS, before development 
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with relevant antibodies following manufacturer’s protocol (Detect: 7-B6-1-Biotin, 
Streptavidin-ALP). 
Controls were PHA (Alere) and PKY (“universal peptide”) peptide168. Tests were 
run in duplicate, with a single negative control (PBMC and APCs in the absence of 
peptide or PHA stimulation).  
2.2.7 Plate Analysis and Normalisation 
Developed plates were imaged and counted using a CTL Immunospot analyser. 
CTL Single Colour software was used for spot counting and QC. Settings were kept 
constant for each reading. Assays were normalised for cumulative analysis by division 
of individual well spots by total number of spots across all wells (minus background). 
This accounted for inter-assay variation derived from plate sensitivity differences, low or 
high PBMC numbers or experimental error resulting in an inter-assay difference. 
2.2.8 Binding Algorithms Inputs 
NetPanMHCII (http://www.cbs.dtu.dk/services/NetMHCIIpan/) was used to predict the 
epitope based on the strongest binding core. Sequences 20-30 amino acids were input 
in FASTA format. Input length was set at either 11, 13 or 15 amino acids (Fig. 2.1). 
 
Figure 2.1. NetPanMHCII input view. 
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HLA-DRB1*0101 was the allele selected, threshold of strong and weak binders 
were left at default parameters (does not affect output), with “print only strongest binding 
core” and “sort output by affinity” checked (ticked boxes, Fig. 2.2). 
 
Figure 2.2 Parameters for NetPanMHCII. 
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2.3 Protein Production for Crystals and HLA-Multimers 
2.3.1 List of Reagents 
TYP media: 16 g/L tryptone, 16 g/L yeast extract, 5 g/L potassium phosphate dibasic & 
5 g/L sodium chloride. 
LB agar for plates: 15 g/L agar bacteriological (Oxoid), 10 g/L tryptone, 5 g/L yeast 
extract, 5 g/L NaCl 
Carbenicillin (carbenicillin direct) antibiotic: Added at 50 mg/L to TYP or LB agar 
following a reduction in temperature after autoclave sterilisation. 
Bacterial Cell Lysis Buffer: 10 mM Tris, 10 mM MgCl2 (Acros organics), 150 mM NaCl, 
10 % glycerol; pH 8.1 
Inclusion Body Wash Buffer: 50 mM Tris, 0.5 % Triton X-100, 100 mM NaCl, 2 mM 
EDTA; pH 8.1 
Inclusion Body Resuspension Buffer: 50 mM Tris, 100 mM NaCl, 2 mM EDTA; pH 
8.1 
Urea Buffer A: 8 M Urea, 20 mM Tris pH 8.1 and 0.5 mM EDTA; pH 8.1 
Urea Buffer B: 8 M Urea, 1 M NaCl, 20 mM Tris pH 8.1 and 0.5 mM EDTA; pH 8.1 
 
HLA Class-II refold buffer: 25 % glycerol, 20 mM Tris, 1 mM EDTA, 20 mM NaCl, 1.48 
g/L (13 mM) cysteamine hydrochloride & 0.83 g/L (3.7 mM) cystamine hydrochloride. 
Crystal buffer: 10 mM Tris, 10 mM NaCl, pH 7.4 
CAPS elution buffer: 50 mM 3-(cyclohexylamino)-1-propanesulfonic acid (CAPS); pH 
11.5 
Neutralisation buffer: 300 mM sodium phosphate; pH 6 
Biomix A – Avidity: 0.5 M bicine buffer; pH 8.3 
Biomix B – Avidity: 100 mM ATP, 100 mM MgO(Ac)2 & 500 μM biotin 
d-Biotin Buffer – Avidity: 500 μM d-biotin 
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Sample loading buffer (4 X): 1 M Tris, 0.008 % bromophenol blue, 10 % SDS, 40 % 
glycerol; pH 6.8 
Reducing sample loading (4 X): 4M dithiothreitol (DTT), 1 M Tris, 0.008 % 
bromophenol blue, 10 % SDS, 40 % glycerol; pH 6.8 
 
All buffers filtered using a 0.45 μm filter and vacuum pump system prior to use or 
application on AKTA FPLC. Chemicals obtained from Sigma or Fisher Scientific unless 
stated. 
2.3.2 HLA-DR1 Plasmids 
For bacterial expression three plasmids were obtained from Dr Chris Holland of 
Cardiff University, each was cloned into a pGMT7 E. coli expression vector with an 
ampicillin resistance gene. The resistance gene allowed growth in carbenicillin 
supplemented media (50 mg/L). Expression of protein was under control of the lac-
operon and could be induced by addition of 0.5 mM Isopropyl β-D-thio-galactoside, 
(IPTG, Fisher Scientific). DR1α-bt was used to produce pHLA that would be used in HLA-
multimers, while non-biotin tagged DR1α was used to produce pHLA for crystallisation. 
 
DR1α: HLA-DRA*01 (Uniprot: P01903, residues [26-207]) 
DR1α with biotin tag (-bt): as above, with C-terminal Biotinlyation signal sequence 
(GLNDIFEAQKIEWHE) joined via a flexible linker (GSGG) 
DR1β: HLA-DRB1*0101 (Uniprot: P04229, residues [30-219]) 
 
2.3.3 Inclusion Body Production 
Individual plasmids were transformed into Rosetta (DE3) competent BL21 E. coli 
(Novagen) by heat shock. 1 μL of plasmid DNA was added to 25 μL of BL21 cells and 
incubated (5 min, ice, gentle agitation). The mixture was heat shocked (42 °C, 2 min) 
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before transfer back to ice (5 min, gentle agitation). Cells were plated on LB agar 
carbenicillin plates and incubated overnight (37 °C). 
Following overnight incubation, 3 distinct bacterial colonies were selected and 
transferred to 30 ml of TYP-carbenicillin to form a starter culture. Starter cultures were 
cultured in an orbital shaker (37 °C, 220 rpm) until the optical density at 600 nm (OD600) 
reached between 0.4 and 0.6. 
Mature starter cultures were transferred to 1 L of TYP-carbenicillin and cultured 
in an orbital shaker (37 °C, 220 rpm) until the optical density at 600 nm (OD600) reached 
between 0.4 and 0.6. At an OD600 of 0.4-0.6, protein expression was induced by addition 
of 0.5 mM IPTG. Following IPTG addition, cultures were maintained for three to four 
hours in order produce sufficient quantities of protein. 
Cells were isolated from cultures by centrifugation (4000 rpm, 20 min), and 
subsequently resuspended in lysis buffer (40 mL/L of cultured cells). 40 ml lysis 
resuspensions were sonicated using a Sonopulse HD 2070 with MS73 probe (Bandelin) 
at 60-90 % power for 20 mins using 2 second intervals. If large volumes of cells were 
obtained then sonication could be repeated, as well as the addition of extra freeze thaw 
steps in between sonication. Complete lysis of all cells was essential for purity at later 
steps. 
Lysed cells were treated with DNAse (160 μg/mL, 2 hours, 37 °C, agitation) 
before high speed centrifugation (10,000 rpm, 20 mins). Pellet was resuspended in triton 
wash buffer, homogenised and centrifuged (10,000 rpm, 20 mins) in order to remove 
irrelevant material. Triton wash step was repeated until a clear white pellet was obtained 
after centrifugation and there was an absence of gel-like substances. 
Clean pellets were resuspended in resuspension buffer (to remove triton) before 
centrifugation (10,000 rpm, 20 mins) and solubilisation of the pellet in urea buffer A (40-
60 ml per litre of bacterial culture, more was added to large quantities of protein). Addition 
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of 8 M urea solubilised the aqueous insoluble inclusion bodies which contain the DR1α 
or DR1β protein, enabling further purification steps. 
2.3.4 Inclusion Body Purification 
Urea solubilised inclusion bodies were filtered using a 0.45 μm filter and vacuum 
pump. Inclusion bodies were purified by anion exchange chromatography (5 mL HiTrap 
Q HP; GE healthcare life sciences) on an AKTApure FPLC system (GE healthcare life 
sciences). The HiTrap column was equilibrated with urea buffer A (3 column volumes), 
and inclusion bodies loaded onto the column until saturation (when protein no longer 
binds to the column). 
Protein was eluted using a NaCl salt gradient (urea buffer B, 0-100 % over 10 
column volumes of buffer) and collected in 1 ml fractions. Fractions that contained 
protein, as indicated by UV absorbance (A280) on the AKTApure, were tested for 
A260/A280 and those with a high DNA content discarded (A260/A280 > 1 indicates DNA 
contamination).  
Remaining protein fractions were analysed by SDS-PAGE (section 2.3.8) to find 
fractions that contain a band at 20 kDa (individual DR1 α or β chain) and minimal other 
impurities. Pure fractions were pooled, the pool concentration measured using a 
NanoDrop ND100 (ThermoScientific) and taken forward for refolding. 
2.3.5 Refolding of HLA Class-II 
Between 1-4 L of HLA refold buffer (size of refold depends on the amount of 
protein required) was prepared at 4 °C. The relevant DR1α-chain and DR1β-chain were 
each slowly added at a concentration of 5 mg/L of refold buffer under continuous mixing. 
Peptide was added at a concentration of 0.5 mg/L of refold buffer. The mixture was stirred 
magnetically for 1-2 hours before incubation at 4 °C for 3-5 days. 
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2.3.6 Purification of Refolded HLA Class-II 
Following incubation, the refold was filtered at 0.45 μm before concentration 
using a Vivaflow crossflow concentration cassette (molecular weight cut-off 10 kDa; 
Sartorius) and peristaltic pump. The refold was concentrated to less than 50 mL (the 
minimal volume reached by the Vivaflow system) before addition of 500 mL of PBS for 
buffer exchange. The PBS refold mixture was then concentrated to 50 mL in the Vivaflow 
system, then further concentrated using 10 kDa MWCO centrifugal filter units (Millipore) 
to 10 ml. 
Correctly refolded pHLA was purified using an immunoaffinity column containing 
the anti-HLA-DR antibody (L243, in house hybridoma) which binds class-II molecules in 
their intact conformation. Columns were equilibrated with PBS (15 mL flowed through) 
before addition of the 10 mL refold concentrate (flowed through the column 3-4 times to 
ensure binding of pHLA to antibody). Following addition of refold concentrate, the column 
was washed with PBS (15 mL) to ensure removal of non-specific binders. 
Bound protein was eluted using CAPS buffer (pH 11.5, 8 mL total volume, applied 
to the column in 2 mL fractions) dripped into the equivalent volume of neutralising buffer 
(pH 6.0) to give a final pH of 7.4. Using a centrifugal filter unit (10 kDa MWCO) the protein 
was buffer exchanged back into crystal buffer (10 mM Tris, 10 mM NaCl, pH 7.4) and 
concentrated to 700 μL. 
If protein was produced for HLA-multimers then biotinylation was carried out as 
described in section 2.3.7. If protein was produced for crystallisation then sample was 
purified by size exclusion column chromatography (gel filtration) on an AKTApure FPLC 
using a Superdex 200HR SEC column (GE healthcare life sciences), equilibrated and 
run with crystal buffer. Pure pHLA protein resulted in a single well-defined peak that was 
checked by SDS-PAGE (section 2.3.8) to give two distinct bands at the 20 kDa marker 
in reducing conditions. 
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2.3.7 Biotinylation and QC Shift Assay 
Biotin was added to refolded HLA-DR1 for HLA-multimer staining (made using 
DR1α-bt inclusion bodies) using a BirA biotinylation kit (Avidity). Refolded pHLA was 
concentrated to 700 μL in crystal buffer (PBS cannot be used to high salt concentration) 
to which 100 μL Biomix A, 100 μL Biomix B, 100 μL d-Biotin 500 μM and 2 μL BirA 
enzyme (Avidity) was added, followed by overnight incubation at room temperature. 
Excess biotin was removed by buffer exchange in a centrifugal filter unit (10 kDa 
MWCO) into PBS and the success of the biotinylation reaction was assessed by a biotin 
shift assay on SDS-PAGE. 5 μg of biotinylated pHLA was incubated with 5 μg of 
streptavidin, and the formation of complexed pHLA-streptavidin multimeric complexes (a 
shift resulting in a smear at high molecular weight) was assessed on SDS-PAGE under 
non-reducing conditions. 
 
2.3.8 SDS-PAGE 
The purity and molecular weight of protein samples was analysed by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 5-10 μg of sample was 
mixed with an equal volume of sample loading buffer for unreduced conditions (intact 
disulphide bonds). Analysis under reduced conditions (broken disulphide bonds) 
required addition of reducing sample loading buffer (with 1 M DTT) and boiling (95 °C, 5 
min) before running on SDS-PAGE.  
Samples were loaded onto Bolt 4-12 % Bis-Tris Plus Gels run in NuPAGE MES 
SDS running buffer in a Bolt Mini Gel Tank (all ThermoFisher Scientific). The gel tank 
was connected to a Bio-Rad Powerpac 200 power supply (Bio-rad) and run at 200 V over 
25 min (longer if necessary). 
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2.3.9 TCR-pHLA Complex Formation 
The F11 TCR was provided by Aaron Wall (Cardiff University) purified by size 
exclusion chromatography. Purified DR1-PKY and F11 TCR were mixed at an equimolar 
ratio to give a total protein concentration of 6 mg/mL in crystal buffer. This mixture was 
taken forward for crystallography and production of TCR-pHLA complex crystals 
(described in chapter 6). 
2.3.10 Protein Crystallography  
Purified pHLA protein (obtained as described in section 2.3.6) was concentrated 
to the maximum possible concentration, generally between 6-10 mg/mL in crystal buffer. 
Crystal trays were set up using the TOPS screen215 with sitting drop vapour diffusion 
plates. Each TOPS screen buffer condition was dispensed into corresponding wells of 
an ARI INTELLI-PLATE 96-2 low volume reservoir plate (Art Robbins Instruments, LLC) 
using an Art-Robbins Gryphon robot (Art Robbins Instruments, LLC.). From the screen, 
60 μL was dispensed into a mother liquor well, and two dispenses of 200 nL into separate 
sitting drop wells. 200 nL of protein sample was dispensed into the top well containing 
200 nL of a TOPS screen buffer. The plate was then sealed with a ClearVue seal 
(molecular dimensions) such that each condition was a closed system. Vapour diffusion 
occurred between the sample well and the mother liquor well to facilitate a change in 
osmotic conditions that would drive crystal formation. Plates were immediately imaged 
using a Formulatrix Rock Imager 2 (Formulatrix, Inc.)  and incubated at 18 °C, with further 
images taken at daily intervals to monitor crystal growth. 
 
2.3.11 X-Ray Crystallographic Sample Preparation and Data Collection 
Wells containing crystals were opened with a scalpel, and crystals cryo-protected 
by the addition of 20 % ethylene glycol diluted in the corresponding TOPS screen buffer. 
Crystals were collected using 20 μm or 40 μm mounted loops (Molecular Dimensions), 
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immediately snap frozen in liquid nitrogen (liq. N2) and placed in a Diamond light source 
storage puck stored in a Dewar vessel containing liq. N2. 
Crystals were subject to X-ray diffraction and data collection at Diamond light 
source (Dicot, England) under supervision of Dr. David Cole, or Dr. Pierre Rizkallah 
(1000 diffraction images taken at 200 ° rotation and 0.2 second exposure time). 
 
2.3.12 Structure Solution from DLS Datasets 
Data sets were obtained from the DLS servers in three file formats (3dii, 3d, dials) 
with details on space group and resolution. Highest resolution data sets were analysed 
first. Data sets were processed using the program suite CCP4 (www.ccp4.ac.uk). 
“MATTHEWS” was used to obtain the number of molecules in the asymmetric unit, the 
details of which were input into “PHASER” with an HLA-DR1 model for molecular 
replacement to occur. This generated a model from the dataset based on the structure 
of HLA-DR1 which was subsequently edited using the visual WinCoot software 
(www.ccp4.ac.uk) and subject to several rounds of refinement using “REFMAC5”.  
Refinement was continued until values of RWORK and RFREE reached acceptable 
levels, below 0.20 and 0.25 respectively, where possible. Model was interrogated visually 
to ensure the molecular backbone fitted the observed electron density at 1 sigma, and 
conformed to Ramachandran bonding principles. Final PDB files were visualised using 
PyMOL graphics software (Schrodinger) and contact tables generated from “NCONT” in 
CCP4 to define the interaction distances and partners. Types of non-covalent interaction, 
i.e. Van Der Waals (vdWs), polar, non-polar hydrophobic and salt bridges were inferred 
based on the details of these tables.  
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2.4 Analysing Epitope-Specific T-cells 
2.4.1 Culture of PBMC for HLA-Multimer Staining 
At day-0, five wells of 200,000 PBMC (from frozen or fresh blood) in 100 μL of 
A5 media was cultured with peptide at 10 μg/mL (1 μg in 100 μL) in a 96 well plate, with 
sterile water in the surrounding wells (37 °C, 5 % CO2). One million total cells were 
necessary for efficient staining on flow cytometry and for sorting of sufficient numbers for 
later clonotyping work. 
As previously described in section 2.2.4, 10 μL of Cell-Kine (Helvetica 
Healthcare) was added per well at day-3. 100 μL of A5 + IL-2 (40 IU per μL) was added 
at day-6. 100 μL of media was replaced at day-9. Cells were “rested” until day-14, 
following which cells were stained and assayed by flow cytometry as described in section 
1.4.3. 
2.4.2 Preparation of HLA-Multimers 
All monomers were multimerised on a dextramer backbone216,217 (Immudex) 
following published methodology. Per individual stain, 0.5 μg of refolded and biotinylated 
pHLA was incubated with 2 μL of phycoerythrin (PE)-conjugated dextramer backbone 
solution (20 min, ice). Solution was spun at high speed (16000 rpm, 30 sec) to pellet 
insoluble material before use. Multimers could be made on the day of staining, or up to 
five days before, stored at 4 °C. 
2.4.3 Flow Cytometry: HLA-Multimer Staining 
PBMC lines cultured as described in section 2.4.1 were combined (estimated as 
1 million total cells) then split into three wells (for test, irrelevant HLA class-II multimer 
and FMO controls) and washed in FACS buffer (400 g, 5 min). Cells were incubated with 
protein kinase inhibitor 50 nM dasatanib (30 min, 37 °C; Axon Medchem). HLA-multimers 
(prepared in section 2.4.2) were made up to a total volume of 10 μL per stain and added 
directly to PBMC lines following dasatanib incubation without washing (30 min, 4 °C). 
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Lines were washed (FACS buffer, 400 g, 5 min), and incubated with “boost” antibody216, 
anti-PE added (10 μg/mL, 20 min, 4 °C; clone PE001, BioLegend). Cells were washed 
twice in PBS buffer, then stained with violet LIVE/DEAD Fixable Dead Cell Stain, Vivid 
(Life Technologies) (5 min, RT). 
The antibody cocktail of remaining stains was added for incubation (20 min, 4 
°C): anti–CD8-allophycocyanin-vio770 (clone BW135/80; Miltenyi Biotec), anti-CD4 
allophycocyanin (clone M-T466; Miltenyi Biotec), anti-CD3-peridinin chlorophyll protein 
(PerCP) (clone BW264/56; Miltenyi Biotec); anti-CD19-Pacific blue (clone HIB19; 
BioLegend); and anti-CD14-Pacific blue (clone M5E2; Bio- Legend). Following cocktail 
incubation, cells were washed twice in FACS buffer before analysis by flow cytometry. 
Cells were sorted on a BD FACS ARIA (BD Biosciences) with the help of central 
biology services (CBS) Cardiff University. Cells were sorted directly into lysis buffer 
(Qiagen) supplemented with 0.5 M DTT, and frozen at – 80 °C for later RNA extraction 
and cDNA isolation described in in section 2.4.4. 
2.4.4 Clonotyping by Next Generation Sequencing 
2.4.4.1 RNA Extraction and cDNA Synthesis 
RNA was extracted from thawed samples using an RNAeasy PLUS micro 
extraction kit (Qiagen) following manufacturers protocol. Purified RNA was used to 
produce cDNA using the SMARTER cDNA synthesis kit (Clontech) following 
manufacturers protocol. 10 μL of purified mRNA was incubated with oligo-dT in a thermal 
cycler (3 min, 72 °C followed by 2 min, 42 °C) to allow annealing of the oligo-dT primer 
to the oligo-A mRNA tail. Following annealing, 4 μL 5X First Strand buffer, 0.5 μL 100 
mM DTT, 1 μL 20 mM dNTP, 0.5 μL RNAse inhibitor and 2 μL SMARTScribe RT and 1 
μL oligo-A primer II were added to the sample for a cyclic incubation (90 min, 42 °C 
followed by 10 min, 70 °C). 
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2.4.4.2 PCR Amplification of cDNA Product 
Two PCR steps were used to amplify the TCRα or TCRβ products from cDNA, 
using a single primer pair. 
The first step: 2.5 μL of cDNA sample with 10 μL 5x high fidelity (HF) buffer, 0.5 
μL 100 mM DMSO, 1 μL 20 mM dNTPs, 5 μL 10X Universal Primer A (forward primer), 
1 μL Primer Cα-R1 or Cβ-R1 (reverse primer) and 0.25 μL Phusion Taq polymerase were 
mixed and made up to a final volume of 50 μL final volume with nuclease free water 
(Ambion). The mixture was incubated (94 °C, 5 min) for the starting denaturation followed 
by 30 cycles (1 cycle consists of 30 secs at 94 °C, 30 secs at 63 °C and 3 min at 72 °C) 
before a final extension (72 °C, 7 min). 
The second step: 2.5 μL of sample from the step out PCR was mixed with 10 μL 
5x high fidelity (HF) buffer, 0.5 μL 100 mM DMSO, 1 μL 20 mM dNTPs, 1 μL Primer short 
(forward primer), 1 μL Primer Cα-R2 or Cβ-R2 (reverse primer) and 0.25 μL Phusion Taq 
polymerase and made up to a final volume of 50 μL final volume with nuclease free water 
(Ambion). 
The mixture was incubated (94 °C, 5 min) for the starting denaturation followed 
by 30 cycles (1 cycle consists of 30 secs at 94 °C, 30 secs at 63 °C for TCR α-chains 
and 66 °C for TCR β-chains and 3 min at 72 °C) before a final extension (72 °C, 7 min). 
Samples were analysed by electrophoresis on a 1% agarose gel (45 min, 90 V). 
Amplified samples of 400 base pairs were excised and purified using a Gel extraction kit 
(Nucleospin). 
2.4.4.3 Next Generation Sequencing 
Purified samples were kindly sequenced by Dr. Meriem Attaf (Cardiff University) 
using an Illumina MiSeq. NEBNext Ultra Library preparation kit (New England Biolabs, 
Cambridge, UK) was used to produce samples that were run on an Illumina MiSeq using 
the MiSeq v2 reagent kit (Illumina).  
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TCR gene usage was determined based on reference sequences from the 
ImMunoGenetics (IMGT) database (imgt.org) and all TCR gene segments were 
designated according to the IMGT nomenclature using MiXCR software. Low quality 
reads, TCRs with one single read (singletons) and TCRs with CDR3 sequences less 
than seven amino acids in length were eliminated. 
Following processing of raw sequencing data, information was processed and 
presented using Microsoft Excel. Motifs were visualised using WEBLOGO 
(http://weblogo.berkeley.edu/logo.cgi) without small sample correction set. 
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3 HLA-DR1 Transduced APCs Facilitate Detection of 
DR1-Restricted T-Cell Responses 
3.1 Abstract 
Cell mediated immunity relies on the presentation of antigenic pHLA molecules 
to T-cells. The nature of an individual’s T-cell response to antigen is determined by the 
T-cell receptor repertoire they are capable of generating and their set of HLA alleles. 
HLA genes exhibit high levels of polymorphism. Across the population this provides a 
high level of immunological diversity in responses to the same antigen.  
Amidst this diversity, common responses mediated by shared HLA alleles are 
present. Knowledge of these HLA-restricted epitopes enables further examination of the 
immune system and aids the development of novel vaccination strategies. To determine 
the HLA-restriction of an in vitro response to peptide, HLA-specific blocking antibodies, 
HLA-matched presenting cells or HLA-multimer staining can be used. Employing such 
techniques during the screening of large peptide libraries in multiple donors is a 
challenge.  
To overcome this, a B-cell line shown to be deficient in HLA class-I expression 
and missing all class-II genes was used. The “naked” line was transduced with HLA-
DR1, and shown to successfully present peptides to cognate CD4+ T-cell clones and 
polyclonal lines. The use of this line during the screening of peptide libraries would allow 
identification of immune responses attributable to HLA-DR1 epitopes without further 
restriction assays. 
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3.2 Introduction 
In vivo, antigen is processed into short peptide fragments and loaded onto HLA 
molecules that are presented on the cell surface. The T-cell receptor (TCR) recognises 
the unique contact surface formed from both the peptide epitope and HLA amino acid 
residues166,218,219. Therefore, when characterising the T-cell response to antigenic 
peptides in vitro, it is useful to know the HLA-restriction of the responding cells. 
Knowledge of HLA-restricted epitopes forms the basis for developing a better 
understanding of the adaptive immune system. Studies involving pHLA multimer 
staining220, clonotypic analysis221, T-cell vaccine design222 and X-ray 
crystallography166,218,219 often examine responses to well defined HLA-restricted 
epitopes. Research at the level of an epitope answers questions concerning antigen 
specific T-cell populations, receptor interactions, antigen processing and molecular 
information that is limited at the level of whole protein or pathogen. 
Finding and characterising HLA-restricted epitopes is a challenge due to the 
polymorphic nature of HLA genes. Peptides may be presented by up to six different 
class-I alleles and up to twelve class-II variants in one individual. Identifying the HLA-
restriction of each response using HLA-blocking antibodies or matched and mismatched 
presenting cells becomes technically difficult on large peptide libraries. The work is 
further complicated when analysing sets of responses in multiple individuals, each with 
a distinct HLA-type.  
Instead of looking at responses to antigen at the level of each individual, it is more 
relevant to focus on a specific allele that is shared in a significant percentage of the 
population. In this case, the target epitopes are those most consistently recognised 
between individuals carrying the allele of interest. The challenge of epitope mapping 
under this genetic focus, is therefore to detect responses to a single HLA, and bypass 
those mediated by all others.  
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In order to do this, the method of non-autologous presentation can be 
employed. In an immunoassay such as an ELISpot, non-autologous APCs of a known 
HLA-type can present peptide to an expanded T-cell line. If the line and non-autologous 
APC have one common HLA allele, and elicit a measurable response to peptide, then 
that response is attributable to presentation by the common allele. 
Developing this concept, if the non-autologous presenting cells expressed only 
a single HLA, then the restriction information of any response generated would be 
implicit. Designing such an APC could be achieved by lentiviral transduction of an HLA 
construct into a cell line that did not otherwise express surface HLA.  
The “naked” cell lines 721.174 and its daughter T2 (174 x CEM.T2) are two 
examples, both are well characterised in the literature as lines deficient in antigen 
presentation machinery and surface HLA expression223. 721.174 cells were generated 
by two cycles of γ-radiation exposure followed by selection for the loss of HLA class-II 
expression224. Analysis revealed these cells to have a homogeneous deletion in the 
class-II locus including all HLA-DR, DQ and part of the DP genes225 (Fig 3.1). The T2 
cell line was made through fusion of 721.174 with CEMR.3 as part of an investigation 
into the trans-acting factors that govern HLA expression in lymphoblast hybrids226.  
Both lines express no class-II and low amounts of HLA-A2 at around 20-50% of 
wild type levels226. In the absence of both TAP and HLA-DM, these lines are impaired in 
their ability to process and present the normal complement of self-antigen via both class-
I and class-II pathways.  
Concerning the class-II pathway, when the T2 line is transduced with HLA-DR3, 
no issues in trafficking or surface presentation227 are observed, instead there is an 
accumulation of HLA-DR3 with bound CLIP (the invariant chain) in the MIIC compartment 
and at the cell surface135. This does not pose a problem in the presentation of short 
exogenous peptides228,229, like those used in this study, but it does prevent processing 
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and presentation of whole, non-denatured protein. Normal function can be restored by 
transduction with HLA-DM, as shown in multiple studies151,230 
 
 
Figure 3.1. Deletion in the 721.174 parent line conferring the “naked” phenotype. 
Taken from Fabb223 et al. The schematic shows the deletion in chromosome 6 missing 
from the naked APC 721.174. The deletion covers all class-II genes except the 
pseudogenes DP-A2 and DP-B1 which are not expressed or necessary for HLA 
function231.  
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3.3 Aims 
The HLA allele HLA-DRB1*0101 (HLA-DR1) is present in 20 % of the European 
Caucasian population. In our laboratory, technologies are in place to study DR1-
restricted responses at the cellular and molecular level through HLA-multimer staining 
and X-ray crystallography. These methods require specific knowledge of DR1-restricted 
epitopes that stimulate cognate CD4+ T-cell populations. 
The aim of this chapter was to develop a methodology for isolating DR1-restricted 
T-cell responses when screening polyclonal PBMC lines against pools of peptide. This 
would require the generation of an APC line expressing only HLA-DR1, using “naked” 
APC lines and lentiviral transduction. Such DR1.APCs could be used on an IFN-γ 
ELISpot in order to reveal DR1-restricted T-cell responses, and eliminate responses 
mediated by other HLA alleles. 
 
Specific aims: 
1) To transduce “naked” APC lines with an HLA-DR1 lentivirus, isolate clones and 
verify HLA-DR1 expression.  
2) To confirm that transduced cells can present HLA-DR1 restricted epitopes to 
cognate T-cells on IFN-γ ELISpot. 
3) To optimise HLA-DR1 peptide presentation to polyclonal lines, and compare 
HLA-DR1 and autologous presentation to identify HLA-DR1 restricted responses. 
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3.4 Results 
3.4.1 Generation of HLA-DR1 Presenting Cells 
HLA-DR1 was successfully cloned into a 2nd generation lentiviral construct and 
packaged virus was harvested from HEK293T cells. Transduction of T2 and 721.174 
cells resulted in a mixed population of transduced and non-transduced lines. DR1 
expressing cells were enriched by magnetic bead purification prior to limiting dilution and 
cloning. The expression of four selected DR1 clones was assessed using pan α-HLA-
DR antibody (L243) via flow cytometry. No HLA-DR1 specific reagents are available, yet 
as the wild type (non-transduced) lines show no HLA-DR expression, all staining could 
be attributed to the transduced HLA.  Expression of HLA was two logs higher than wild 
type populations, with a relatively uniform and consistent MFI between the different 
clones (Fig. 3.2A-B). 
In order to assess surface expression levels of HLA-DR relative to other antigen 
presenting cells, the pan HLA-DR staining of a 174.DR1 and T2.DR1 clone, their 
corresponding wild type lines, and two immortalised B-LCLs were compared (Fig. 3.2C). 
The immortalised B-LCLs, one homozygous for HLA-DR1 and one heterozygous were 
derived from healthy donors and thus expressed wild type levels of HLA and antigen 
processing genes. Both natural B-LCLs had higher expression than transduced clones. 
This was observed in previous studies with cells lacking antigen-processing genes, 
where wild type expression levels are restored upon transduction with HLA-DM151,232. 
The implications of the absence of HLA-DM in peptide presentation are evaluated in 
section 3.5. 
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Figure 3.2 Expression levels of HLA-DR across wild type and transduced cell lines 
on flow cytometry using pan anti-HLA-DR antibody (L243). (A) HLA-DR expression 
in the 721.174 wild type cell line and four examples of 721.174 DR1 expressing clones 
obtained by limiting dilution from the transduced line. (B) The same data shown for the 
T2 lineage. (C) Comparison of HLA-DR expression on transduced clones and two B-LCL 
lines with wild type levels of HLA expression. 
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3.4.2 DR1 Presentation to CD4+ T-cell Clones on IFN-γ ELISpot 
When using an IFN-γ ELISpot assay to detect T-cell responses to an antigen, the 
lower limit of detection is a single cognate T-cell. This sensitivity means that even the 
weakest T-cell affinities and smallest responses are visible at minimal cell numbers. 
Separating relevant responses from background, i.e. the signal to noise ratio, may be 
challenging, especially when working with polyclonal lines to multiple peptides. 
Complicating factors such as aberrantly active cells, low intensity responses, and high 
background associated with strongly responding lines are encountered.  
Given these complications, it was logical to test the peptide presentation capacity of 
the transduced APCs with a cleaner system. This was achieved using a cultured CD4+ 
T-cell clone (DCD10) specific to an influenza haemagglutinin peptide presented by HLA-
DR1124. The clone DCD10 recognises the thirteen amino acid peptide HA306-318 
(PKYVKQNTLKLAT) and is used as a model system in our laboratory for CD4+ T-cell 
IFN-γ production168.  
In this assay, 50,000 peptide-pulsed APCs were used to form a uniform lawn of 
presenters in a single well with 300 T-cells. The pulsing of wild type cells elicited a smaller 
but positive IFN-γ response (> 20 SFC) at very high peptide concentrations of 10-3 M, 
but no response at the lower concentration of 10-5 M. In comparison, DR1 transduced 
presenters were consistently able to stimulate cognate T-cells at both concentrations to 
the same level (Fig 3.3). Presentation by wild type cells at 10-3 M was attributed to 
ineffective washing of non-specifically bound peptide, a problem identified and discussed 
in later sections.  
This assay confirmed the ability of these transduced APCs to present DR1 specific 
peptide. The next challenge was to isolate restricted responses from polyclonal lines 
specific to multiple peptides.  As no difference in presentation capacity between T2 and 
721.174 was apparent, the 174.DR1 clone was used in all future work.  
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Figure 3.3 Presentation of HA peptide 306-318 (PKYVKQNTLKLAT) to the cognate 
CD4+ T-cell clone DCD10 by wild type and transduced antigen-presenting cells on 
IFN-γ ELISpot. 300 T-cells were plated onto 50,000 peptide pulsed APCs at two different 
concentrations of HA peptide. Representative images of IFN-γ ELISpot wells shown at 
each concentration below. Number of spot forming cells for each well were background 
subtracted and averaged over the number of repeats (mean with SD error bars, n = 3). 
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3.4.3 Dissecting DR1 Responses from Polyclonal Lines 
In order for HLA-restriction to be inferred accurately using DR1 presentation in the 
polyclonal setting, it was necessary to compare with autologous presentation and 
observe consistent differences (Fig. 3.4A-B). Pools of peptides from the matrix protein 
were used to expand DR1+ donor PBMC for fourteen days, and lines subsequently 
tested using both autologous and DR1 presentation methods. The contents of the Matrix 
(M1) pools is discussed, in detail, in chapter 4. Briefly, each of the ten pools contains a 
mixture of five different peptides, twenty amino acids in length, representing the 
sequence of the M1 protein.  
At this stage, the M1 peptide pools served as an optimisation platform for the 
development of a successful protocol. With ten distinct pools covering a highly 
immunogenic protein, the span of results and challenges encountered were 
representative of future assays.  
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Figure 3.4: Using DR1 cells to identify HLA-DR1 restricted T-cell responses from 
polyclonal PBMC lines. Culture of PBMC with a pool of distinct peptides results in a 
polyclonal line. (A) Probing of this line via an autologous presentation ELISpot, will 
highlight all responses. (B) Probing via a DR1 ELISpot, will reveal those responses to 
epitopes within the pool restricted to HLA-DR1. 
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3.4.4 Comparing Expansion Conditions: FCS versus Human Serum 
The analysis of a line expanded against a specific peptide or peptide pool requires 
a background control (same assay conditions, in the absence of peptide restimulation). 
The background control is an indication of how “active” or stimulated cells are in culture 
conditions, a significant factor being the serum used during expansion. The majority of 
studies culture cells in human serum, the source of which is non-commercial and is 
supplied in batches, which must be tested to ensure efficacy. Some labs use foetal calf 
serum (FCS) with some success214. Due to its increased availability and lower cost, it 
potentially provides an alternative to human serum. 
As part of early optimisation, a side-by-side comparison of both serums was carried 
out following standard protocol. When human PBMC were cultured with FCS serum, 
widespread activation was observed on both ELISpot formats (Fig 3.5A, 3.5C). 
Background controls for each line were displayed alongside tests, with similar levels of 
activity seen in both. In comparison, background levels in human serum were much lower 
than their corresponding test wells (Fig 3.5B, 3.5D).  
ELISpot assay data are conventionally presented with background subtraction (Fig 
3.5E, 3.5F); the resulting signal-above-background value allows inter assay comparison, 
and forms part of the criteria for a positive result. As shown, with high background SFC 
values in FCS, the data was meaningless, with most responses failing to meet the 20 
SFC per 105 significance level (Fig 3.5E). In human serum, the responses were of 
varying intensity and significance, and some pools demonstrated strong T-cell reactivity 
(Fig. 3.5F). Such strong response frequencies to the M1 peptide pool were expected 
based on previous studies213,233,234. 
Testing of this protocol change served as an introduction to assay optimisation 
before more significant experiments were undertaken. All subsequent assays were 
performed in human AB serum. This serum was not commercially obtained; therefore 
each new batch was tested and validated before further use.  
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 Figure 3.5: Comparison of Foetal Calf Serum (FCS) and Human AB Serum in 
expansion and ELISpot media. Autologous presentation ELISpot assays on peptide 
pool expanded lines using FCS and human serum are shown in (A) and (B) respectively. 
Background SFC values (white bars, negative control, no peptide) are side by side with 
the test (peptides added) SFC value (dark bars). DR1 presentation ELISpot assays using 
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FCS and human serum are shown in (C) and (D) respectively, in the same format as 
above. When the relevant background SFC values have been subtracted from each 
respective line SFC value, resulting values above 20 SFC per 100,000 PBMC 
(represented by dashed line) are defined as positive. This is applied to (A-D) to 
generate graphs shown in (E) and (F) for FCS and human serum respectively. 
Autologous presentation is shown side-by-side with DR1 presentation for comparison. 
Number of SFC for each well are background subtracted averaged over the number of 
repeats (mean with SD error bars, n = 2). 
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3.4.5 Distinguishing between Autologous and DR1 Presentation  
Having established growth conditions with AB serum, the next step was detailed 
comparison of autologous and DR1 presentation on polyclonal lines. Here, we would 
expect autologous presentation to show a vast spread of responses mediated by multiple 
HLAs, with a reduction in responses when using DR1 presenting cells. Those peptide 
pools that elicited a response in both systems would warrant further investigation.  
A key methodological consideration was the efficacy of washing. If DR1 presenting 
cells were inadequately washed after pulsing with peptide, then weakly or non-
specifically bound peptide would be present in the ELISpot well. These peptides, not 
specific to DR1, would be free to dissociate and stimulate responses through autologous 
presentation. In such circumstances, the DR1 ELISpot would mirror the results pattern 
seen with autologous presentation. A clear difference between the techniques was 
necessary to identify peptide pools harbouring DR1-restricted responses. 
 
Figure 3.6: Using a PBS based wash Technique gives a clearer distinction between 
autologous and DR1 presentation. (A-B): Lines to M1 peptide pools were expanded 
and cells from the same line were divided and tested for responses on ELISpot using 
both autologous presentation (black bars) and DR1 presentation (white bars). For the 
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assay shown in (A), following peptide pulsing DR1.APCs were washed using standard 
RPMI media. For the assay in (B), DR1.APCs were washed in PBS (mean with SD error 
bars, n = 2).  
 
The standard laboratory methodology for washing peptide-pulsed APCs in 
preparation for an ELISpot assay involves the use of RPMI media as wash buffer. Using 
RPMI, no consistent distinction was visible between the autologous and DR1 
presentation methods, with all pools showing responses above the 20 SFC cut off, 
defined as a positive result (Fig. 3.6A). Under stringent PBS washing, DR1 presentation 
gave consistently lower responses than autologous presentation, with fewer pools 
eliciting a positive DR1 response (Fig 3.6B).  This reduction in reactivity to each pool 
under DR1 presentation conditions was expected, given that not all peptides in each pool 
will be capable of binding to DR1, and from those that are, not all will constitute an 
epitope and elicit a response.  
The same technique was further tested using two DR1 restricted T-cell clones: one 
specific for a viral epitope (DCD10 and HA306-318 peptide) and the other for a cancer 
epitope (GD.D104 and 5T4xxx-xxx, peptide sequence not disclosed)214. This was a 
modification of the assay discussed in section 3.4.2 (Fig 3.3), in that wild type cells not 
expressing DR1 were pulsed alongside DR1.APCs, and the ability of each to activate 
their respective clones on ELISpot was measured (Fig 3.7).  
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Figure 3.7 Assessment of presentation to DR1 restricted T-Cell clones after 
peptide pulsing by 174.WT and 174.DR1 APCs under stringent PBS wash 
conditions. Two clones were used, DCD10 specific to HA306-318 and GD.D104 specific 
to 5T4xxx-xxx. APCs were pulsed with respective peptides at three concentrations as 
shown, with relevant negative controls (0 M). Each repeat (n=2) is displayed in the 
ELISpot plate image, with number of spots as counted by the software in the top left 
corner of the well grid. 
 
The PBS wash technique was able to reduce the IFN-γ response to wild type cells 
(DR1 negative cells) to nearly zero SFC, while maintaining DR1 restricted responses at 
10-4 M and 10-6 M.   
As an additional control, a DR1 negative donor was used to investigate how 
restrictive DR1 presentation was against a donor with no T-cell specificity to this HLA. In 
this case, autologous presentation yielded a normal response pattern against the M1 
pools, while DR1 presentation elicited no responses above 20 SFC (Fig. 3.8). This was 
seen as the strongest indication of the technique’s success in limiting responses to only 
those being presented by DR1, and preventing non-specific binding of peptide to pulsed 
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presenting cells. The assay was ready to be implemented in the larger screening of three 
proteins in two separate DR1+ donors. 
 
Figure 3.8 Comparison of autologous presentation and DR1 presentation in a DR1 
Negative donor. Lines to M1 peptide pools were expanded and cells from the same line 
were divided and tested for responses on ELISpot using both autologous presentation 
(black bars) and DR1 presentation (white bars) in a DR1 negative donor (mean with SD 
error bars, n = 2). 
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3.5 Discussion 
In this chapter, naked APCs were transduced with HLA-DR1 and demonstrated 
to efficiently present peptides to both CD4+ T-cell clones, and polyclonal lines derived 
from DR1+ donor PBMC. Methodological considerations such as culture serum and 
effective removal of non-specific peptide were taken into account to ensure that the 
protocol achieved the aim of identifying DR1-restricted responses. 
As this methodology was the basis for epitope mapping of the conserved 
influenza proteins, certain parameters related to DR1 presentation on ELISpot would 
impact both the nature of the epitopes identified, and those that were potentially 
overlooked. These parameters are evaluated in this section based on literature and 
experimental observations, with conclusions taken into consideration for coming 
experiments.  
3.5.1 Presentation of Peptide by DR1 in the Absence of HLA-DM 
As shown in Figure 3.1 the naked APC lines have a deletion that includes HLA-
DM in addition to other HLA genes. The role of HLA-DM (fully detailed in Chapter 1) is 
to catalyse the dissociation and binding of peptides to HLA class-II in the MIIC 
compartment of a cell. The outcome of its action is to favour presentation of high affinity 
peptides by HLA class-II, through the equilibrium-like conditions that allow the most 
kinetically stable pHLA conformations to predominate and be secreted to the cell 
surface164. Therefore, peptides with a low affinity for class-II are less likely to be 
presented if processed in the MIIC compartment, i.e. when entering the cell as whole 
protein.  
Yet, the addition of low affinity peptides as partially digested protein or as 
synthetic peptide fragments bypasses affinity-based selection. This is because short 
peptides or digested protein can be loaded onto class-II molecules in the recycling 
endosomal compartment162,163, where selection is not mediated by HLA-DM and is thus 
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permissive of weak and low affinity binders. This work was elegantly carried out by the 
Unanue group235,236.  
Thus, transduced APCs lacking HLA-DM have pHLA at their surface that 
predominantly contains CLIP (the invariant chain)135. Yet the addition of synthetic peptide 
at concentrations far in-excess of those found naturally, permits endocytosis and 
presentation through the recycling endosome compartment. Therefore, the absence of 
DM does not negatively impact peptide presentation on the T2.DR1 and 174.DR1 cells 
as displayed in the literature and experiments from this chapter. 
3.5.2 A More Diverse DR1 Peptide Repertoire? 
In the DR1.APC presentation system, the use of synthetic peptide (bypassing 
DM-mediated selection), and the abundance of low affinity CLIP-pHLA (for easy 
dissociation in the recycling endosome) may result in a more diverse DR1 peptide 
repertoire than under “natural” conditions. This is unavoidable when using synthetic 
peptide libraries and must be considered and addressed in later experiments.  
The main considerations are whether the resulting T-cell responses are directed 
to “real” epitopes that are processed and presented naturally, and whether response 
magnitudes are comparable in vivo. The observation of a strong response to peptide on 
IFN-γ ELISpot does not always correlate with, or is not directly attributable to, in vivo 
responses to whole protein or virus. A clear example of this is the presence of cross-
reactive T-cell memory populations to HIV epitopes in unexposed blood donors237,238. 
Such work confirms that cross-reactive memory populations are capable of mounting 
detectable responses to epitopes, against which they were not initially primed. 
To address this issue in subsequent chapters, the aim was to identify robust and 
reproducible responses shared between multiple donors. These criteria would decrease 
the probability of focusing on irrelevant responses that may not represent bona fide, 
processed epitopes. 
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3.5.3 Presence of A2 
When first described, 174 and T2 cells were shown to express low levels of the HLA 
class-I allele HLA-A2 at 20-50 % of wild type expression levels226. Although lower, this 
does not diminish the ability of these cells to present peptides that can bind HLA-A2 and 
elicit non-DR1 responses on ELISpot. Consequently, A2+ DR1+ donors were avoided in 
the peptide pool stage of the screening process, as the presence of A2 responses would 
confound results at this stage and incur off target responses. 
Yet, the very high prevalence of the HLA-A2 allele in European Caucasians means 
that the DR1+ A2+ genotype is common. Such donors were recruited at a later stage, 
upon completion of screening when individual epitopes were defined into shorter peptide 
sequences, and the likelihood of both a DR1 epitope and an A2 epitope within the same 
sequence was reduced. 
3.5.4 Future Work 
In this chapter, DR1 transduced APCs were able to isolate HLA-DR1 restricted 
CD4+ T-cell responses from polyclonal lines on IFN-γ ELISpot. This enabled early 
identification of peptides that contain a DR1-restricted epitope, and overcame the need 
for blocking antibodies or the use of matched and mismatched presenting cells. In this 
way, the process of screening large peptide libraries in subsequent chapters was 
simplified. Development of this method allowed advancement to more complex studies 
within the timeframe of the project.  
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4 Identification of HLA-DR1 Restricted Epitopes within 
the Internal Influenza Proteins 
4.1 Abstract 
The adaptive immune response to influenza-A is comprised of humoral and cell 
mediated immunity. Humoral effector immunity is directed at the external proteins 
haemagglutinin (HA) and neuraminidase (NA), while cell mediated immunity can 
additionally target the internal proteins. Relative to HA and NA these proteins are highly 
conserved, and individuals with strong CD8+ and CD4+ T-cell responses against them 
show reduced symptom severity and protection from pandemic strains. 
CD4+ T-cells recognise peptide fragments presented on HLA class II molecules 
through their TCR. Few CD4+ T-cell influenza epitopes have been characterised in the 
literature and even fewer for HLA-DR1. In order to study the CD4+ T cell response to the 
conserved internal proteins Matrix (M1), Nucleoprotein (NP) and Polymerase Basic-1 
(PB-1) in detail, peptide libraries of these three proteins were analysed using DR1.APCs 
on IFN-γ ELISpot using pooling matrices in two DR1+ donors. 20-30 amino acid regions 
associated with immunogenicity were identified, and the amino acid sequence of these 
regions analysed using an HLA binding algorithm to find the likely core sequence of the 
epitope. 
Based on binding algorithm predictions, shorter peptides were tested for 
immunogenicity in four DR1+ donors. Crystal structures of two of these epitopes were 
generated and analysed in order to confirm the predicted anchor residues and gain 
insight into potential TCR contact residues. The epitopes that showed strong and 
consistent responses were taken forward in later chapters for further analysis using HLA-
multimer staining and clonotypic dissection.  
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4.2 Introduction 
Historically, the immunology of influenza has centred on the challenge of 
generating effective vaccination strategies and understanding the serological responses 
that ultimately prevent infection. This has led to a focus on the properties of antigenic 
shift and drift in the surface proteins haemagglutinin (HA) and neuraminidase (NA), which 
enable the virus to evade pre-existing antibody responses. The epidemiology associated 
with these proteins has been highly studied and much is known about the immunogenic 
regions and the protective nature of responses to them239–241. 
However, research into the cell mediated response is not limited to solvent 
exposed conformational epitopes on the virion surface. Instead, the ability of a T-cell to 
recognise short linear sequences derived from any of the viral proteins means that 
responses to the internal elements could have an equal importance. These elements are 
protected from antibody based selection pressure, and are central to viral structure and 
replicative function. When amino acid sequences of the eight viral proteins from different 
strains and subtypes are aligned, the internal elements show very high levels of 
conservation relative to HA and NA200,242.  
Having established that cell mediated immunity can respond to all viral proteins, 
recent studies have shown that a large percentage of T-cell responses are directed 
towards these elements234,242,243 in different challenge platforms and disease settings. 
Some of the major finds have shown that the magnitude of pre-existing responses to 
Matrix-1 (M1) and Nucleoprotein (NP) confer protection from severe disease when the 
antibody repertoire has been breached i.e. in seronegative patients48,213. Polymerase 
Basic-1 (PB1) has also be identified as an important and highly conserved target of 
immune responses, although with less immunogenicity than M1 and NP213,233,234.  
The exact role of these responses, whether they are truly protective or not, is still 
the subject of debate, with studies suggesting they are markers of severe infection68 and 
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others suggesting they inhibit seroconversion or the formation of a novel antibody 
response during infection with an unseen strain242,244. 
 
 
Figure 4.1 Schematic showing the structural representations of three internal 
influenza proteins. Matrix (1EA3245), Nucleoprotein (2Q06184) and Polymerase Basic 1 
(4WSB190). Data on the number of molecules per virion246. 
  
MSLLTEVETYVLSIVPSGPL
VLSIVPSGPLKAEIAQRLED
KAEIAQRLEDVFAGKNTDLE
VFAGKNTDLEVLMEWLKTRP
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ILSPLTKGILGFVFTLTVPS
GFVFTLTVPSERGLQRRRFV
ERGLQRRRFVQNALNGNGDP
QNALNGNGDPNNMDKAVKLY
NNMDKAVKLYRKLKREITFH
MSLLTEVETYVLSIVPSGPLKAEIAQRLEDVFAGKNTDLEVLMEWLKTRPILSPLTKGILGFVFTLTVPSERGLQRRRFVQNALNGNGDPNNMDKAVKLYRKLKREITFH
Matrix (M1)
252 Amino Acids
3000 Molecules per virion
Nucleoprotein (NP)
498 Amino Acids
1000 Molecules per virion
Polymerase Basic-1 (PB1)
757 Amino Acids
30-60 Molecules per virion
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The common theme throughout the literature is that strong responses to these 
proteins exist, and that they are highly important in both protection and mediation of 
symptom severity. Although CD4 and CD8 T-cells are equally implicated, CD4+ T-cells 
play a more diverse and complex role in regulating the immune response. Through B-
cell interactions they facilitate generation of an effective antibody response, they help 
prime and direct CD8 T-cells to sites of infection, suppress inflammation and have 
potential cytotoxic and innate-like functions during the antiviral state64,101,247,248.  
CD8+ T-cell responses to influenza have been relatively well studied. For 
example, epitopes like B35-LPF and A2-GIL have been characterised using 
crystallography249, biophysical and clonotypic analysis250, as well as being applied as 
diagnostic markers222. However, because of the absence of available techniques and 
study platforms, CD4+ T-cell influenza responses have been less well characterised.  
The majority of data on CD4+ T-cell mediated immunity to influenza is limited to 
protein-specific responses213,242; only a few recent studies have performed detailed 
epitope characterisation233,251,252.This is a major challenge if we want to understand 
which epitopes confer protection in multiple people with the same HLA allele, and then 
elucidate the structural and biophysical mechanisms behind this. By understanding the 
relationship between an epitope’s sequence in the context of its host HLA, we can 
identify anchor and TCR contact residues that may be susceptible to mutation or 
potential therapeutic enhancement. 
As our understanding of key HLA class-II epitopes and CD4+ T-cell responses 
progresses, new vaccination strategies, insights into epidemiology, and specific 
diagnostic markers may follow. 
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4.3 Aims 
While the internal proteins of the influenza virus have been demonstrated as 
highly immunogenic for CD4+ T-cells, it is not known how many epitopes are present 
within these proteins that can generate robust and reproducible responses restricted to 
a single HLA allele. Furthermore, are these epitope-specific responses shared across 
the population in all individuals who possess the same HLA allele? 
In order to address these questions, the aims of this chapter were to screen the 
internal influenza proteins M1, NP and PB1 using DR1.APCs and PBMC from two HLA-
DR1+ donors on IFN-γ ELISpot. This would enable isolation of 20-30 amino acid 
immunogenic regions that contained DR1-restricted epitopes. These regions could be 
analysed using HLA-Binding algorithms in order to elucidate the binding registers which 
comprise the minimal epitopes.  
The epitope sequences could be confirmed by testing shorter peptides, 13-16 
amino acids in length, and X-ray crystallographic analysis of refolded pHLA proteins. 
Screening of short peptides against additional HLA-DR1+ donors would assess how 
common these epitope-specific responses are in the population and identify those 
epitopes which generated robust and reproducible immunogenicity. 
 
Specific aims: 
1) To screen peptide libraries of the internal influenza proteins Matrix-1 (M1), 
Nucleoprotein (NP) and Polymerase Basic-1 (PB1) using DR1.APCs in a 
pooling matrix format against PBMC from two HLA-DR1 donors. 
2) To isolate the individual 20-30 amino acid regions that elicited IFN-γ 
responses from the peptide pools. 
3) To analyse these regions using HLA-binding algorithms in order to elucidate 
the binding registers which comprise the minimal epitopes.  
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4) To test shorter peptides, 13-16 amino acids in length, in four HLA-DR1 donors 
to assess how common these responses were across the wider population. 
5) To crystallise short peptides in HLA-DR1 and analyse structural information 
to validate binding algorithm predictions and identify the residues that 
mediate TCR recognition.  
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4.4 Results 
4.4.1 Peptide Libraries and Pooling Matrix Design 
Synthetic peptide libraries of the three internal proteins, Matrix-1 (M1), 
Nucleoprotein (NP) and Polymerase Basic-1 (PB1) were obtained commercially. Each 
library consisted of peptides usually twenty amino acids in length with an overlap of ten 
amino acids to ensure full coverage. For each internal protein, a unique pooling matrix 
was arranged, where each peptide was only present in two distinct pools (Fig. 4.2). This 
arrangement allowed pool specific responses to be cross-referenced, and thus individual 
peptides common to immunogenic pools to be identified. In this way, large numbers of 
peptides could be analysed for immunogenicity in a reduced number of assays.  
Figure 4.2 Architecture of pooling matrices for M1, NP and PB-1. Pool number is in 
grey, while overlapping peptides are in white. Protein acronym is in the top left box of 
each matrix. 
M1 P-1 P-2 P-3 P-4 P-5
P-6 1 2 3 4 5
P-7 6 7 8 9 10
P-8 11 12 13 14 15
P-9 16 17 18 19 20
P-10 21 22 23 24
NP P-1 P-2 P-3 P-4 P-5 P-6 P-7
P-8 1 2 3 4 5 6 7
P-9 8 9 10 11 12 13 14
P-10 15 16 17 18 19 20 21
P-11 22 23 24 25 26 27 28
P-12 29 30 31 32 33 34 35
P-13 36 37 38 39
PB1 P-1 P-2 P-3 P-4 P-5 P-6 P-7 P-8 P-9
P-10 1 2 3 4 5 6 7 8 9
P-11 10 11 12 13 14 15 16 17 18
P-12 19 20 21 22 23 24 25 26 27
P-13 28 29 30 31 32 33 34 35 36
P-14 37 38 39 40 41 42 43 44 45
P-15 46 47 48 49 50 51 52 53 54
P-16 55 56 57 58 59 60 61 62 63
P-17 64 65 66 67 68 69 70 71 72
P-18 73 74
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4.4.2 Overview of Screens in two HLA-DR1+ Donors 
PBMC from two HLA-DR1+ donors were used to screen pooling matrices using 
the HLA-DR1 presentation and IFN-γ ELISpot methodology described in the previous 
chapter. The aim was identification of pool specific IFN-γ responses that were 
consistent across multiple replicates, and common to both donors. In this way, the 
likelihood of finding robust and reproducible responses in the wider HLA-DR1 population 
was increased. 
4.4.2.1 Matrix (M1) 
The M1 protein is documented as being highly immunogenic to both CD4+ and 
CD8+ T-cells213,233,242. For such an immunogenic protein, it was likely that multiple, 
potentially overlapping epitopes (presented by different HLAs) were concentrated across 
the peptide sequence. This was observed in the cumulative response pattern to peptide 
pools (Fig 4.3A) and in individual assays where eight out of ten pools showed some level 
of immunogenicity (Fig 4.3B). 
Pool-2 elicited a positive response from both donors in every assay, while pool-
3, pool-4, pool-8 and pool-10 showed responses present in both donors in at least one 
assay each. Weaker and inconsistent responses were observed to other pools. These 
may have been a result of assay variation, or responses private to only one donor.  
Five pools indicated were taken forward for further analysis, with cross 
referencing of these pools isolating six peptides to be investigated individually (Fig 4.3C) 
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Figure 4.3 Summary of assays on M1 peptide pools. 
(A) Each pool specific SFC result is normalised by dividing by the total number of SFC 
across all peptide pools in that particular assay to give a percentage value. Percentage 
vales are stacked for each pool to give a cumulative representation of the responses 
across multiple assays in two donors. (B) Representation of each assay, with the 
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response to a pool filled in green if the SFC number was a positive result (greater than 
20 SFC per 100,000 PBMC). Arrows indicate the pools taken forward for further analysis. 
(C) Cross-referencing of positive pools indicating the peptides to be investigated 
individually (underlined in orange boxes). 
 
4.4.2.2 Nucleoprotein 
Like M1, the influenza nucleoprotein is highly immunogenic and multiple epitopes 
were likely present across the 402 amino acid sequence analysed. The response pattern 
to the thirteen peptide-pools showed a large degree of replicate variation (Fig 4.4). This 
inconsistency is exemplified across five separate assays, where 12 of 13 pools were able 
to elicit a response greater than 20 SFC in at least one replicate (Fig 4.4B).  
Amidst this large degree of assay variation, consistent and common responses 
were present. Pool-11, pool-7 and pool-5 were seen in both donors and generated the 
highest cumulative responses (Fig.4.4A). Shared responses were observed to pool-3, 
pool-4 and pool-13, these were positive in three of five assays. Pool-10 exhibited a large 
response in the cumulative analysis, yet this was largely attributed to a single assay, and 
neither donor saw this pool more than once, so it was not taken forward (Fig 4.4C). 
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Figure 4.4 Summary of assays on NP peptide pools. Format and presentation is the 
same as in Fig 4.3. (A) Cumulative normalised analysis of all responses. (B) 
Representation of pools that elicited a positive result in each assay. (C) Cross-
referencing of pooling matrix. 
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4.4.2.3 Polymerase Basic-1 (PB1) 
PB1 is the largest of the three proteins analysed, the least abundant in the virion 
and the least immunogenic. Consequently, for a given length of sequence fewer epitopes 
were expected relative to M1 and NP. This was observed as a much clearer response 
pattern with fewer transient and inconsistent responses, despite a larger number of 
peptides in each pool. 
 Cumulative analysis highlighted six immunogenic pools, with minimal reactivity 
towards others (Fig 4.5A). Examination of individual assay results (Fig 4.5B) revealed 
that these highlighted responses were not common to each donor, with only pool-2, pool-
5 and pool-13 shared. Pool-7 and pool-14 showing strong and consistent responses in 
a single donor. Pool-12 appeared large in cumulative analysis but was dominated by a 
single assay and was therefore discounted. 
Pool-2, pool-5 and pool-13 fitted the criteria for further investigation, while pool-7 
and pool-14 did not, yet were highly consistent in their respective responders. Given the 
lower overall immunogenicity and small number of peptides to be investigated for this 
protein, these pools were taken forward in the hope that any epitopes found may be of 
interest in later studies with additional donors. 
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Figure 4.5 Summary of assays on PB-1 peptide pools. Format and presentation is 
the same as in Fig 4.3. Arrows indicate the pools taken forward for further analysis. Blue 
arrows indicate the pools which were clearly positive in both donors. Orange arrows 
indicate pools positive for only one donor.  
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4.4.3 Identification of Immunogenic Peptides 
In order to identify individual peptides, the pool matrices were cross-referenced 
based on the responses determined in the previous section. Individual peptides were 
tested by re-stimulation of a line expanded against the relevant parent pool. Each line 
was confirmed as responsive to the expansion pool, before it was restimulated with the 
relevant individual peptide. This method ensured that potential intra-pool interactions 
during the expansion phase, for example competition for HLA binding between pool 
constituents, were maintained; and testing was not performed on cultures that were 
biased to produce one response to a single peptide. 
In addition, peptides not identified as immunogenic by the pooling matrices, 
were included in each set of assays. These control peptides and standard negative 
controls (no peptide) ensured responses were specific, and not the result of an over-
stimulated culture, in which non- or partially-specific responses to all peptides are 
observed (often with high background levels relative to other lines). All IFN-γ ELISpot 
assays were performed with HLA-DR1 APCs. 
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Figure 4.6 Individual peptide analyses of regions identified from pool assays on 
HLA-DR1 IFN-γ ELISpot. (A) Matrix-1, (B) Nucleoprotein, (C) Polymerase Basic-1.  
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Figure 4.6 Individual peptide analyses of regions identified from pool assays on 
HLA-DR1 IFN-γ ELISpot. (A) Matrix-1, (B) Nucleoprotein, (C) Polymerase Basic-1.  
For each assay, a line cultured against a parent pool, and shown to be reactive to that 
pool on IFN-γ ELISpot, was then retested with specific individual peptides from that pool. 
Due to limited numbers of PBMC and a broad range of testing that occurred, not all 
peptides were tested equal numbers of times in each donor (mean with SD error bars, 
donor 1: n = 2, donor-2: n = 3). 
 
4.4.3.1 Matrix (M1) 
Testing of peptides identified through cross-referencing of M1 pools revealed 
peptide-22, and the overlapping peptide-13 and peptide-14 to elicit responses in both 
donors (Fig 4.6A). These individual peptides accounted for the observed reactivity of the 
M1 pools. 
Although the inclusion of negative control peptides ensured that responses were 
not aberrant occurrences, these peptides resulted in the discovery of responses not 
explicitly observed in the pooling data. For example, for pool-2: peptide-12 and peptide-
22 were specifically tested, with either peptide-7 or peptide-2 included as a negative 
control. Here peptide-2 gave a positive and repeatable response in donor-2. As this was 
used as one of multiple of negative control peptides, it was not extensively tested in 
donor-1 (the overlapping peptide-3 was), so responses in this donor were not observed. 
Analysis of the immune epitope database (IEDB) revealed an HLA-DR1 epitope 
within peptide-2 (and partially in its overlapping partner peptide-3), which had been highly 
characterised in early influenza literature253, and may have been the potential mediator 
of this response. It was therefore carried forward under the assumption it may be 
generating a consistent sub-dominant or private response, which could be of interest in 
later investigations. 
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4.4.3.2 Nucleoprotein (NP) 
Testing of individual nucleoprotein peptides revealed the overlapping peptide-38 
and peptide-39 to elicit the strongest responses in both donors (Fig 4.6B). Peptide-28 
elicited consistent but weaker responses. The overlapping peptide-24 and peptide-25 
had very weak responses close to the significance cut off, with values of 10-20 SFC seen 
in multiple repeats in both donors. This region was taken forward for further analysis, but 
it was likely to contain a subdominant epitope with weak reactivity. 
These identified peptides did not fully account for the observed responses to the 
NP pools (Fig 4.4); as pool-5 was consistently recognised in both donors, yet testing of 
peptide-5 (negative control) and peptide-26 revealed no responses. This suggested the 
pool contained immunogenic peptides that were not flagged-up by a relevant cross-
referencing pool, or that responses were missed through insufficient testing during the 
individual assays. This pool was later investigated using binding algorithms in section 
4.4.4 in order to elucidate the peptide to which the consistent responses could have been 
directed. 
4.4.3.3 Polymerase Basic-1 (PB1) 
Three peptides were shown to be immunogenic from PB1 (Fig 4.6C), of which 
peptide-34 gave consistent and positive responses in each donor. Peptide-41 showed 
strong reactivity in donor-2 but was slightly below the significance level in donor-1. A 
similar trend was observed for peptide-29. These three peptides appeared to account for 
the pattern of pool reactivity, especially for peptide-41/pool-14 where the responses are 
predominantly through donor-2 (Fig 4.5B). Although this may be a private response, the 
consistency and lack of other immunogenic peptides meant that it was taken forward for 
sequence analysis and testing in multiple HLA-DR1+ donors. 
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4.4.3.4 Summary of Identified Regions 
 
Table 4.1 Summary of identified regions found by pools and individual analysis. 
Parent protein, corresponding peptide numbers, amino acid sequence and the position 
of those residues within the whole protein are listed. 
 
  
M1 2 VLSIVPSGPLKAEIAQRLED 11-30
3 KAEIAQRLEDVFAGKNTDLE 21-40
Combined VLSIVPSGPLKAEIAQRLEDVFAGKNTDLE 11-40
M1 13 AGALASCMGLIYNRMGAVTT 121-140
14 IYNRMGAVTTEVAFGLVCAT 131-150
Combined AGALASCMGLIYNRMGAVTTEVAFGLVCAT 121-150
M1 22 QMVQAMRTIGTHPSSSAGLK 210-230
NP 28 GIDPFRLLQNSQVFSLIRPN 271-290
NP 38 RASAGQISVQPTFSVQRNLPFER 371-393
39 QPTFSVQRNLPFERATIMAAFTG 379-402
Combined RASAGQISVQPTFSVQRNLPFERATIMAAFTG 371-402
NP 24 ARSALILRGSVAHKSCLPAC 231-250
25 VAHKSCLPACVYGLAVASGY 241-260
Combined ARSALILRGSVAHKSCLPACVYGLAVASGY 221-260
PB1 29 NVVRKMMTNSQDTELSFTIT 284-203
PB1 34 NVLSIAPIMFSNKMARLGKG 335-354
PB1 41 PGMMMGMFNMLSTVLGVSIL 405-424
PeptideProtein
Sequence 
Position
Peptide 
Number
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4.4.4 Defining Epitopes within Long Sequences 
Immunogenic regions 32 to 20 amino acids in length from each of the three 
proteins were identified following the screening process (Table 4.1). The observed 
immunogenicity could have arisen from single or multiple epitopes within these 
sequences, presented by HLA-DR1 independent of proteolytic cleavage. Each long 
peptide will theoretically be able to adopt multiple binding registers when presented in 
the open-ended HLA class II groove. Within a peptide, the binding register or “core” is 
defined by the P1, P4, P6 and P9 residues which anchor into the HLA binding pockets. 
Each binding register represents an epitope with the potential to stimulate a distinct T-
cell population (for more see introduction section on class II processing and 
presentation). 
The challenge of decoding which of multiple potential registers or “cores” result 
in the observed immunogenicity is the reason why many studies define long sequences 
but do not progress further243,252. Those that do progress require “chop-down” or sub 
libraries of shorter peptides combined with further immuno- or binding-assays to provide 
conclusive information233. These methods are comprehensive but time consuming, and 
produce the clearest result when using a single T-cell clone instead of a polyclonal line. 
It is also unclear how informative using reduced length peptides are when 
screening the HLA-Class II system. Residues beyond the core, i.e. flanking regions, may 
have a stabilising effect254, with the optimal peptide length for a T-cell assay suggested 
as 18-20 amino acids255. Shorter peptides may activate cognate T-cells less efficiently, 
due to weaker HLA binding or a greater disposition to proteolytic cleavage of the core 
nonamer. Experimentally distinguishing between an important flanking residue and an 
anchor residue may be inconclusive depending on the sequence in question.  
Based on these limitations and the timeframe of the PhD project, obtaining chop-
down libraries and T-cell clones for nine distinct peptide sequences in two donors was 
not feasible. Instead, an alternative strategy was undertaken. 
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4.4.4.1 Using HLA-Binding to Identify Epitopes 
There are many factors which influence immunodominance, or the magnitude of 
a response to an epitope, such as processing256, antigen abundance257 and the stability 
of the pHLA complex258. Work in  cancer has demonstrated that epitopes which exhibit 
strong HLA binding generally elicit stronger cognate T-cell responses than epitopes 
which bind weakly259. In vivo, when antigen processing and presentation occurs via the 
MIIC compartment in the presence of HLA-DM, the natural processing machinery exerts 
a selection preference for epitopes that form the most stable pHLA class II 
complexes141,260. Although this high affinity selection process is bypassed when using 
molar excess of synthetic peptide, it will have been undoubtedly relevant during priming 
of cognate memory populations that have been restimulated and identified in this study. 
Thus, the working hypothesis was that within the regions identified, the 
immunogenic epitopes are comprised of registers that bind HLA-DR1 with highest 
affinity. The binding strength of different registers within a region could be estimated 
using prediction algorithms, and the preferred registers tested using peptides between 
13-14 amino acids in length.  
 
4.4.4.2 Outputs of Binding Data 
HLA class-II crystal structures and information on eluted peptides using mass 
spectrometry have provided a wealth of data on the amino acid sequences capable of 
binding to specific HLA proteins and the characteristics of peptide anchor residues and 
HLA binding pockets. This information forms the basis of HLA binding algorithms, which 
predict the affinity of each potential binding register in a given sequence based on the 
physical characteristics of each amino acid. 
The algorithm used here was NetPanMHCII 3.1261–264. The 32-20 amino acid 
sequences were processed, and predictions analysed. The algorithm outputs a 
sequence of specified length (e.g. 13-mer peptides), identifies the 9-amino acid binding 
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“core” and gives a predicted affinity. The results are ranked in order of strongest to 
weakest binders, and each core is displayed only once, in the most favoured register 
position (Fig 4.7A). 
A key factor of the program is that it takes into account flanking sequences and 
chemical properties beyond the core into the overall affinity prediction. Therefore, when 
comparing a specific core within different output lengths (e.g. 11-mers and 15-mers), the 
size and amino acid composition of the flanking region will change. The resulting affinity 
differences may impact the ranking order of potential cores within a given input sequence 
(Fig 4.7B).  
Generally, the ranking order of potential cores is independent of output length, 
but this can still affect a number of examples (see following section). Taking this into 
consideration, summarised outputs (Table 4.2) were derived from the consensus 
predictions of all possible binding 11-mers, 13-mers and 15-mers. This ensured binding 
registers were not estimated from only the anchor residues within each core, but included 
potential flanking contributions as well. 
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Figure 4.7A Example of the output of NetPanMHCII 3.1. Two overlapping peptides 
were identified from the previous section. The algorithm processes the sequence by 
analysis of all possible 13-mer binding registers with respect to HLA-DR1 (DRB1*0101).  
Registers are ranked based on predicted binding affinity (nM) strongest to weakest. The 
top sequences capable of binding are displayed. For each possible binding register the 
“core” 9 amino acids defined by peptide anchor residues at P1, P4, P6 and P9 is shown. 
The output is set so that each core is displayed once (see materials and methods). 
  
AGALASCMGLIYNRMGAVTTEVAFGLVCAT
IYNRMGAVTTEVAFGLVCAT
AGALASCMGLIYNRMGAVTT
M1 Peptide-14
M1 Peptide-13
Overlapping Peptides Identified in Screens
Sequence Processed By Algorithm
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Figure 4.7B Example with M1 peptide-2 and peptide-3 of how the output length can 
impact the predicted binding affinities and hence ranking of each potential core 
within a sequence.   
The same M1 sequence (VLSIVPSGPLKAEIAQRLEDVFAGKNTDLE) was processed 
based on three different output lengths: 11-mer, 13-mer and 15-mer. The resulting top 
binding cores and predicted affinities of the housing register are shown. The relative 
ranking position of each core with respect to one another changes. There is no overall 
top ranked consensus across three output lengths, so in this example two cores 
(LSIVPSGPL and LKAEIAQRL) must be taken for further investigation.
Output length Can Impact Predicted Affinities
Output Length = 11 Amino Acids
Output Length = 13 Amino Acids
Output Length = 15 Amino Acids
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Core-1 Core-2
M1 2 VLSIVPSGPLKAEIAQRLED 11-30 LSIVPSGPL LKAEIAQRL
3 KAEIAQRLEDVFAGKNTDLE 21-40 LKAEIAQRL N/A
Combined VLSIVPSGPLKAEIAQRLEDVFAGKNTDLE 11-40 LSIVPSGPL LKAEIAQRL
M1 13 AGALASCMGLIYNRMGAVTT 121-140 YNRMGAVTT LIYNRMGAV
14 IYNRMGAVTTEVAFGLVCAT 131-150 YNRMGAVTT LIYNRMGAV
Combined AGALASCMGLIYNRMGAVTTEVAFGLVCAT 121-150 YNRMGAVTT LIYNRMGAV
M1 22 QMVQAMRTIGTHPSSSAGLK 210-230 VQAMRTIGT MRTIGTHPS
NP 28 GIDPFRLLQNSQVFSLIRPN 271-290 FRLLQNSQV N/A
NP 38 RASAGQISVQPTFSVQRNLPFER 371-393 FSVQRNLPF N/A
39 QPTFSVQRNLPFERATIMAAFTG 379-402 FERATIMAA FSVQRNLPF
Combined RASAGQISVQPTFSVQRNLPFERATIMAAFTG 371-402 FERATIMAA FSVQRNLPF
NP 24 ARSALILRGSVAHKSCLPAC 231-250 LRGSVAHKS ALILRGSVA
25 VAHKSCLPACVYGLAVASGY 241-260 YGLAVASGY CVYGLAVAS
Combined ARSALILRGSVAHKSCLPACVYGLAVASGY 221-260
PB1 29 NVVRKMMTNSQDTELSFTIT 284-203 VRKMMTNSQ N/A
PB1 34 NVLSIAPIMFSNKMARLGKG 335-354 MFSNKMARL VLSIAPIMF
PB1 41 PGMMMGMFNMLSTVLGVSIL 405-424 FNMLSTVLG N/A
IMFSNKMARLGKG
GMFNMLSTVLGVS
PeptideProtein
DPFRLLQNSQVFS
LPFERATIMAAFT
PTFSVQRNLPFER
No Consensus
NVVRKMMTNSQDT
Sequence 
Position
NetMHCIIPan 3.1 Prediction Reduced Length Peptide 
for Testing
SGPLKAEIAQRLED*
GLIYNRMGAVTTEV**
Peptide 
Number
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Table 4.2 Summary of immunogenic regions and the corresponding binding 
predictions by NetPanMHCII 3.1. The reduced length peptides chosen for further 
testing are based on the predictions and are displayed in the final column. Single amino 
acids highlighted in red, are those missing from one of the two parent peptide sequences 
while the remaining residues are present in both (8 of 9 residues found in both parent 
peptides, red is the one missing). 
*The predicted core in this region agreed with a 14-amino acid sequence 
SGPLKAEIAQRLED detailed in published work253. **The predicted core of the 14-amino 
acid sequence of GLIYNRMGAVTTEV agreed with published work finding this to be an 
HLA-DR1 epitope233. 
4.4.4.3 Analysis of Binding Predictions 
For certain immunogenic regions, the top predicted cores were unanimous and 
gave estimated binding affinities less than 20 nM (for simplicity all affinities are based on 
13-mer predictions), suggesting strong binding to HLA-DR1. The strongest predicted 
binders were in the NP peptide-28 (core: FRLLQNSQV, 5 nM) and M1 peptide-13/14 
(core: YNRMGAVTT, 7 nM) and PB1 peptide-41 (core: FNMLSTVLG, 10 nM). These 
three regions had an aromatic residue at position P1, known to favour binding in that 
pocket265, and hydrophobic residues at P4. The anchor residues at P6 and P9 were 
uncharged but varied in size and polarity. 
The M1 peptide-22 (core: VQAMRTIGT, 17 nM) also showed a single core with 
predicted binding highly favoured over other cores in the same sequence. Instead of an 
aromatic at P1 a bulky aliphatic residue, valine, was present. Replicating motifs in the 
strong binders detailed above, the residue at P4 was methionine, with P6 and P9 both 
threonine.  
Within this analysis a number of complex, overlapping regions of potential 
immunogenicity were observed. For M1 peptide-2/3 three different cores of similar affinity 
were predicted (LSIVPSGPL, 37 nM; IVPSGPLKA 54 nM; LKAEIAQRL, 61 nM), each 
with an aliphatic leucine or isoleucine at the first anchor position. In this case, only one 
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core (LKAEIAQRL) displayed any relative overlap. The other cores did not overlap with 
peptide-3 by more than three residues. 
LKAEIAQRL was complete in peptide-2, but contained 8 amino acids in peptide-
3, missing only the first anchor. Loss of the first anchor has been shown in other studies 
to maintain some level of response to an otherwise complete peptide233, and may have 
explained the consistent but weak responses to peptide-3.  
Examination of the IEDB and early literature showed the sequence containing 
this core (LKAEIAQRL) to have been characterised as a HLA-DR1 epitope253. The 
sequence defined in the literature was selected for further investigations 
(SGPLKAEIAQRLED). The absence of this information would have necessitated full 
investigation of each core, exemplifying the challenge certain immunogenic regions may 
pose. 
NP peptide-38 and peptide-39 were the final two components of the NP peptide 
library and as a result were longer, at 23 amino acids each, in order to accommodate the 
full c-terminal sequence of the protein. They overlapped by 14 amino acids, and within 
this overlapping region a core (FSVQRNLPF) was predicted at 49 nM affinity. Yet 
peptide-39 contained a non-overlapping core with an affinity of 28 nM (FERATIMAA). 
Both predictions contained the aromatic phenylalanine as the P1 first anchor.  
As a result, reduced peptides corresponding to each core were chosen for 
testing. It was hoped that a strongly dominant epitope would be characterised, given the 
magnitude of responses observed to these two peptides and their parent pools. 
A similar strategy was applied to PB1 peptide-34 where two cores (MFSNKMARL 
and VLSIAPIMF) of similar affinity (44 nM) were observed and two corresponding 
reduced 13-mer peptides chosen for further analysis. Neither core appeared overly 
favourable, with a methionine or a valine at the first anchor then proline or methionine at 
position 6. 
The most difficult analysis occurred with the overlapping NP peptide-24 and 
peptide-25. These peptides gave responses close to, or below the significance cut off in 
individual assays (Fig 4.6C), and were carried forward to look for any obvious binding 
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register. Four binding cores, three of similar affinity (22-29 nM) and one weaker (78 nM) 
were present, none of which fully overlapped both peptides, and each showing variation 
depending on output length. This complexity, coupled with the relatively weak SFC 
numbers observed during screens meant that this region was not investigated further. 
From these predictions, peptides 13-14 amino acids in length were obtained at 
high synthetic purity (>90 %). A slightly longer sequence containing the core 
VQAMRTIGT was ordered (Table 4.3) to include 5 amino acids at the N-terminus 
(instead of 2-3) permitting crystallographic investigation of the N-terminal flanking region. 
The reduced sequences of M1 peptide-2 and peptide-13/14, contained 3 amino acids to 
conform with sequences used in literature studies. 
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4.4.5 Confirmation of Epitope Immunogenicity 
Nine peptides of reduced length were taken forward for testing (Table 4.3). These 
peptides were ordered commercially at 90 % purity (HPLC) in order to reduce the risk of 
impurities and unwanted chemical modifications shown to impact immunogenicity266. 
Testing was expanded to include two additional HLA-DR1+ donors, and was performed 
on lines cultured against a single peptide only. 
Reduced peptides showed a 
specific pattern of immunogenicity 
when compared across four donors 
(Fig 4.8). The peptides GLI and QAR 
gave strong and consistent responses 
in each individual and assay. SGP, 
GMF and DPF showed a reduced 
response strength in terms of relative 
SFC but were recognised in three of 
the four donors. These five peptides 
were carried forward for further 
analysis. 
The remaining peptides LPF, NVV, PTF and IMF elicited minimal responses 
below the significance level when tested (Fig 4.8B). IMF represented one of two 
predicted cores in PB1 peptide-34; this elicited no detectable responses in two donors, 
despite positive responses to the parent 20-mer in the side-by-side assays. 
  
Protein Short Peptide Sequence Position
M1 SGPLKAEIAQRLED 17-30
GLIYNRMGAVTTEV 129-142
QARQMVQAMRTIGTHP 208-222
NP DPFRLLQNSQVFS 273-285
LPFERATIMAAFT 388-401
PTFSVQRNLPFER 380-392
PB-1 NVVRKMMTNSQDT 284-297
IMFSNKMARLGKG 342-354
GMFNMLSTVLGVS 410-422
Table 4.3 Short peptides for further testing. 
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Figure 4.8. Summary analysis of IFN-γ DR1 ELISpot testing on lines cultured with 
short peptides across 4 HLA-DR1+ donors. (A) Cumulative analysis on normalised 
SFC, where each response was dividing by the total number of SFC across all peptide 
tested in that particular assay to give a percentage value. Percentage vales are 
stacked to give a cumulative representation of the responses across multiple assays in 
four donors.  
(B) Representation of each assay, with the response to a specific peptide filled in green 
if the SFC number was a positive result (greater than 20 SFC per 100,000 PBMC). Boxes 
are orange if a response was borderline (of two replicates one was just above the 
significance level and one was just below but the mean was below 20 SFC). White 
indicates no response. Dark grey indicates not tested. 
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Follow-up experiments, revision of data and analysis of the literature shed light 
on why some of these peptides failed to replicate the reactivity seen to their parent 
peptide. Misidentification of the core was only specific to one example, other possible 
reasons related to the HLA-DR1 presentation methodology and precursor frequencies in 
the sample blood. For case-by-case explanation of why some peptides may have failed 
to elicit responses, see discussion section 4.5.4.  
These results identify some of the epitopes that may be providing protection from 
Influenza in the HLA-DR1+ population. Later assays using a larger starting number of 
PBMC would overcome some methodological issues such as precursor frequency and 
begin to explore the prevalence and genetic make-up of these responses across the 
population.  
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4.4.6 Confirming Algorithm Predictions Using Crystal Structures 
To confirm that the chosen sequences bound to HLA-DR1 as predicted by the 
binding algorithms in the previous section, several reduced length peptides were refolded 
to produce class-II monomer for crystallisation. Crystal trays were set up using the TOPS 
screen215, an array of HEPES and Tris buffered conditions optimised for crystallisation 
of HLA-class I protein.  
Crystals were obtained for QAR and SGP from concentrations of 8.00 mg/ml and 
8.23 mg/ml respectively (Fig. 4.9). QAR crystals from condition A11 diffracted to 1.64 -
1.70 Å resolution and SGP from condition F9 to 2.66 – 3.96 Å. The data sets of highest 
resolution were solved to generate structures (Table 4.4) that were used to explore the 
orientation and features of each peptide within the class-II binding groove. 
These proteins were of interest, as neither had a typical aromatic anchor at the 
P1 position in the first HLA binding pocket, being leucine for SGP and valine for QAR. 
Structural analysis would be able to identify if these were the true anchors, and ensure 
that the peptide was not forming disordered conformations or unpredicted interactions 
with the HLA. Of the other reduced peptides which were refolded only GLI and DPF 
produced crystals which diffracted to < 4 Å, but these failed to produce data sets that 
could be solved to any satisfactory level. 
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Figure 4.9. Images and details of the successful crystallisation conditions for (A) 
SGP and (B) QAR. TOPS-F9 and A11 correspond to positions on the 96 well screen, 
with exact contents detailed below. White scale bar corresponds to 200 μm. 
 
Table 4.4. Crystallographic Data Table. SGP details in the left column and QAR in the 
right. 
  
SGP QAR
Resolution 2.66 1.64
Completeness 98.9% 99.8%
Space Group P 1 21 1 P 21 21 2
R Value 0.200 0.197
Free R Value 0.261 0.238
Free R Value Test Set Size 4.8% 5.0%
Free R Value Test Set Count 1267 2819
Mean B Value 42.95 39.43
Number of Reflections 25022 54085
RMS Deviations From Ideal Values
Bond Lengths 0.016 0.018
Bond Angles 2.220 1.997
TOPS-A11
0.1 M Sodium Cacodylate
pH 6.0
0.2 M Ammonium Sulphate, 
20 % PEG 8000
TOPS-F9
0.1 M Tris
pH 7.5 
0.2 M Ammonium Sulphate, 
25 % PEG 4000
QARQMVQAMRTIGTHP
8.00 mg / ml
SGPLKAEIAQRLED
8.23 mg / ml B A 
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4.4.6.1 Peptide Anchor Residues 
The features of the peptide which facilitate binding and p-HLA complex stability 
are the backbone (main chain) contacts and four buried residues that sit in binding 
pockets that “anchor” into the HLA. Polar contacts between the backbone and side 
chains of the binding groove hold the main chain in highly rigid conformation as observed 
by B-Factor analysis (Fig. 4.10) that is a consistent feature of class-II structures127,267. 
Anchors agreed with the predicted cores assigned in section 4.4.4 by net pan 
MHC II. The first binding pocket of HLA-DR1 is highly hydrophobic and accommodates 
large aliphatic or aromatic residues. This was occupied by leucine and valine for SGP 
and QAR respectively, each residue had a low B-factor (dark blue Fig. 4.10) and was 
buried deep within the HLA (Fig. 4.11).  
The P4 residues occupying the second binding pocket had greater B-factors (Fig. 
4.10) and were not buried as deeply within the HLA (Fig. 4.11C, 4.11G). This pocket has 
been shown to bind acidic side chains in other crystal structures267. The acidic side chain 
P4Glu of SGP formed polar contacts with DR1βGln70 and DR1βArg71 (Fig. 4.12A), 
while QAR-P4Met, a large hydrophobic residue was buried closer to the hydrophobic 
surface of the pocket (coloured orange Fig. 4.11G) and formed no polar contacts (Fig. 
4.12B). 
At P6 the situation was reversed, with SGP-P6Ala forming no polar contacts (Fig. 
4.12A), and QAR-P6Thr forming polar contacts with DR1αAsp66 and DR1αAsn62 (Fig. 
4.12B). The P9 pocket is hydrophobic with SGP-P9Leu deeply buried (Fig. 4.12A), but 
the comparatively smaller polar QAR-P9Thr-OH forming a polar contact with 
DR1αAsn69 at the pocket entrance, with QAR-P9Thr-CH3 buried towards the 
hydrophobic pocket (Fig. 4.12B). 
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Figure 4.10. B-factor and electron density representation of each peptide at 0.3 
sigma. (A) SGP peptide shown at 2.66Å. (B) QAR shown at 1.66Å. Anchor residues are 
underlined. B-factor colouring spectrum represents lowest B-factors in dark blue, and 
increasingly high B-factors as lighter blue, green, yellow, orange and red. This represents 
the degree of order based on elastic scattering.  
S  G  P  L K  A  E I  A Q  R  L E  D
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Figure 4.11. Identification of peptide anchor residues and orientation within the 
binding pockets. Binding grooves of (A) SGP and (E) QAR, with HLA surface in green 
and peptide sticks coloured by B-factor. Each binding pocket and corresponding anchor 
residue is circled white. To better show the binding pockets for P1, P4 and P9 they are 
shown below each groove picture (SGP – B, C, D and QAR- F, G, H), both peptide and 
HLA are coloured by element (carbon orange, nitrogen blue, oxygen red, sulphur yellow). 
This displays the likely hydrophobic interactions (orange) as well as potential polar or 
charged contacts (red/blue).  
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Figure 4.12. Polar interactions between the peptide and side chains of the binding 
groove. The HLA groove is displayed by secondary structure representation for (A) SGP 
and (B) QAR, with side chains shown. α-chain in green, β-chain in blue. Peptide is 
displayed in stick format with a black carbon backbone. Side chain and backbone sticks 
are coloured by element (carbon orange, nitrogen blue, oxygen red, sulphur yellow). 
Polar interactions between peptide backbone and side chain with HLA grove side chains 
are represented by black dashed lines.  
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4.4.6.2 Defining the Epitope: TCR contact residues? 
The literature definitions of an HLA class-II epitope are very broad, with any 
length of peptide capable of stimulating a CD4+ T-cell response defined as an epitope. 
At the molecular level, solvent exposed amino acids at, or close to, the conventional 
docking site of the TCR could help define what the T-cell “sees” and hence, the epitope.  
For HLA-DR1 these TCR contact residues are P2, P3, P5, P7 and P8 but may 
include N- and C-terminal flanking residues beyond the core, specifically P-1 as detailed 
in several complex structures167,219. The orientation of these contact residues was 
analysed for both QAR and SGP (Fig. 4.13). Inside the core (P1-P9), residues SGP-
P2Lys, SGP-P8Arg and QAR-P5Arg are charged and thus capable of forming salt 
bridges with incoming TCR chains. Polar glutamines at SGP-P7 and QAR-P2 have 
hydrogen bonding potential, and aliphatic isoleucines at SGP-P5 and QAR-P7 may 
contribute to hydrophobic interactions. 
Beyond the core, at C-terminal positions P10 and P11, charged residues were 
present in each peptide that may bind the TCR β-chain. At the N-terminal position P-1 of 
SGP, proline presented a hydrophobic surface for interaction, while serine and glycine 
showed high B factors and may not be oriented toward the TCR interface. 
The N-terminal flank of QAR consists of five residues, QARQM, and presents a 
more complex morphology (Fig. 4.13C, 4.13D). Based on B-factor analysis, the terminal 
P-5Gln and P-4Ala were disordered and fell over the DR1 α-chain (Fig. 4.13D), while the 
P-3Arg was oriented such that the side chain guanidinium group pointed out, away from 
the core (Fig. 4.13C). The P-2Gln side chain lay over the DR1 β-chain, while P-1Met 
chain pointed up, and was the most likely residue to form hydrophobic interactions with 
the TCR.  
The observation that the N-terminal flank of QAR loops back over the DR1 α-
chain, instead of pointing away from the likely TCR interface is of interest, as the flanking 
residues may be poised to make TCR interactions in this conformation. Whether this 
occurs when in complex with the TCR requires further investigation. 
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Figure 4.13. Orientation of potential TCR contact residues and QAR N-terminal 
flanking region. For (A) SGP and (B) QAR, peptide is coloured by B-factor in stick 
format, with the HLA α-chain in green behind. Charged side chains are labelled positive 
or negative. Arrows point in the side chain direction for each potential contact position 
(P-1, 2, 3, 5, 7, 8, 19, 11). The N-terminal peptide flanking residues are shown for QAR 
from the side (C) and top-down (D).  
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4.5 Discussion 
Due to variation of influenza surface proteins (HA and NA), the investigation of 
its most conserved proteins at the epitope level may offer insight into the nature of the 
immune response. CD4+ T-cells sit at the heart of the cell mediated response, yet the 
epitopes that facilitate their action have not been studied in detail. 
In this chapter, several immunogenic regions of the internal proteins of Influenza 
were identified initially in two HLA-DR1+ donors. These regions were analysed using 
HLA-binding algorithms and the predicted core epitopes tested in four DR1+ donors with 
highly pure peptides of a reduced length. Five consistently immunogenic epitopes were 
found: three from M1, one from NP and one from PB1. Crystallographic analysis 
confirmed binding algorithm predictions for two epitopes and indicated the likely solvent 
exposed residues that mediate T-cell recognition. 
Although five HLA-DR1 epitopes were defined, it is likely that a complete picture 
of the immune response meditated by this allele has not been revealed. Especially for 
the larger proteins NP and PB-1, where the single epitopes identified account for a 
fraction of the total response to screening pools.  
The reasons for this are related to the process of epitope mapping, which is highly 
complex and is affected by multiple factors that can confound or halt each stage of 
investigation. These include: the variable nature of the immune response, the overall 
immunogenicity of a protein, concentration of epitopes across a sequence, presentation 
by different HLA alleles, donor responses to culture conditions, the use of synthetic 
peptides and the screening methodology itself. 
These factors are assessed in the following discussion in order to account for the 
identified, misidentified and potentially overlooked DR1 epitopes within these proteins.   
4.5.1 The Precursor Frequency and Sensitivity of Cognate T Cells 
Assuming that an epitope is presented by HLA-DR1, and that a cognate T-cell 
population exists in the peripheral blood of a donor, the limiting factors in identification of 
a response are the precursor frequencies of cognate cells and their sensitivity to antigen. 
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In these experiments, every T-cell line was set up with a starting number of 600,000 
PBMC.  This means if a T-cell is present in peripheral blood at a frequency higher that 1 
in 600,000, it is likely that it will be detected in every assay. If the frequency is less than 
1 in 600,000 then the probability of detection decreases, for example, to one positive 
result in every two assays. 
During epitope mapping, the precursor frequency of a population is balanced by 
its sensitivity to antigen, which can be defined as the propensity to expand in culture and 
the magnitude of its cytokine response during an immunoassay.  A T-cell may be present 
at a high precursor frequency, yet not proliferate with high efficiency or elicit strong IFN-
γ responses on ELISpot. For these less active T-cells, it could require a greater number 
of precursors to reach consistent and positive levels of detection above background. 
Precursor frequency and T-cell sensitivity may be related, but these factors are 
mainly attributed to the most recent exposure to antigen (during influenza infection or 
vaccination) and the biophysical characteristics of the TCR and pHLA interaction, 
respectively. Other factors such as pHLA stability and antigen presentation may play a 
role, but are unlikely to limit detection, due to the excess of synthetic peptide used in 
culture and immunoassay conditions.  
 Ultimately, the epitopes found in the chapter were chosen for their ability to elicit 
strong and consistent responses, with M1 short peptides GLI and QAR followed by NP 
short peptide DPF best satisfying these criteria. Epitopes such as M1-SGP (weak but 
consistent IFN-γ responses) and PB1-GMF (strong but inconsistent IFN-γ responses) 
may have been on the threshold of detection based on their balance of precursor 
frequency and sensitivity.  
Responses below or close to this threshold, in either donor, could partially 
account for the transient and inconsistent response patterns seen towards the peptide 
pools. Such responses could have been detected in only one or two assays, and would 
have been discounted due to lack of consistency. Such thresholds and parameters have 
given rise to the terms immunodominant and sub-dominant when attempting to classify 
epitopes based on their tendency to elicit a response of a defined magnitude. 
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4.5.2 Culturing with a Peptide Pool versus an Individual Peptide 
In the previous section, the term “propensity to expand in culture” was 
deliberately used. This has relevance when appraising the response to a peptide pool or 
an individual peptide. In culture, the addition of cytokines such as IL-2 and growth factors 
are intended to drive T-cell expansion in response to antigen, yet if multiple antigens are 
present i.e. multiple peptides in a peptide pool, the cytokine balance or milieu may be 
influenced by the dominant responses.  
For example, if a peptide, which elicits a strong Th1 response, is present, this 
may drive expansion of clones to other peptides through helper cytokines that would 
have been insensitive under normal culture conditions. Conversely, if Th17 or Th2 or T-
regulatory responses were stimulated, suppressive or different phenotypes, which do not 
favour expansion of IFN-γ producing cells may have arisen from a culture. 
The second factor when culturing with a pool, is whether peptide competition for 
HLAs exist during the activation and expansion process? I.e. do peptides that bind 
strongly outcompete others that bind to the same HLA, and inhibit responses to weak 
binders? This question has been explicitly tested by the Kwok group in tetramer guided 
epitope mapping studies268,269. Lines were cultured to a mixed pool of immunodominant 
and subdominant peptides and the resulting tetramer stains compared to lines cultured 
with individual peptides268. Counterintuitively, these experiments showed that the mixed 
pools favoured responses to all peptides, including subdominant, and suggested that 
competition for the same HLA during the expansion process was not a limiting factor.  
Their explanation of the increased response to subdominant peptides was that 
greater cytokine release, or “help,” contributed to the expansion of weaker 
populations. Not suggested by them, is whether a stabilising effect on that particular HLA 
occurs, thus ensuring that other weakly binding epitopes are more likely to be presented. 
The greater abundance of the complementary HLA at the cell surface due to stabilisation 
with a strong binder would increase the probability of loading and presentation of other 
peptides via the recycling endosome (see class II presentation introduction). 
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What this means for pools and the methodology used in this chapter is that the 
detection of a response to a subdominant (low sensitivity or low precursor frequency) 
epitope will be highly influenced by the binding characteristics and responses of other 
peptides in the same pool. Therefore, a response may be detected in one peptide pool, 
while in another with different constituents, it may not. 
This applies explicitly in the case of M1 peptide-2, where a response was 
detected from the highly immunogenic M1 pool-2, which contained a dominant epitope 
(VQAMRTIGT). Yet the corresponding parent pool-6 showed minimal HLA-DR1 
responses. 
Peptide-2 was detected by chance as it was used as a negative control. Many 
other subdominant responses may have been present that were missed due to these 
dynamic interactions. Whether such subdominant responses in culture (associated with 
low proliferative capacity and low antigen sensitivity), are also subdominant in vivo and 
hence of lesser clinical relevance is an important future consideration.  
4.5.3 Using Algorithms to Define Epitopes 
The use of algorithms was based on the premise that the immunogenic epitopes 
are comprised of registers that bind HLA-DR1 with highest affinity. The strategy was 
undertaken for practical reasons and it appears successful, with strong responses to 
peptides that had predicted affinities less than 20 nM (Fig 4.8). The SGP 14-mer peptide 
has a predicted affinity of 67 nM, and showed consistent but relatively reduced response 
strength in terms of SFC. 
In the misidentified regions, or pool responses that were unaccounted for, did the 
strategy of epitope prediction fail? This is highly relevant to epitopes such as SGP, where 
a consistent and detectable response is present but the binding affinity of predicted cores 
was not sufficiently skewed towards a single register. Analysis of the process detailed in 
this chapter suggest this only applies to M1-SGP itself, and NP peptides-24/25 where 
the potential predictions coupled with weak responses deterred from further 
investigation. 
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In the cases of NP peptide-38/39 and PB1-34 two potential cores were identified 
in each, and tested where possible. These regions are specifically discussed in section 
4.5.5, but their misidentification or lack of responses did not result from algorithm failure, 
instead methodological and practical issues were to blame. 
Following the converse argument, were strongly binding epitopes identified 
through algorithm predictions missed by the pool screening methodology? Indeed, 
input of each entire protein sequence into the binding algorithm, and analysis of the top 
20 hits per sequence, finds all 5 epitopes that were detected and characterised here 
ranking highly. The cores from peptides M1-GLI and NP-DPF are the top ranked in their 
respective proteins, while PB1-GMF core is 5th highest and M1-QAR 8th.  
Yet, strong binding cores are not the sole criteria for an epitope, as shown with 
NP-FSV and NP-FER which were not able to elicit consistent responses.  Where 
peptides bind an HLA with very high affinity but elicit no IFN-γ response is an interesting 
area of investigation. Whether they are simply not processed in vivo (and therefore have 
no memory populations) or are not Th1 epitopes i.e. Th17 (IL-17 producers) or regulatory 
(IL-10) is beyond the scope of this investigation. It is also possible that they are simply 
presented through another HLA allele that outcompetes HLA-DR1 during processing, 
something directly observed here (see section 4.5.5). 
4.5.4 Epitope Missed within Highly Immunogenic Peptide Pools 
Following a thorough review of binding algorithm and summarised assay data, 
some potential epitopes were highlighted that could have explained responses to pools 
in which immunogenic peptides were not identified. 
4.5.4.1 Nucleoprotein Pool-11 
NP peptide pool-11 was extremely immunogenic in both donors, yet only peptide-
28 was identified. Analysis of binding predictions for the whole NP protein shows peptide-
23 to contain the second strongest binding core. This peptide was never tested as its 
corresponding parent pool gave consistently weak responses. 
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All three cores from the discontinued investigation of peptide-24 and peptide-25 
feature in the top 10 from NP and potentially warrant further investigation. 
4.5.4.2 Polymerase Basic-1: Pool-5, Pool-12 and Pool-13  
During the analysis of PB1, a major source of confusion were the strong 
responses to pool-5 and pool-13, coupled with the inconsistent but strong response to 
pool-12. Analysis of the top ten binding cores within the whole PB1 protein revealed eight 
to be contained in the immunogenic pools-5, 12 or 13, from which only two peptides were 
identified (FNMLSTVLG and VLSIAPIMF) and carried forward for further investigation.  
Peptide-32 was tested in two assays but did not yield any response, while all 
others (peptide-50, peptide-25, peptide-22 and peptide-33) were not tested as the 
relevant cross-reactive pool was not sufficiently active, potentially due to the factors 
discussed. 
Had epitope prediction been coupled with assay results from the beginning, it is 
possible that even more HLA-DR1 responses could have been identified within NP and 
PB1. Such lessons will be relevant in returning to this study and in future epitope mapping 
projects. 
4.5.5 Analysis of Three Misidentified Epitopes 
It is likely that some epitopes associated with HLA-DR1, particularly sub-
dominant or transient responses were missed. Had the goal been to fully map these 
protein for every possibly response then greater effort would have been applied in this 
endeavour. Instead, the goal was identification of the shared and consistent 
responses - those that may be mediating protection and limiting symptom severity. 
Those regions that were initially identified as fitting the above criteria, but did not 
fully mature are discussed in this final section. These regions are still of interest, as they 
serve as specific case studies of the complications encountered during epitope mapping, 
and it is worth accounting for their incomplete progress. 
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4.5.5.1 NP-38 & NP-38: FSVQRNLPF & FERATIMAA 
The key to these peptides relies on a discussion from the previous chapter, which 
states that the HLA-DR1 presentation methodology could present a more diverse peptide 
repertoire than that presented in vivo, due to the use of synthetic peptide and the 
recycling endosomal pathway. The NP peptides 38/39 contained two predicted cores 
(FSVQRNLPF and FERATIMAA), both of which were tested and gave minimal and 
inconsistent responses via DR1 presentation. This was puzzling due to the strong 
responses to full-length peptides and parent pools (Fig. 4.3.A and 4.5.B) and the 
absence of other strong binders within this region. 
Further analysis was carried out by repeating the assays using normal 
autologous presentation side-by-side with DR1 presentation (data not shown). This 
experiment and subsequent analysis of the literature clarified the responses patterns 
observed. For both short peptides, autologous presentation but not DR1 presentation, 
yielded positive results in two donors tested, and a strong response (greater than 200 
SFC) in each donor. Analysis of recent literature showed each peptide contains epitopes 
presented through another HLA allele. 
FSVQRNLPF has been characterised as a DR12 epitope270, the other DR allele 
of donor-2 who displayed the strongest response. FERATIMAA is a well-documented 
B*35/B*07 epitope that elicits strong CD8+ T-cell responses across the population250. 
The explanation for why these two peptides were consistently detected on an HLA-DR1 
screening platform is the primary concern. It appears to be explained by their length of 
23 amino acids, and the fact they both contain strong DR1 binding cores. It is possible 
that each peptide was loaded during the pulsing process, highly stable to PBS washing 
of APCs, before addition to the overnight ELISpot assay, during which cleavage and 
exchange to other donor HLA antigens could take place. 
4.5.5.2 PB1 Peptide-29: VRKMMTNSQ 
The only case where an inconsistent response from the pool screens was 
investigated further was that of PB1 peptide-29. This was due to the lack of other 
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immunogenic regions within this protein. Of the two cross-referenced pools, the strongest 
responses were to PB1 pool-13, which contained another more immunogenic epitope 
within peptide-34. Responses to the other parent pool, PB1 pool-2 were detected in 2 of 
5 assays (one per donor), but when detected, the response magnitudes were strong 
(~100 SFC), suggesting a low precursor frequency of highly sensitive clones.  
Subsequent investigation yielded a reduced peptide PB1-NVV that gave negative 
responses during testing. The reduced peptide chosen was based on a unanimous 
prediction from the parent peptide, although its binding affinity was the weakest of all 
those tested. This again could be an example of where a 20-mer is more effective at 
eliciting a response than a 13-mer, and hence when an epitope is on the threshold of 
detection, this makes a measurable difference. 
Initial pooling interactions, weak HLA binding and a low precursor frequency likely 
account for the poor response to this reduced peptide. If the assays were repeated, lines 
could be set up with a greater number of starting PBMC to overcome low precursor 
frequency, and both DR1 and autologous presentation could be tested side-by-side to 
account for weak HLA binding, or the potential that this epitope was presented 
predominantly through another HLA. 
4.5.5.3 PB1-34: MFSNKMARL & VLSIAPIMF 
This was the final peptide for which a strong response was found to the parent 
pools and the individual peptide demonstrated no reactivity. From PB1 peptide-34 two 
cores were present in the same sequence, both predicted as binding with 40 nM affinity. 
Only one peptide (IMFSNKMARLGKG) was obtained and tested. Results show no 
detectable response in two donors and further testing was not carried out. Testing of the 
second core will be carried out in future investigations. 
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4.5.6 Future Work 
The identified epitopes from the internal proteins matrix, nucleoprotein and 
polymerase basic-1 that elicited consistent responses in four HLA-DR1+ donors were 
taken forward for further analysis. Having established that each epitope was able to 
stimulate a PBMC line of IFN-γ producing CD4+ T-cells in four donors, the next step was 
to probe the magnitude and specificity of these responses at the cellular level. This would 
permit clonotypic analysis of relevant populations and a better understanding of the cells 
that ultimately mediate immunity to the conserved elements of the influenza virus. 
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5 Epitope-Specific CD4+ T-cells from HLA-DR1 
Donors Exhibit Shared Cellular and Genetic 
Characteristics 
5.1 Abstract 
In the context of an acute infection, analysis of epitope-specific CD4+ T-cell 
populations and their constituent T-cell receptor (TCR) sequences can help resolve the 
cellular and genetic characteristics that mediate immunity and protection.  
Using five epitopes derived from conserved influenza proteins identified in the 
preceding chapter, analysis of CD4+ T-cell populations in five HLA-DR1 donors was 
performed. HLA-multimer staining enabled stratification of epitopes based on the 
magnitude of their cellular responses, while TCR sequences of epitope-specific 
populations were obtained using next generation sequencing with the α-chain data fully 
analysed. TRAV gene usage and CDR3α diversity were compared between donors, 
while CDR3α motifs and amino acid frequencies were compared for each TRAV gene 
(and CDR3 length) in order to dissect the underlying genetic and physical architecture. 
Focused TRAV gene usage was observed in response to two epitopes, with 
broader usage observed in response to four other epitopes. Epitopes with broader TRAV 
gene usage appeared to show greater response magnitudes and reproducibility in all 
donors. TCR CDR3α amino acid motifs were identified with strong conservation of 
physical properties such as charge and polarity at key positions. Additionally, several 
“public” TCR amino acid sequences were identified.  The described work contributes to 
further understanding of CD4+ T-cell immunity to conserved influenza proteins, revealing 
unexpected sharing of response characteristics across multiple HLA-DR1 donors. 
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5.2 Introduction 
The use of fluorochrome-conjugated HLA-multimer technology allows the direct 
enumeration of epitope-specific T-cell populations by flow cytometry. This is useful when 
probing polyclonal lines expanded from PBMC, where cells of interest can be analysed 
relative to their parent population of CD8+ or CD4+ T-cells. The mean fluorescence 
intensity (MFI) of HLA-multimer binding cells can indicate the relative avidities of the 
overall population or sub-populations that respond to an antigen. The relative magnitude 
and MFI of an epitope-specific population may be linked to the efficacy and strength of 
the resulting T-cell response and thus relate to protection from disease. 
Subsequent clonotypic analysis can dissect the genetic composition of antigen-
specific populations based on their constituent TCR sequences. This is of interest when 
analysing the diversity and V(D)J gene usage of TCRs that respond to a particular 
epitope. In response to immunodominant HLA-class I influenza epitopes, examples of 
both highly focused221,271 and diverse repertoires250 have been found in multiple 
individuals. Limited data are available for  influenza-specific CD4+ T-cells, with 
clonotypic analysis restricted to HA307-319 in three HLA-DR1 donors168,272. 
When looking across human and mice populations, sharing of TCR sequences 
at the amino acid and nucleotide level is observed in response to important 
autoimmune273,274 and viral epitopes249,275. This sharing, termed “publicity,” is thought to 
arise from an increased prevalence of certain TCRs in the naïve repertoire due to 
convergent recombination276,277. TCRs from this enriched pool may have an increased 
probability of selection in response to immunodominant epitopes following repeated 
exposure278 and may be important indicators of the epitope-specific responses which 
confer protection. 
The study of public responses to the universal HLA-A2 restricted M158-66 epitope 
has spanned two decades of research221,279 and provided a wealth of information on 
CD8+ T-cell repertoire dynamics278,280,281 and structural insights249,250. No parallel exists 
for CD4+ T-cell responses to influenza or other highly transmissible viral pathogens.  
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Those studies which have compared epitope-specific CD4+ T-cell populations 
have mainly focused on single epitopes272 in chronic viral or autoimmune 
settings271,273,282–284. It is not known how acute infection shapes the responding CD4+ T-
cell repertoires, and whether strong comparisons with CD8+ T-cell mediated immunity 
exist.  Acute infections may not exhibit the same gene usage patterns seen in response 
to either self or persistent antigens.  
Given that peptides are presented by HLA class-II in a flat, extended 
conformation5 with a natural variation in flanking length169,170, it is hypothesised that 
responding TCR repertoires may exhibit greater diversity and wider gene usage than 
class-I responsive repertiores285. Testing of this hypothesis requires several distinct 
epitopes and multiple donors to begin to encompass the many potential responses that 
could arise. 
In this chapter, comparison of epitope-specific CD4+ T-cell responses in multiple 
individuals identified shared cellular and genetic patterns that mediate immunity in the 
HLA-DR1+ population. Similar cellular responses, biased TRAV gene usage, conserved 
CDR3α amino acid residues and public TCR sequences were all observed. These 
observations helped guide further structural analysis in order to elucidate the molecular 
mechanisms of TCR repertoire recognition, and raised further questions concerning 
epitope-specific immunity. 
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5.3 Aims 
When using HLA-multimer staining to analyse epitope-specific cell populations, 
it is important to establish that identified cells are functionally relevant. The first aim of 
this chapter was to confirm that multimer staining correlated with effector function by 
comparison of IFN-γ ELISpot and flow cytometry data from the same cell populations 
expanded against conserved influenza epitopes. 
The second aim was to assess the extent to which five different HLA-DR1+ 
donors were able to respond to the same conserved epitopes. Specifically, were all 
donors able to respond, and were the responses comparable in terms of %CD4+ T-cells 
and MFI? 
The final aim was to investigate the TCR sequences that mediate epitope-
specificity through clonotypic analysis. Examination of TRAV gene usage, CDR3 length 
and amino acid composition would provide insight into how conserved the mechanisms 
of TCR recognition are across individuals who share a common HLA allele. 
 
Specific aims: 
1) To compare the techniques of IFN-γ ELISpot and HLA-multimer staining on the 
same lines expanded against conserved influenza epitopes to see if correlations 
exist. 
2) To assess the epitope-specific populations in five HLA-DR1 donors using HLA-
multimers and flow cytometry. 
3) To analyse the clonotypic information from epitope-specific CD4+ T-cells in five 
donors through fluorescence activated cell sorting and next generation 
sequencing. 
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5.4 Results 
5.4.1 Flow Cytometry Analysis of Epitope-Specific CD4+ Populations 
In order to analyse epitope-specific populations on flow cytometry, biotin tagged 
pHLA-monomers were generated using recombinantly expressed HLA-DR1 α- and β-
chains, and synthetic peptide. Six batches of monomer comprising three matrix peptides 
(SGP, GLI, QAR), one nucleoprotein (DPF), one polymerase basic-1 (GMF) and one 
control HA peptide (PKY) were successfully produced using the same high purity 
peptides tested in the previous chapter. 
Small quantities of monomers (2-3 μg) were multimerised as needed using a PE-
conjugated dextran backbone, and used to stain expanded polyclonal lines with an 
optimised protocol217. HLA-multimer populations were quantified within 
CD3+/Live/CD4+/CD8- populations by percentage of the parent CD4+ population and 
the mean fluorescence intensity (MFI) of the multimer binding cells. Irrelevant HLA-DR1 
multimers and fluorescence minus one (FMO) were used to set each HLA-multimer gate. 
5.4.1.1 Comparison of HLA-Multimer Staining and IFN-γ ELISpot Data 
In the previous chapter, each of the six peptides was able to elicit strong and 
consistent IFN-γ ELISpot responses restricted to HLA-DR1. Side-by-side analysis of 
ELISpot responses with flow cytometry data determined any correlation between the 
techniques and hence indicated the extent to which multimer binding cells exhibited TH1 
functionality. 
PBMC from two HLA-DR1 donors were expanded to each peptide; IFN-γ ELISpot 
was performed on day-12 followed by HLA-multimer staining of the same lines on day-
14 (Fig. 5.1). 
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 Figure 5.1. Comparison of HLA-Multimer staining and IFN-γ ELISpot responses in 
two HLA-DR1 donors. Donor numbers correspond to experiments detailed in the 
previous chapter. HLA-multimer stains are shown alongside irrelevant HLA Class-II 
multimer negative controls for donor-2 (A) and donor-5 (B) with % of CD4+ T-cells shown 
for each gate. Data for each epitope is shown as a colour-coded row. (C) IFN-γ ELISpot 
data for each donor and epitope is displayed as SFC per 100,000 PBMC with 
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background (negative control) subtracted, donor-2 in black, donor-5 in hatched bars 
(mean with SD error bars, n = 2). FMO controls and gating strategy in appendix section 
8.2. 
 
HLA-multimer+ populations were observed in response to each epitope, with 
stronger shifts and greater numbers in donor-5 (Fig. 5.1B). Donor-2 had slightly lower 
shifts (in terms of MFI) but as fewer cells were obtained for analysis, the staining was 
weaker (Fig. 5.1A). When compared to IFN-γ ELISpot results (Fig. 5.1C), the epitopes 
that showed consistent staining and > 100 SFC in both donors were GLI and PKY, while 
QAR and DPF each showed consistent staining and > 50 SFC (a positive response is > 
20 SFC per 100,000 starting PBMC). 
The epitopes SGP and GMF showed donor-specific inconsistencies between the 
numbers of cells stained on flow cytometry and the corresponding IFN-γ responses. It is 
probable that this results from a discrepancy in the ELISpot immunoassay, or limited 
activity in the cell line. HLA-multimer staining may offer a more reliable quantification of 
epitope-specific responses, especially when quantified with respect to parent 
populations. 
An attempt to correlate both sets of data was carried out using regression 
analysis (Fig. 5.2). This yielded limited success, all correlations were positive, yet only 
one (donor-5 IFN-γ SFC vs %CD4+) gave a significant R-squared value greater than 
0.70 (p = 0.006). This may be the result of ELISpot variation, with more advanced 
immunoassay techniques such as intracellular cytokine staining showing greater 
correlations. Ultimately, these epitope-specific populations do show functionality and are 
worth investigating further. 
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Figure 5.2. Regression analysis of flow cytometry statistics (%CD4+ and MFI) with 
IFN-γ ELISpot data (SFC). Analysis is shown for each donor separately, with linear trend 
lines fitted and R-squared and p values shown on each plot. Donor-2 IFN-γ versus 
%CD4+ (A) and MFI (B) Donor-5 IFN- γ versus %CD4+ (C) and MFI (D). 
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5.4.1.2 Analysis of Epitope-Specific Populations in Five DR1 Donors 
Given that two donors exhibited comparable responses to each epitope tested, 
additional multimer staining were performed in three more HLA-DR1 donors. Four of 
these donors had been used to confirm the immunogenicity of the epitopes characterised 
in the previous chapter, while the responses in another were examined for the first time. 
The first question driving this investigation was whether all HLA-DR1 donors 
tested had epitope-specific T-cells that could be expanded and detected from one million 
starting PBMC? Following this, were the T-cell response magnitudes to each epitope 
comparable between donors, or highly donor specific? 
Staining was performed in each donor at day 12-14 following expansion (Fig. 
5.3A). Multimer analysis gates were set using FMO and an irrelevant HLA class-II 
multimer (Fig. 5.3B), the analysis was repeated twice using PBMC samples taken at 
different time points in donor-3 and donor-5 to investigate reproducibility (data not 
shown). Epitope-specific responses were detectable in all donors, with the exception of 
GMF in donor-1 and DPF in donor-4. 
Donor-4 appeared to have preferential expansion of CD19+ cells after 14 days in 
culture and as a result had fewer numbers of CD3+ cells, evident visually when 
comparing stains. Inspection of the plots show variation in magnitude and the 
fluorescence shifts of epitope-specific populations. GLI, PKY and QAR show larger 
populations and more consistency between donors than SGP, DPF and GMF.  
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Figure 5.3A. Comparison of epitope-specific stains in 5 HLA-DR1 donors.  
Continued on next page.  
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Figure 5.3. Comparison of epitope-specific stains in 5 HLA-DR1 donors.  
Epitope-specific data (A) and corresponding lines stained with irrelevant HLA class-II 
multimers (B) are presented in colour-coded rows, and donor specific data in columns. 
Gate % of parent CD4+ T-cells are detailed on each plot. Where stains are coloured 
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white (donor-4, DPF and donor-1, GMF) this represents insignificantly stained 
populations when compared to the irrelevant control and FMO. Gates were set by 
irrelevant and FMO controls. 
 
When normalised data (Fig. 5.4A, 5.4B) and mean values were compared (Fig 
5.4C, 5.4D), the matrix epitope GLI showed the highest %CD4+ and MFI values across 
five donors. The control HA-PKY epitope exhibited a similar magnitude to GLI but 
showed less consistency between donors. This suggests that GLI and PKY consistently 
elicit the strongest responses with respect to other HLA-DR1 epitopes, potentially a result 
of increased precursor frequency or an increased avidity of the cognate TCR population 
(see discussion section 5.5). 
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Figure 5.4. Comparison of epitope-specific HLA-multimer staining in five HLA-DR1 
donors. Negative controls, irrelevant HLA class-II multimer staining show in hatched 
bars on all plots. (A) %CD4+ T-cells which comprise HLA-multimer+ CD4+ T-cells. (B) 
Raw MFI of HLA-multimer+ CD4+ T-cells per donor and epitope. (C) Mean %CD4+ value 
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across five donors per epitope (n = 5, SD error bars). (D) Mean MFI value across all 
donors per epitope (n = 5, SD error bars). 
5.4.2 TCR α-Chain Analysis of Epitope-Specific CD4+ T-cells 
In order to understand the genetic basis of these CD4+ T-cell responses, 
clonotypic analysis of epitope-specific populations was carried out. Where possible, 
HLA-multimer positive CD4+ T-cells from the stains in the previous section (Fig. 5.4) 
were sorted by FACS. Messenger RNA was extracted and used for cDNA synthesis, 
which was amplified by two rounds of PCR. The PCR product was analysed using next 
generation sequencing, yielding detailed information about the TCR α-chain usage for 
each epitope. 
Samples were obtained for GLI and PKY epitopes in all five donors, while QAR, 
DPF and SGP samples were obtained for all except donor-4. Samples for GMF were 
obtained for donor-2, 3 and 5.  
A threshold of 50 reads per sequence was set; any clonotypes with fewer than 
50 reads were eliminated. This value was based on the presence of low-frequency TCR 
sequences in multiple samples from the same donor, i.e. they did not show epitope 
specificity. The biological nature of these TCRs, cross reactive or cellular contamination, 
are yet to be determined. A small number of such sequences were present below 50 
reads, hence the threshold value (see example in appendix section 8.3). 
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Figure 5.5. Summary of TCR α-chain data in five donors. (A) Number of clonotypes 
per epitope from each donor. The results of one sample per donor are shown. (B) 
Distribution of CDR3 TCR α-chain lengths (number of amino acids) across all samples 
in all donors, specific to each epitope. 
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Between two and twenty-one distinct α-chain clonotypes were detected in each 
sample (Fig. 5.5A). Fewer clonotypes comprised the response to DPF and GMF, while 
other epitopes showed a large range depending on the donor.  
CDR3α lengths in response to each epitope from eight to twenty amino acids 
when measured from the primary cysteine to the terminal phenylalanine. The majority of 
samples centred around 12-16 amino acids, with epitope-specific patterns emerging 
(Fig. 5.5B).  
GLI and PKY showed resemblance to a normal distribution, with modal values at 
14 and 13 amino acids respectively. Other epitopes showed slightly skewed plots with 
QAR favouring 13 amino acids or longer, and GMF peaking at 14 amino acids with a 
skew towards shorter sequences. SGP and DPF had bimodal distributions; both had a 
mode of 12, followed by lower use of 13-17 amino acid lengths. 
These length distributions may reflect the optimal number of CDR3 amino acids 
necessary for good contacts with cognate pHLA surfaces. However, it is one of many 
factors contributing to the receptor ligand interface; others such as the germline encoded 
CDR1 and CDR2 sequences may exert a much greater and more obvious impact. 
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5.4.3 Epitope-Specific TRAV Gene Usage 
When investigating epitope-specific responses, analysis of V gene usage in 
multiple individuals can identify genetic bias that is shared across the population249,279. 
Recent human studies of CD4+ T-cells in celiac disease271,284 and HIV286 have found 
repertoires exhibiting highly restricted use of certain TRAV and TRBV genes, as well as 
TRAJ and TRBJ. These may represent important interactions between the germline-
encoded CDR1 and CDR2 amino acids and the pHLA surface that facilitate binding167. 
In order to analyse the responses, TRAV gene usage was normalised for each 
donor (as a fraction of the total number of epitope-specific clonotypes) and cumulative 
results presented for each epitope (Fig. 5.6). 
Two epitopes, QAR (number of clonotypes, n = 60, 4 donors) and GMF (n = 21, 
3 donors), each exhibited highly biased use of a single gene (Fig. 5.6A, 5.6B). QAR 
responses using TRAV38-2/DV8 had an average frequency of 61 % in four donors 
(range 54 -73 %). GMF responses using TRAV2 averaged 72 % in three donors (range 
67-75 %), representing the highest gene usage seen across all epitopes. The average 
frequencies were greater than 50 %, but much less than some examples in CD8 T-cell 
responses where average frequencies greater than 90 % have been observed for 
specific V genes in response to influenza epitopes250. Comparative data for other CD4+ 
responses is not available, having been carried out on small populations of clones271 or 
using qPCR based sequencing methodologies286.  
Usage to the remaining epitopes showed less bias and lower average 
frequencies in response to highlighted genes. SGP (n = 42, 4 donors) showed a broader 
use of three TRAV genes (Fig, 5.6C). TRAV23DV6 was the top hit in three of four donors 
with an average of 36 % (range 0-57 %), there was limited use of TRAV13-2 (average 
26 %, range 6-43 %) and TRAV5 (average 15 %, range 0-33 %). 
Analysis of DPF (n=19, 4 donors) was skewed by low numbers of clonotypes 
(Fig. 6D), and showed no apparent usage pattern common to more than two donors. 
The final two epitopes GLI (n = 62) and PKY (n = 57), generated the strongest 
responses across all donors (section 5.4.1). Analysis of TRAV usage for both epitopes 
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in five donors showed the broadest gene usage of all epitopes tested. GLI TRAV usage 
(Fig. 5.6E, 5.6F) was focused in three genes, TRAV2 (average 26 %, range 11-36 %), 
TRAV16 (average 21 %, range 9-33 %) and TRAV38-1 (average 14 %, range 6-20 %), 
with usage specific to two donors displayed in six additional genes. 
In response to PKY (Fig. 6G, 6H), TRAV8-4 (average 11 %, range 0- 16 %), 
TRAV8-6 (average 13 %, range 0-38 %), TRAV13-1 (average 25 %, range 0-45 %) and 
TRAV14DV4 (average 11 %, range 0-18 %) were each used by four of five donors tested. 
These relatively broader usage patterns may suggest GLI and PKY are less 
limited in the selection of TRAV genes capable of forming strong structural interactions 
through their germline regions. Although speculative, it could explain the stronger 
responses observed, as there would be a larger theoretical pool of CD4+ T-cells with the 
potential to respond to these ligands. 
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Figure 5.6. Analysis of epitope-specific TRAV gene usage in multiple donors. 
Donor specific frequencies of each gene with respect to the total number of clonotypes 
per epitope were calculated. Frequencies for each gene were plotted as a cumulative 
analysis of the responses from all donors to each epitope: QAR (A), GMF (B), SGP (C), 
DPF (D), GLI (E), PKY (G) 
Breakdown of usage patterns by donor are shown for the epitopes GLI (F) and PKY (H) 
as a cumulative analysis of dominant TRAV genes. 
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5.4.4 TCRα CDR3 Diversity 
Analysis of an epitope-specific CD4+ T-cell response at the level of CDR3 
sequences reveals the clonotypic diversity of a sample. In this analysis, epitope-specific 
TCR α-chain CDR3 amino acid sequences were presented for each donor (Fig. 5.7). The 
Shannon index (H’) was calculated for every sample, with lower H’ values corresponding 
to lower biological diversity. The mean H’ value and standard deviation across all donors 
for each epitope was calculated. 
QAR exhibited the highest levels of diversity across four donors, with a mean H’ 
of 1.77 (SD 0.52) and pie charts containing multiple small slices in each donor. Donor-3 
had a highly dominant TCR at greater than 75 % frequency, while in all other donors the 
dominant sequence occupied between 25-50 % of the total. Based on this data, and 
section 5.4.3 (Fig. 5.6A), the response to QAR was likely mediated by a large pool of 
TRAV38-2 clonotypes with the capacity to compete for the same pHLA. 
PKY showed similar levels of diversity across five donors (mean 1.65, SD 0.37), 
although a greater number of large slices (> 20 % of the total, less than 50 %) and fewer 
small slices were observed. The prevalence of large slices may indicate that two to five 
dominant, high avidity, clones are competing for PKY in each donor; this may account 
for the large MFI values seen in the corresponding flow cytometry data (Fig. 5.3). 
In contrast, GLI showed responses dominated by single clones in five donors 
(greater than 50 %) with multiple smaller slices in the remaining 50 % that contribute to 
relatively diverse responses (mean 1.41, SD 0.35). The mean H’ value for SGP was 
similar, but the variation between donors was the highest of all epitopes (SD 0.76), with 
little consistency in H’ values or pie chart architecture. This suggests the nature of the 
response to SGP was specific to each donor, with no similar patterns observed across 
the population (at this same size). 
GMF had a lower mean H’ value, highly consistent across three donors (SD 0.18), 
with three to five clonotypes in equilibrium (slices > 10 %) across each sample, and few 
small slices.  
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DPF exhibited the least response diversity of all epitopes in four donors (mean 
0.72). The pie charts were dominated by large slices, in some cases greater than 75 %, 
which indicate fewer clonotypes contributing to each response (Fig. 5.3). The CDR3 
structural requirements necessary to bind HLA-DR1 presented DPF at sufficient avidity 
may be very narrow and therefore it contrasts strongly with the highly diverse responses 
seen in other epitope samples. 
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Figure 5.7. Clonotypic diversity in response to each epitope across all donor 
samples. Pie charts were compiled using TCR sequence frequency in each donor, with 
the corresponding Shannon diversity index calculated from the same data shown below 
each chart. Mean H’ values and standard deviation are calculated for each epitope. 
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5.4.5 Public CDR3 Amino Acid Sequences 
Given the strength of CD4+ T-cell responses and focused gene usage in 
response to the characterised epitopes, it was of interest to search for public TCR 
sequences that were shared in multiple donors. Few public sequences (by CDR3 amino 
acids) have been characterised in response to HLA-Class II epitopes286,287, and none in 
response to the conserved internal proteins of influenza. 
Analysis of TCR α-chain data across five donors showed fifteen shared 
sequences (Table 5.1). Thirteen of which were shared between two donors in response 
to the same epitope, while two, (PKY-CAASFSDGQKLLF and QAR-CAYLTGTASKLTF) 
were shared between three donors. Several sequences were identical the amino acid 
level, but differed at the nucleotide level (red letters in table 5.1), an indicator of 
convergent recombination in the generation of publicity276,277. 
These public sequences were rare, but highly important, as they represent TCR 
mediated immunity that is conserved between individuals to the codon level. Preferential 
expansion of these clonotypes during infection is likely to have resulted in a precursor 
frequency that permits consistent detection in multiple HLA-DR1 individuals. These TCR 
sequences may be highly protective and therefore have been driven out under viral 
selection pressure across the population. 
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Table 5.1. Shared TCRα CDR3 amino acid and nucleotide sequences in response 
to each epitope. Nucleotide differences are highlighted in red. Sequences identical at 
the genetic level are coloured blue. Epitope and donor number are listed in the far-left 
column, followed by CDR3 amino acid sequence, genetic sequence, then V and J gene 
(left to right). 
Donor CDR3 Genetic Seq V Gene J gene
SGP 123456 1  2  3  4  5  6  7  8  9  0  1  2  3  4  5  6  
1 CAASSRIYNQGGKLIF TGTGCAGCAAGCTCCCGGATTTATAACCAGGGAGGAAAGCTTATCTTC TRAV23DV6 TRAJ23
2 CAASSRIYNQGGKLIF TGTGCAGCAAGCAGCCGCATTTATAACCAGGGAGGAAAGCTTATCTTC TRAV23DV6 TRAJ23
1234 1  2  3  4  5  6  7  8  9  0  1  2  3
1 CAATRRGADGLTF TGTGCAGCAACCAGGAGAGGTGCTGACGGACTCACCTTT TRAV23DV6 TRAJ45
2 CAATRRGADGLTF TGTGCAGCCACAAGGAGAGGTGCTGACGGACTCACCTTT TRAV23DV6 TRAJ45
GLIYN 123456 1  2  3  4  5  6  7  8  9  0  1  2  3  4
2 CAFMRYNAGNMLTF TGTGCTTTCATGAGGTATAATGCAGGCAACATGCTCACCTTT TRAV38-1 TRAJ39
3 CAFMRYNAGNMLTF TGTGCTTTCATGAGATATAATGCAGGCAACATGCTCACCTTT TRAV38-1 TRAJ39
123456 1  2  3  4  5  6  7  8  9  0  1  2  3  4
1 CALREANTGNQFYF TGTGCTCTAAGGGAGGCTAACACCGGTAACCAGTTCTATTTT TRAV16 TRAJ49
5 CALREANTGNQFYF TGTGCTCTAAGAGAGGCGAACACCGGTAACCAGTTCTATTTT TRAV16 TRAJ49
QAR 1234 1  2  3  4  5  6  7  8  9  0  1  2  3  
1 CAYITGTASKLTF TGTGCTTATATTACCGGCACTGCCAGTAAACTCACCTTT TRAV38-2DV8 TRAJ44
2 CAYITGTASKLTF TGTGCTTATATAACCGGCACTGCCAGTAAACTCACCTTT TRAV38-2DV8 TRAJ44
12345 1  2  3  4  5  6  7  8  9  0  1  2  3  
1 CAYLAGTASKLTF TGTGCTTATTTAGCCGGCACTGCCAGTAAACTCACCTTT TRAV38-2DV8 TRAJ44
3 CAYLAGTASKLTF TGTGCTTATTTAGCAGGCACTGCCAGTAAACTCACCTTT TRAV38-2DV8 TRAJ44
1234 1  2  3  4  5  6  7  8  9  0  1  2  3  
2 CAYLTGTASKLTF TGTGCTTATTTGACCGGCACTGCCAGTAAACTCACCTTT TRAV38-2DV8 TRAJ44
CAYLTGTASKLTF TGTGCTTATCTTACCGGCACTGCCAGTAAACTCACCTTT TRAV38-2DV8 TRAJ44
CAYLTGTASKLTF TGTGCTTACTTAACCGGCACTGCCAGTAAACTCACCTTT TRAV38-2DV8 TRAJ44
CAYLTGTASKLTF TGTGCTTACCTTACCGGCACTGCCAGTAAACTCACCTTT TRAV38-2DV8 TRAJ44
3 CAYLTGTASKLTF TGTGCTTATTTAACCGGCACTGCCAGTAAACTCACCTTT TRAV38-2DV8 TRAJ44
CAYLTGTASKLTF TGTGCTTATCTGACCGGCACTGCCAGTAAACTCACCTTT TRAV38-2DV8 TRAJ44
CAYLTGTASKLTF TGTGCTTACCTCACCGGCACTGCCAGTAAACTCACCTTT TRAV38-2DV8 TRAJ44
5.1 CAYLTGTASKLTF TGTGCTTACCTAACCGGCACTGCCAGTAAACTCACCTTT TRAV38-2DV8 TRAJ44
DPF 12345 1  2  3  4  5  6  7  8  9  0  1  2  
2 CAYRSTGNQFYF TGTGCTTATAGATCAACCGGTAACCAGTTCTATTTT TRAV38-2DV8 TRAJ49
5 CAYRSTGNQFYF TGTGCTTATAGGAGCACCGGTAACCAGTTCTATTTT TRAV38-2DV8 TRAJ49
GMF 123456 1  2  3  4  5  6  7  8  9  0  1  2  3  4  
3 CAVEEGSSASKIIF TGTGCTGTGGAGGAGGGAAGCAGTGCTTCCAAGATAATCTTT TRAV2 TRAJ3
5 CAVEEGSSASKIIF TGTGCTGTGGAGGAAGGCAGCAGTGCTTCCAAGATAATCTTT TRAV2 TRAJ3
3 CAVEGDNAGNMLTF TGTGCTGTGGAGGGGGATAATGCAGGCAACATGCTCACCTTT TRAV2 TRAJ39
5 CAVEGDNAGNMLTF TGTGCTGTGGAGGGGGATAATGCAGGCAACATGCTCACCTTT TRAV2 TRAJ39
PKY
2 CAASFSDGQKLLF TGTGCAGCAAGTTTTTCAGATGGCCAGAAGCTGCTCTTT TRAV13-1 TRAJ16
3 CAASFSDGQKLLF TGTGCAGCAAGTTTTTCAGATGGCCAGAAGCTGCTCTTT TRAV13-1 TRAJ16
5 CAASFSDGQKLLF TGTGCAGCAAGTTTTTCAGATGGCCAGAAGCTGCTCTTT TRAV13-1 TRAJ16
1 CALSNDYKLSF TGTGCTCTGAGTAACGACTACAAGCTCAGCTTT TRAV9-2 TRAJ20
2 CALSNDYKLSF TGTGCTCTGAGTAACGACTACAAGCTCAGCTTT TRAV9-2 TRAJ20
2 CAMSATDSWGKLQF TGTGCAATGAGTGCAACTGACAGCTGGGGGAAATTGCAGTTT TRAV14DV4 TRAJ24
3 CAMSATDSWGKLQF TGTGCAATGAGTGCAACTGACAGCTGGGGGAAATTGCAGTTT TRAV14DV4 TRAJ24
12345 1  2  3  4  5  6  7  8  9  0  1  2  3  4  
2 CAMSPTDSWGKLQF TGTGCAATGAGTCCAACTGACAGCTGGGGGAAATTGCAGTTT TRAV14DV4 TRAJ24
3 CAMSPTDSWGKLQF TGTGCAATGAGTCCTACTGACAGCTGGGGGAAATTGCAGTTT TRAV14DV4 TRAJ24
123 1  2  3  4  5  6  7  8  9  0  1  2  3  
3 CVVYTGTASKLTF TGTGTGGTTTATACCGGCACTGCCAGTAAACTCACCTTT TRAV12-1 TRAJ44
5 CVVYTGTASKLTF TGTGTGGTATATACCGGCACTGCCAGTAAACTCACCTTT TRAV12-1 TRAJ44
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5.4.6 Analysis of Amino Acid Motifs in Response to Each Epitope 
Theoretically, certain common trends should exist in the physical characteristics 
of the CDR3 regions that mediate epitope-specific responses; for example, conservation 
of charged or polar residues in the centre of the CDR3 region that facilitate binding. Motif 
based analysis is a common tool used in studies on epitope-specific TCR populations. 
In order to visualise the amino acid usage of CDR3 regions, sequence motif 
software was used (WebLOGO) and amino acids were coloured based on polarity, 
charge, aromaticity and conformation (proline). The clearest approach to visualising 
patterns of amino acid usage involved stratifying CDR3 sequences based on their parent 
TRAV genes and length (Fig. 5.8). In this way, key features remained visible and were 
not lost amidst the detail of multiple unrelated genes and length variations. 
Inspection of motifs appear to show conserved physical properties in response 
to some epitopes. For example, in response to SGP (Fig. 5.8A) the majority of motifs 
favour a basic residue, five amino acids from the starting cysteine. This residue was 
followed by a predominance of polar uncharged residues close to the c-terminus. 
Motifs in response to GLI favoured two or more polar-uncharged residues 
positioned centrally and close to the c-terminus in four of the five TRAV genes analysed 
(Fig. 5.8B). No pattern was apparent at N-terminal residues.  
When looking at TRAV38-2 motif responses to QAR (Fig. 5.8C), the N and C 
termini appeared highly conserved, while the central amino acids were charge neutral, 
predominantly non-polar with a low frequency use of polar residues. There was a 
complete absence of charged residues in the central region in all lengths, suggesting a 
highly hydrophobic interface between the TCR CDR3α and the pHLA. The only other 
motif in response to QAR, TRAV2, showed an acidic residue at C-terminal position five, 
but the remaining positions conform to the uncharged pattern observed before. 
The small number of TCRs detected in response to DPF (Fig. 5.8D) and GMF 
(Fig. 5.8E) meant that only one motif was created for each epitope, and it was hard to 
read into any significant usages. Four motifs were created for PKY (Fig. 5.8F), these 
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favour central acidic residues spread across positions 5-9 in each 11-mer, 12-mer and 
13-mer CDR3 length motifs. 
The patterns within observed motifs in response to SGP, GLI, QAR and PKY 
were striking and appeared highly unique to each epitope. Identification of patterns and 
physical characteristics at specific CDR3 positions form a base for modelling interactions 
between the pHLA and its cognate repertoire. If congruent physical characteristics can 
be found in the relevant HLA class-II crystals structures, then explanations of gene usage 
bias and amino acid motifs can be explored. 
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Figure 5.8. Amino acid motif analysis of α chain CDR3 regions in all sequences 
obtained in response to each epitope. A minimum of three TCR sequences are 
represented in each plot. Representations are proportional in terms of length of CDR3, 
which is detailed on the x-axis of each plot. Y-axis is the size proportion (bits) in height. 
The specific TRAV gene is detailed above each set of plots. (A) SGP (B) GLI (C) QAR 
(D) DPF (E) GMF and (F) PKY. 
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5.5 Discussion 
In this chapter, the CD4+ T-cell responses to five conserved internal influenza 
epitopes and one external haemagglutinin epitope were compared by flow cytometry 
across five donors. Two epitopes, M1-GLI and HA-PKY, exhibited consistent and strong 
responses in each donor, while the remaining epitopes showed variability and donor 
specific patterns. Where possible, the TCR-α clonotypic repertoires were dissected to 
investigate the gene usage and sequences that mediated responses to each epitope. 
Highly focused TRAV gene usage was observed in responses to M1-QAR and 
PB1-GMF, with other epitopes eliciting broader usage across multiple donors. TCR 
sequence diversity in response to each epitope varied, with highest diversity seen in 
response to M1-QAR and the lowest to NP-DPF. Several of the epitope-specific α-chains 
exhibited distinct CDR3 motifs involving conserved use of charged, polar or hydrophobic 
amino acids at single or multiple positions across the loop. Several public CDR3 
sequences, identical at the amino acid and/or nucleotide level, were shared in up to three 
of the five donors. 
The observations detailed here raise some important topics of discussion on the 
cellular and genetic features that underlie CD4+ T-cell mediated immunity. 
5.5.1 Response Hierarchies and Protective Capacity  
The epitopes HA-PKY and M1-GLI were detailed as eliciting the best responses 
relative to other epitopes based on the %CD4+ and MFI values (Fig. 5.4). From the six 
epitopes tested, these two exhibited the largest and most consistent response patterns 
in five donors. This confirmed earlier IFN-γ ELISpot responses (section 5.4.1 and chapter 
4) and suggested these peptides were stimulating a greater number of precursors with 
high avidity TCRs and strong proliferative profiles. Yet the question remains as to 
whether the hierarchy we observe in the in vitro setting, especially when using HLA 
multimer reagents, relates to the magnitude of in vivo responses and protective capacity. 
Methodological explanations for these strong responses may involve the half-life 
of synthetic peptides in culture, or the corresponding quality of the HLA-multimer reagent 
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used. The persistence of peptide in culture, increased stability of pHLA complexes and 
resulting pHLA multimer reagents may combine to improve expansion, avidity and flow 
cytometry staining, thus creating a response hierarchy less representative of the true in 
vivo response characteristics and effectiveness of protection. 
Work in mice with HLA class-I epitopes and LCMV has demonstrated that the 
relationship between protective capacity of an epitope and its cognate T-cell population 
is complex257,288. Epitope-mediated protection did not correlate with the number of 
functionally active cognate T-cells, but was instead related to the minimum amount of 
antigenic peptide necessary for recognition i.e. the sensitivity.  
Therefore, peptide titrations and ex vivo analysis may complement the response 
hierarchies observed here to provide a more accurate picture of the protective capacity 
of epitope-specific populations. 
5.5.2 Explaining Public/Shared Clonotypic Features 
Three notable findings in this chapter concern the shared properties of TCR-α 
chains that facilitate recognition of epitopes between multiple donors. Specifically, highly 
focused TRAV gene usage, the presence of public TCR sequences and the conservation 
of certain amino acids across CDR3 motifs. The explanations of all three phenomena 
are intrinsically related and likely to have an underlying structural basis. This will be 
explored in detail in the following chapter using TCR-pHLA complex data, but will be 
discussed briefly here in relation to the observed findings.  
5.5.2.1 Focused TRAV Gene Usage 
TRAV gene usage is determined by both the germline-encoded amino acids that 
contact the pHLA (CDR1 and CDR2) and the CDR3 sequences capable of being 
generated. The CDR1 and CDR2 loops form the majority of HLA specific contacts and 
may place limitations on those TRAV genes that can recognise a specific allele5. 
The α-chain CDR1 loop has been shown in multiple TCR-pHLA complex 
structures219,289 to form interactions with both the N-terminus of the peptide and the HLA 
class-II binding groove. Therefore, certain germline-encoded CDR1 residues may form 
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highly favourable peptide and HLA contacts that result in focused TRAV usage in 
response to an epitope. This may explain the striking patterns associated with QAR and 
GMF, where single TRAV genes dominated each response. 
In response to other epitopes such as GLI, DPF and PKY where TRAV usage is 
broader, the structural requirements imposed by α chain CDR1 and CDR2 interactions 
may be less stringent. This could result from a greater conformational diversity in TCR 
docking orientation (crossing angle)5, or beta chain interactions which exert a greater 
energetic contribution to binding and permit flexible α-chain conformations. 
5.5.2.2 Public CDR3 Sequences 
Although CDR3 sequences are not germline encoded, N-terminal (e.g. TRAV9-
2) and C-terminal (e.g. TRAJ20) germline elements (e.g. CALS and SNDYKLSF) can 
remain unaltered if few nucleotide additions or deletions have taken place during 
recombination (e.g. CALSNDYKLSF, public PKY sequence detailed in Table. 5.1). 
Similar CDR3 sequences arising from minimal somatic alteration of V(D)J 
elements are likely to be present in multiple individuals across the population (convergent 
recombination). If they can facilitate recognition of epitopes relevant in common diseases 
and infections, they will constitute public T-cell responses276,277.  
Where epitope-specific TRAV gene usage is highly focused due to CDR1 and 
CDR2 structural constraints, the probability of publicity may also be increased. This is 
because fewer genes, and therefore a narrower pool CDR3 sequences, are available to 
facilitate recognition. In this way, structural limitations can increase the likelihood of 
public TCRs.  
This may explain the abundance of shared TCR sequences in response to QAR 
(Table. 1), where gene usage was nearly exclusive to TRAV38-2DV8. All three public 
CDR3 amino acid sequences are distinct at the nucleotide level, and relatively short at 
thirteen amino acids; both features have been highlighted as evidence of convergent 
recombination276,277. 
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Public sequences in response to other epitopes where gene usage was broader 
also show a predominance of short sequences twelve to fourteen amino acids in length. 
Only one longer public sequence, sixteen residues in length, was identified. 
5.5.2.3 Conserved CDR3 Amino Acid Usage 
In the absence of identical sequences, patterns were observed within CDR3 
motifs that were highly consistent across TRAV genes, donors and CDR3 lengths. Two 
examples are the presence of a non-germline arginine at CDR3α6 in TRAV23 responses 
to SGP (Fig. 5.8A), and a central asparagine at CDR3α7 in multiple TRAV genes specific 
to GLI (Fig. 5.8B). Many more examples were present where single or several amino 
acids with identical physical properties were positionally conserved. 
The primary explanations are probably structural, where specific side chain 
properties are necessary to form CDR3α interactions with the unique pHLA surface 
formed by each epitope within HLA-DR1. Each surface presents a patchwork of charged, 
polar and hydrophobic regions that preferentially accommodates certain CDR3 amino 
acids in combination with CDR1 and CDR2 determined binding orientations.  
If a TCR has the correct TRAV gene (and β chain), but does not have certain 
positionally conserved residues necessary for binding, recognition will not occur and this 
is evident across the epitope-specific motifs. 
5.5.3 Future Work 
In this chapter, epitope-specific CD4+ T-cells from five HLA-DR1 donors 
exhibited similarities and striking patterns at the cellular and genetic level. These 
response characteristics demonstrated a degree of sharing in the mechanisms which 
underlie CD4+ T-cell recognition across the population. Further investigations aimed to 
explain these response characteristics by analysis at the molecular level. 
In the subsequent chapter, a specific recognition mechanism was studied 
directly. Two different TCRs, each in complex with DR1-PKY, were compared structurally 
in order to visualise how their CDR loops interacted with both the peptide and HLA. 
Corresponding clonotypic sequence information and complex structural data were 
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aligned in order to rationalise features such as gene usage bias and CDR3 amino acid 
motifs. In this way, the structural basis of observed genetic characteristics observed in 
this chapter were better understood, and this work helped inform future investigations 
into CD4+ T-cell repertoires and antigen recognition.  
Future work, to complement data presented here, includes analysis of TCR β-
chain sequence information, ex vivo HLA-multimer staining and ex vivo IFN-γ ELISpot 
assays to assess the magnitude of these responses in the absence of culture. As part of 
a longitudinal investigation into the importance conserved epitopes in influenza infection, 
their cellular and genetic analysis pre- and post-vaccination, or post-infection, could be 
highly informative. 
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6 Recognition of DR1-PKY by Two Distinct TRAV8-4 
TCRs is Mediated by Residues that are Conserved 
across PKY-Specific TCRα Repertoires  
6.1 Abstract 
X-Ray crystallography can be used to generate protein structure information at 
atomic resolution. This enables detailed analysis of secondary and tertiary structure, 
solvent-exposed and buried surface area as well as the location of amino acid side 
chains that are available to interact with other molecules. This information can answer 
mechanistic questions concerning binding partners, enzyme active sites and 
conformational flexibility. 
In order to investigate the binding of TCRs specific to the HA306-18 peptide “PKY” 
and explain the corresponding α-chain sequence information in the previous chapter, 
two TCR-pHLA ternary complex structures were compared. The structures were 
analysed in order to understand the contribution of each CDR loop in binding both the 
peptide and the HLA.  
This allowed rationalisation of gene usage and CDR3 motifs present in cognate 
TCRα repertoires from five HLA-DR1 donors. Specific CDR1α germline-encoded 
contacts and CDR3α rearranged contacts were identified as key structural features in 
pHLA recognition by the epitope-specific T-cells of multiple donors. This analysis 
provided a blueprint by which other CD4+ T-cell repertoire information could be analysed 
following the generation of relevant structural complexes.  
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6.2 Introduction 
Analysis of protein structures at atomic resolution can identify molecular 
mediators of receptor-ligand interactions that result in biological phenotypes. X-ray 
crystallography relies on the successful diffraction of X-rays by a protein crystal to 
produce diffraction patterns. The mathematical attributes of these patterns can be 
decoded by Fourier transform to produce an electron density map of the repeating unit 
constituting the crystal lattice. 
The polypeptide chain is fitted to the density map in order to agree with observed 
data and build the protein structure. At high resolution (<3 Å) detailed orientation of amino 
acid side chains and peptide backbone can be observed. These can help understand 
how sub units of a protein or binding partners can come together through non-covalent 
interactions, and identify the critical residues needed for their formation. 
When analysing immune receptors, such as the TCR and pHLA molecules, 
several questions can be answered through interrogation of structural data. Structures 
of the pHLA alone, such as those presented in chapter 4, provide information on the 
anchor and solvent-exposed residues that constitute an epitope. Many such class-II 
structures have been published127,267. Yet less than twenty human pHLA class-II 
molecules in complex with a cognate TCR are available at present289, and only five for 
HLA-DR1, from which only one is a viral epitope219. 
6.2.1 Features of the TCR-pHLA Class II Protein Complex 
A conceptual challenge of immunology is understanding how the TCR is capable 
of distinguishing between a vast pool of structurally similar HLA molecules in order to 
facilitate a T-cell response to very specific peptides. Several theories on the mechanisms 
of T-cell activation38,290, the necessity of TCR cross-reactivity211,212,291, the evolutionary 
origin of the TCR, the contributions of class-II flanking regions285, the role of self antigen9, 
the thymic development of regulatory T-cells22,292 and the relevance of non-canonical 
binding have arisen around the subject of TCR recognition23,27,293. 
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Structural information is a primary source of information to help understand some 
of these questions. When analysing a TCR-pHLA complex, several features provide 
indications of how the epitope is recognised with high levels of specificity.  
The crossing angle is defined as the binding orientation of the TCR over the pHLA 
molecule5, and roughly described as the angle between the peptide and a line passing 
between the α and β chain of the TCR. This parameter, when calculated in the same 
manner, allows comparison of docking geometries relative to the peptide backbone and 
indicates the extent of peptide or HLA interactions. Following this direct identification of 
TCR to pHLA contacts, the TCR “footprint,” can elucidate the binding regions of each 
CDR loop. For both class-I and class-II systems, germline CDR1 and CDR2 amino acids 
have been estimated to account for 75 % of the interface contacts23, and are thought to 
account for HLA-specific recognition. The CDR2 makes contacts exclusively to the HLA, 
while the CDR1 loop sits closer to the peptide and forms additional epitope-specific 
interactions in several cases289. The CDR3 loop predominantly contacts the peptide, 
forming strong, discriminatory interactions that facilitate epitope-specific recognition. 
Exceptions to this “canonical” binding modes exist, and are the focus recent 
research31,32. 
6.2.2 Rationalising Repertoire Information using Structural Analysis 
Through identification of the peptide and HLA specific contacts made by germline 
and somatic TCR residues, structural information can further our understanding of the 
immune response to specific epitopes. A number of recent studies have compared 
complex structural data to TCR repertoire information in order to explain gene usage 
bias and CDR3 sequence patterns250,294.  
This work has predominantly been carried out in HLA class-I systems, while the 
few class-II studies have used TCR sequences derived from clones167,219,284,295 or β-chain 
information solely272. Large scale epitope-specific repertoire analysis and structural 
alignment with HLA class-II has not been undertaken. The difficulty in obtaining paired 
sequence information followed by crystallising the TCR-pHLA in complex, means that 
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structural information will always be the limiting factor relative to the abundance of 
epitope-specific TCR sequence information. For this reason, a minimal number of crystal 
structures serve as the model around which much clonotypic information is understood.  
6.2.3 PKY as a Model System 
In previous chapters, PKY was used as a positive control due to its ability to 
generate a consistent HLA-DR1 specific immune response. It has historically been used 
to investigate several aspects of HLA class-II antigen processing and presentation as 
well as the response to influenza haemagglutinin296. It is termed “universal” due to its  
ability to bind to multiple HLA-DR alleles and elicit strong immune responses168,219. 
Abundant CD4+ T-cell response information exists in response to this epitope, and it 
remains the closest class-II system available to A2-GIL (M158-66)249 in terms of available 
structural166,219 and clonotypic219,272 information related to influenza responses at the 
population level. This availability of a published TCR-pHLA-DR1 crystal structure219 
makes PKY the ideal candidate to begin structural and repertoire data comparisons. 
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6.3 Aims 
Structural analysis can identify the interactions between a TCR and cognate 
pHLA that are central to recognition. These interactions may be highly conserved across 
diverse TCR repertoires that are specific to the same epitope.  
The aim of this chapter was to compare two distinct αβTCRs, both utilising 
TRAV8-4 but differing in their CDR3α sequence and paired β-chain, in order to assess 
the extent of these conserved interactions in the recognition of DR1-PKY. The identified 
structural features and key residues could be aligned with clonotypic sequence 
information to understand whether such features were conserved across PKY-specific 
repertoires or were unique to specific TRAV genes and sequences. 
 
Specific aims: 
1) To compare two TCR HLA-DR1 crystal complex structures to identify 
similarities and differences in the features that mediate recognition of the 
HA306-318 epitope (PKYVKQNTLKLAT). 
2) To align the identified structural interactions with TRAV gene usage bias and 
CDR3α motifs obtained from PKY specific repertoire data in five HLA-DR1 
donors. 
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6.4 Results 
6.4.1 Comparison of TCR-pHLA Complex Structures 
In order to understand the interactions between two different TCRs and the same 
pHLA, inspection of two complex structures using the PKY peptide (HA306-318) presented 
by HLA-DR1 was carried out. The first structure was a published complex with the HA1.7 
TCR219 (Fig. 6.1) and utilised a flexible octapeptide linker between the peptide and TCR 
to increase the probability of trimer formation (TCR-pHLA). The HA1.7 TCR was derived 
from a CD4+ T-cell clone specific to the PKY peptide which also cross-reacts with the 
same peptide presented by HLA-DR4 for which another complex structure has been 
published. 
The second structure was solved in our group (refolding of pHLA was performed 
by the author, the TCR was refolded by Aaron Wall and structure solution was performed 
by Dr David Cole) and remains unpublished. It consists of PKY bound by HLA-DR1 and 
complexed with the F11 TCR at 1.9 Å resolution (Fig. 6.2). The F11 TCR was sequenced 
from a PKY specific clone derived from Donor-1, and both chains appeared in their 
clonotypic sequence information at low frequency, as well as in data from the same donor 
in published studies168. 
The affinities of HA1.7 and F11 for DR1-PKY have been determined by BIAcore 
analysis168 as 50 μM and 26.7 μM respectively (25 °C). These are much weaker than 
affinities determined for class-I viral epitopes297. When compared to the published 
affinities of the public JM22 TCR (TRAV27, TRBV19) for A2-GIL (M156-64) of 6 μM298 and 
1.79 μM250, these interactions are between four to twenty-five times weaker (depending 
on values used). This is consistent with weaker average TCR affinities for available 
class-II systems than those for class-I297 and points to fundamental structural differences 
that could be explored further. 
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Gene HA1.7 F11 
TRAV TRAV8-4 TRAV8-4 
TRAJ TRAJ48 TRAJ30 
 
  
TRBV TRBV28 TRBV24-1 
TRBJ TRBJ1-2 TRBJ1-2 
 
  
Sequence   
CDR1α SSVPPY SSVPPY 
CDR2α YTSAATLV YTSAATLV 
CDR3α CAVSESPFGNEKLTF CAVSEQDDKIIF 
 
15-mer 12-mer 
CDR1β MDHEN KGHDR 
CDR2β SYDVKM SFDVKD 
CDR3β CASSSTGLPYGYTF CATSDESYGYTF 
 
14-mer 12-mer 
 
Table 6.1. Genetic and amino acid composition of HA1.7 and F11 TCRs. Where text 
is in red, the same gene and amino acids are present in each TCR sequence. 
 
Each TCR utilises the same TRAV gene (TRAV8-4) but have different TRBV 
genes and distinct CDR3α sequences of differing lengths (Table 6.1). When repertoires 
show bias towards a limited number of TRAV genes, as observed in this study, is this 
because they contact the pHLA in a highly conserved manner, despite having distinct 
CDR3α lengths, amino acid composition and β-chain pairing? 
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Each structure shows TCR binding in a similar orientation (Fig. 6.1, 6.2), with the 
TCR α-chain over the N-terminus of the peptide and the DR1β-groove helix, while the 
TCR β-chain sits over the C-terminus and the DR1α-groove helix.  
The orientation of the TCR over the pHLA is quantified by the “crossing angle”, a 
parameter with a high level of variability across many complex structures in both class-I 
(37-90°) and class-II (37-115°) systems289 (Fig. 6.1B, 6.2B). Between HA1.7 and F11, 
angles of 47.22° and 47.43° respectively were within 0.5 degrees, demonstrating a highly 
conserved binding orientation despite the presence of distinct β-chains. 
When secondary structural features were aligned, both pHLA components show 
high levels of overlap (Fig. 6.3). HLA similarity was most apparent, while TCR chain 
alignment showed greater variation, specifically in the CDR3 loops, which exhibited 
minimal overlap due to their distinct lengths. Polar contacts between the peptide 
backbone and HLA were highly conserved (Fig. 6.4), reflecting the significant rigidity and 
conservation in epitope presentation. Many of the interactions documented in published 
HLA class-II structural data127 and those determined in this project (chapter 4) were 
present, in addition to peptide-specific side chain contacts made with the HLA.  
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Figure 6.1. HA1.7-DR1-PKY complex structure secondary structural 
representation and data table. Structural data taken from PDB file 1fyt published by 
Hennecke et al219. Three orientations are shown: (B) 0° facing down the binding grove 
from the N-terminus, (A) +90 facing the DR1 α-chain, (C) -90 facing the DR1 β-chain. 
Structures are represented by secondary structure cartoon analysis. 
 
 
 
 
 
TCRαTCRβ
HLA-
DR1α
HLA-
DR1β
0  + 90  - 90  
A B C 
HA1.7 Complex Resolution 2.60 RMS Deviations From Ideal Values
Completeness 99.6 Bond Lengths 0.008
Space Group C 1 2 1 Bond Angles 1.500
R Value 0.221
Free R Value 0.255
Free R Value Test Set Size 5.0%
Free R Value Test Set Count 1871
Mean B Value 38.7
Number of Reflections 37122 Crossing Angle 47.22
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Figure 6.2. F11-DR1-PKY complex structure secondary structural representation 
and data table. Three orientations are shown: (B) 0° facing down the binding grove from 
the N-terminus, (A) +90 facing the DR1 α-chain, (C) -90 facing the DR1 β-chain. 
  
TCRαTCRβ
HLA-
DR1α
HLA-
DR1β
0  + 90  - 90  
A B C 
F11 Complex Resolution 1.91 RMS Deviations From Ideal Values
Completeness 99.9 Bond Lengths 0.019
Space Group P 21 21 2 Bond Angles 1.944
R Value 0.206
Free R Value 0.240
Free R Value Test Set Size 4.9%
Free R Value Test Set Count 4762
Mean B Value 55.4
Number of Reflections 91698 Crossing Angle 47.43
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Figure 6.3. Structural comparison of F11 and HA.17 complexes by secondary 
structural overlay alignment. (A, B, C) Three complex orientations are shown rotated 
in the z plane. (D) View of the peptide overlay in stick representation within the binding 
groove. Overlay alignment was carried out by the align function in PyMol viewer, giving 
the closest overlap of the majority of each structure.  
TCRαTCRβ
HLA-
DR1α
HLA-
DR1β
0  + 90  - 90  
A B C 
D 
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Figure 6.4. Stabilising polar peptide contacts with the HLA groove for (A) HA1.7 
complex and (B) F11. Polar contacts are represented by black dashed lines between 
the backbone and side chains of the peptide, and the side chains of amino acids that 
constitute the HLA binding groove.  
A
B
HA1.7 Complex
F11 Complex
P K Y V K Q N T L K L A T
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6.4.2 TCR-pHLA Interface 
The amino acid interactions that govern T-cell to epitope recognition occur at the 
contact interface between the pHLA and the TCR. The interface is formed by non-
covalent interactions such as salt bridges, hydrogens bonds and van der Waals (vdWs) 
forces, which contribute to form an energetically favourable binding event. By analysing 
the nature of these interactions in a TCR-pHLA complex structure, CDR amino acid 
properties essential for either peptide or HLA binding can be identified. 
Inspection of 4 Å contact footprints (Fig. 6.5A, 6.5B)) showed that the majority of 
peptide residues were contacted by either the CDR3α (blue) or CDR3β (turquoise) loop 
over the central region of the HLA. CDR2α (green) and CDR2β (pink) loops exclusively 
contacted the HLA on the outside of the groove, while the CDR1α (red) and CDR1β 
(yellow) loops contacted the inside of the groove, within 4 Å of both peptide and HLA. 
The total number of atom to atom contacts within 4 Å was similar for each 
complex, with 112 for HA1.7 and 102 for F11. The binding affinities determined at 50 μM 
and 26.7 μM for HA1.7 and F11 respectively indicate that number of atom to atom 
contacts is not the sole determinant of affinity.  
These contact footprints, and overlays of the CDR backbone loops (Fig. 6.5C, 
6.5D), confirm the “canonical” binding mode of both TCRs: with CDR3s predominantly 
contacting the peptide, CDR2s exclusively contacting the HLA, and the CDR1s in 
proximity to both components. CDR1 and CDR2 loops appeared highly conserved in 
orientation above the contact region, while CDR3 loops exhibited variation due to the 
difference in length.  
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Figure 6.5. TCR Contact Footprint representation over pHLA surface plot. Surface 
of the HLA that does not bind TCR is shown in grey, peptide in white, amino acids 
contacted by the TCR are coloured according to the CDR loop (see central key) for (A) 
HA1.7 and (B) F11 complexes. Colours are shown at the solvent exposed surface and 
represent regions that are within 4.00 Å distance of the TCR. 
(C) HA1.7 and (D) F11. Direct overlay of each TCR CDR loop (backbone represented 
as a coloured tube) above the contact footprint in uniform red colouring. The entire CDR 
HA1.7 Complex F11 ComplexA B
CDR1 α
CDR2 α
CDR3 α
CDR1 β
CDR2 β
CDR3 β
α-chain
β-chain
α-chain
β-chain
N C
C D
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loops according to IMGT definition are represented. See later figures for analysis of 
individual amino acid contributions. 
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6.4.3 Understanding Repertoires with Structural Information 
In the previous chapter, the analysis focused on the gene usage and CDR3 motifs 
of the TCR α-chain repertoires in response to specific epitopes. Observed in response 
to PKY was a biased usage of four TRAV genes (TRAV8-4, TRAV8-6, TRAV13-1, 
TRAV14) and a prevalence of acidic residues in the CDR3α motifs across a range of 
lengths. Here, we investigate these interactions and provide a structural explanation for 
the epitope-specific bias and patterns.  
6.4.3.1 CDR1α Interactions 
As seen from contact footprints and CDR loop overlays, the CDR1α loop sat close 
to the inner side of the DR1β-chain groove helix and the N-terminal peptide residues, 
with the CDR2α loop directly over the DR1β-chain. Both the HA1.7 and F11 TCRs utilised 
CDR1α residues CDR1αVal28, CDR1αPro29 and CDR1αTyr31 at the contact interface 
(Fig. 6.6 & Table 6.2). CDR1αVal28 and CDR1αPro29 made conserved vdWs 
interactions with DR1βHis81 in both complexes (Fig. 6.6B, 6.6D). Additionally, 
CDR1αVal28 was involved in a peptide contact with P-1Lys and P2Val in both complexes 
(Fig. 6.6A, 6.6C). CDR1αTyr31 was employed slightly differently by the two TCRs, 
making vdWs contacts with DR1βGln70 in the F11 structure (Fig. 6.6D), and vdWs 
contacts with DR1βThr77 in the HA1.7 structure (Fig. 6.6B).  
Interestingly, CDR1αVal28 was present in two of the genes selected (TRAV8-4 
and TRAV8-6) (Fig. 6.6E). The other two genes not encoding CDR1αVal28 (TRAV13-1 
and TRAV14DV4), contained Ala or Pro in this position, both small weakly hydrophobic 
residues that would be congenial with the binding mode employed by CDR1αVal28. 
CDR1αPro29 was only selected in TRAV8-4, with CDR1αSer27 being present in the 
other V-genes observed. However, Ser has similar properties in terms of size and charge 
to Pro, so could be structurally compatible during CDR1 loop ligation with DR1-PKY.  
CDR1αTyr31 and CDR1αSer27 were conserved in all of the genes identified in 
PKY specific repertoires (Fig. 6.6E).  Further genetic investigation demonstrated that 
only TRAV8-4, TRAV8-6, TRAV13-1 and TRAV14DV4 contained a motif that included 
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Val/Ala/Pro28, Pro/Ser29, Tyr31 and Ser27. Thus, the structural analysis suggested how 
the V-genes detected during recognition of DR1-PKY have been uniquely selected to 
make important contacts with the HLA and peptide. These observations help to illuminate 
the structural basis of conserved selection of specific TCRα V-genes in response to DR1-
PKY. 
Whether these CDR1α residues are essential, or dispensable, for TCR binding 
to DR1-PKY would require further structural or mutational analysis in order to account 
for their contribution to the gene usage pattern. 
6.4.3.2 CDR2α Interactions with DR1β 
CDR2α interacted exclusively with the DR1β-chain (Fig. 6.7 & Table 6.3). The 
contacts were mediated by CDR2αSer51 and CDR2αAla52 vdWs interactions in both 
structures, as well as an additional vdWs contact between CDR2αTh50 and DR1βGln70 
in the F11 complex (Fig. 6.7B). 
The CDR2α contacts were fewer in number (Table 6.3) and contained no polar 
interactions when compared to CDR1α. When compared to the other genes that mediate 
the PKY specific response, only Ser51 appeared conserved (Fig. 6.7C). This may point 
to a lower importance of CDR2α in recognition of DR1-PKY, and suggests these 
interactions are not critical for TCR binding. 
 
NOTE FOR ALL FIGURES: Where the amino acids are represented in stick format 
(the peptide/side chains/CDRs in this case), black corresponds to carbon atoms, 
red to oxygen atoms (which may carry a negative dipole or charge) and blue to 
nitrogen atoms (which may carry a positive dipole or charge). 
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Figure 6.6 CDR1α Contacts with both peptide and HLA. 
Figure legend on following page.  
A
E
B
S S V P P Y
S S V S V Y
D S A S N Y
T S D P S Y G
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Pro30
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Tyr31
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Pro30
Pro27
Tyr31
C D
Peptide Contacts HLA Contacts
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Peptide Contacts HLA Contacts
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HA1.7 CDR1α
F11 CDR1α
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Figure 6.6 & Table 6.2. CDR1α Contacts with both peptide and HLA. HA1.7 CDR1α 
(black chain) contacts with (A) peptide (orange chain) and (B) HLA (blue chain) with side 
chains within 4 Å shown by dashed lines. Corresponding F11 CDR1 contacts with (C) 
peptide and D. HLA. E. CDR1 sequences of the top genes identified in clonotyping data, 
with acidic residues coloured in red. 
Table 6.2. Corresponding Contact details of all atoms within 4.00 Å. Between the CDR1α 
loop and the peptide (shaded in grey) or the HLA. 
NO. AA ATOM Contact NO. AA ATOM DIST
28 VAL  CG2[ C]:  DR1-β 81 HIS  NE2[ N] 3.84
28 VAL  CG2[ C]:  Peptide 307 LYS  O  [ O] 4.00
Peptide 309 VAL  CG2[ C] 3.19
29 PRO  CG [ C]:  DR1-β 81 HIS  ND1[ N] 3.80
DR1-β 81 HIS  ND1[ N] 3.76
DR1-β 81 HIS  CE1[ C] 3.61
DR1-β 81 HIS  NE2[ N] 3.89
31 TYR  OH [ O]:  DR1-β 77 THR  CB [ C] 3.73
DR1-β 77 THR  CG2[ C] 3.93
HA1.7 TCR Contacts
TCR CDR1α Peptide/HLA Contact
NO. AA ATOM Contact NO. AA ATOM DIST
27 SER  O  [ O] DR1-β 81 HIS  CE1[ C] 3.93
28 VAL  CB [ C] DR1-β 81 HIS  NE2[ N] 3.95
28 VAL  CG1[ C] DR1-β 81 HIS  NE2[ N] 3.86
Peptide 2 LYS  CB [ C] 3.91
Peptide 4 VAL  CG1[ C] 3.98
29 PRO  CD [ C] DR1-β 81 HIS  CG [ C] 4.00
DR1-β 81 HIS  ND1[ N] 3.71
31 TYR  OH [ O] DR1-β 70 GLN  CG [ C] 3.65
DR1-β 70 GLN  CD [ C] 3.41
DR1-β 70 GLN  NE2[ N] 3.83
DR1-β 70 GLN  OE1[ O] 3.54
F11 TCR
TCR CDR1α Peptide/HLA Contact
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Figure 6.7 & Table 6.3. CDR2α contacts with the peptide and HLA.  
(A) HA1.7 CDR2α (black chain) contacts with HLA (blue chain) within 4 Å shown by black 
dashed lines. (B) Corresponding F11 contacts. (C) CDR2α sequences of the top genes 
identified in clonotyping data. Underlined amino acids are those mediating contact in the 
above images. 
Table 6.3. Corresponding Contact details of all atoms within 4.00 Å.  
HA1.7 CDR2α-HLA Contacts F11 CDR2α-HLA Contacts
A B
Ser51
Thr50
Ala52
Ser51
Ala52
NO. AA ATOM Contact NO. AA ATOM DIST
51 SER  OG [ O]:  DR1-β 77 THR  CG2[ C] 3.91
52 ALA  CB [ C]:  DR1-β 69 GLU  OE2[ O] 3.48
HA1.7 TCR Contacts
TCR CDR2α Peptide/HLA Contact
NO. AA ATOM Contact NO. AA ATOM DIST
50 THR  O  [ O] DR1-β 70 GLN  CG [ C] 3.84
51 SER  C  [ C] DR1-β 73 ALA  CB [ C] 3.90
51 SER  O  [ O] DR1-β 73 ALA  CB [ C] 3.71
51 SER  CB [ C] DR1-β 77 THR  CG2[ C] 3.30
51 SER  OG [ O] DR1-β 77 THR  CG2[ C] 3.34
52 ALA  O  [ O] DR1-β 69 GLU  OE2[ O] 3.46
F11 TCR
TCR CDR2α Peptide/HLA Contact
TRAV 8-4
TRAV 8-6
TRAV 13-1
TRAV 14 DV4
C
Thr50
Y T S A A T L V
Y L S G S T L V
I R S N V G E
Q G S Y D Q Q N
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6.4.3.3 CDR3α Interactions and Repertoire Motifs 
The hypervariable CDR3α and CDR3β loops account for the majority of TCR to 
peptide interactions. The variability arising from V(D)J recombination engenders the host 
with a highly diverse pool of TCR sequences capable of recognising vast numbers of 
potential pathogenic epitopes. Where multiple distinct TCR sequences see the same 
epitope, conserved amino acid features or physical properties that mediate the 
interaction are likely to be present. This phenomenon of epitope-specific sequence 
“motifs” or conserved positional properties has been observed in CD8+ and CD4+ T-cell 
repertoires, a limited number of which have corresponding structural complex data281,294. 
Analysis of the TRAV8-4 HA1.7 and F11 CDR3α interactions display a similar 
pattern (Fig. 6.8A, 6.8B) despite a difference in length of three amino acids, and greater 
overall TCR footprint of the longer CDR3 loop (Fig. 6.5A). Both CDR3α-chains utilised 
the side chains of three residues to interact with the peptide, two of which were acidic 
(CDR3αGlu94 and CDR3αGlu102 in HA1.7; CDR3αGlu94 and CDR3αAsp97 in F11) 
and formed highly favourable salt bridges with corresponding basic residues in the 
peptide (Lys P-1 and P3). The third interaction was weaker and distinct to each TCR: 
CDR3αPhe97 to P5-Asn in HA1.7, and in F11, CDR3αGln95 to P2Val. 
These interactions account for the predominance of acidic residues spread 
across the motifs derived from TCR α-chain repertoire information in the four dominant 
TRAV genes (Fig. 6.8C). A degree of flexibility in the CDRα loops and the opportunity to 
form two salt bridges with either P-1-Lys or P3-Lys could allow for positional variation in 
the occurrence of acidic residues across the motif plot. 
The prevalence of acidic residues in response to PKY has been observed in other 
studies on CD4+ T-cell clones specific to DR1-PKY and DR4-PKY, and was initially 
predicted based on the PKY amino acid sequence. Yet this is the first example where 
large scale CD4+ T-cell repertoire data and motif comparison to more than one structure 
has been undertaken. The defining message is that for the same or similar TRAV gene 
with distinct CDR3 sequences and β-chain pairing, the germline CDR1α and CDR2β 
interactions with pHLA and TCR orientation are conserved. The conserved orientation is 
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likely to be favourable and facilitates hypervariable CDR3α sequences to interact with 
peptide via conserved amino acid motifs or positional properties. This means that amidst 
the vast potential of immune diversity, the interactions that determine epitope-specific 
CD4+ T-cell recognition are focused and consistent in repertoires derived from multiple 
donors.  
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Figure 6.8. CDR3α loop contacts with the peptide and corresponding acidic 
enriched motifs from repertoire data.  
(A) HA1.7 CDR3α (black chain) to peptide (orange chain) contacts. (B) F11 CDR3α to 
peptide contacts. (C) CDR3α Motif clonotyping data for different gene/length 
combinations, acidic residues shown in red and basic residues in blue. 
A
B
C
TRAV13-1 11-mer
TRAV13-1 13-mer
TRAV8-4 12-mer
TRAV8-6 13-mer
TRAV8-4
CAVSEQDDKIIF
P K Y V K Q N T L KLAT
TRAV8-4
CAVSESPFGNEKLTF
P K Y V K Q N T L KLAT
TRAV14DV4 14-mer
Phe97
Glu102Glu94
Glu94
Asp97
Gln95
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Table 6.4A. Corresponding Contact details of all atoms within 4.00 Å between 
HA1.7 CDR3α and peptide.  
NO. AA ATOM Contact NO. AA ATOM DIST
94 GLU  OE1[ O]:  Peptide 307 LYS  CE [ C] 3.56
94 GLU  OE2[ O]:  Peptide 307 LYS  CE [ C] 3.86
94 GLU  CD [ C]:  Peptide 307 LYS  NZ [ N] 3.41
94 GLU  OE1[ O]:  Peptide 307 LYS  NZ [ N] 3.27
94 GLU  OE2[ O]:  Peptide 307 LYS  NZ [ N] 2.83
96 PRO  CB [ C]:  DR1-β 70 GLN  CG [ C] 3.34
DR1-β 70 GLN  NE2[ N] 3.89
96 PRO  CG [ C]:  DR1-β 70 GLN  NE2[ N] 3.65
97 PHE  CE2[ C]:  DR1-β 66 ASP  O  [ O] 3.67
DR1-β 70 GLN  CB [ C] 3.77
97 PHE  CZ [ C]:  DR1-β 70 GLN  CB [ C] 3.36
97 PHE  CE1[ C]:  DR1-β 70 GLN  CG [ C] 3.86
97 PHE  CZ [ C]:  DR1-β 70 GLN  CG [ C] 3.55
97 PHE  CE1[ C]:  Peptide 312 ASN  OD1[ O] 3.61
Peptide 312 ASN  ND2[ N] 3.97
102 GLU  OE1[ O]:  DR1-α 58 GLY  CA [ C] 3.72
102 GLU  CD [ C]:  DR1-α 61 ALA  CB [ C] 3.94
102 GLU  OE2[ O]:  DR1-α 61 ALA  CB [ C] 3.17
102 GLU  CD [ C]:  Peptide 310 LYS  NZ [ N] 3.42
102 GLU  OE2[ O]:  Peptide 310 LYS  NZ [ N] 3.21
102 GLU  OE1[ O]:  Peptide 310 LYS  NZ [ N] 3.55
HA1.7 TCR Contacts
TCR CDR3α Peptide/HLA Contact
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Table 6.4B. Corresponding Contact details of all atoms within 4.00 Å between F11 
CDR3α and peptide.  
NO. AA ATOM Contact NO. AA ATOM DIST
94 GLU  OE1[ O] Peptide 2 LYS  CD [ C] 3.88
Peptide 2 LYS  CE [ C] 3.96
Peptide 2 LYS  NZ [ N] 2.93
94 GLU  CD [ C] Peptide 2 LYS  NZ [ N] 3.90
95 GLN  OE1[ O] DR1-β 77 THR  C  [ C] 3.99
95 GLN  NE2[ N] DR1-β 77 THR  O  [ O] 3.71
95 GLN  CD [ C] DR1-β 77 THR  O  [ O] 3.73
95 GLN  OE1[ O] DR1-β 77 THR  O  [ O] 2.97
95 GLN  NE2[ N] Peptide 4 VAL  CB [ C] 3.66
95 GLN  CB [ C] Peptide 4 VAL  CG1[ C] 3.74
95 GLN  CD [ C] Peptide 4 VAL  CG1[ C] 3.92
95 GLN  NE2[ N] Peptide 4 VAL  CG2[ C] 3.57
96 ASP  CB [ C] DR1-α 55 GLU  OE2[ O] 3.69
96 ASP  CG [ C] DR1-α 55 GLU  OE2[ O] 3.97
96 ASP  OD2[ O] DR1-α 55 GLU  OE2[ O] 3.35
97 ASP  OD2[ O] Peptide 5 LYS  CE [ C] 3.30
97 ASP  CG [ C] Peptide 5 LYS  NZ [ N] 3.57
97 ASP  OD2[ O] Peptide 5 LYS  NZ [ N] 2.72
Peptide 7 ASN  CG [ C] 3.94
97 ASP  CG [ C] Peptide 7 ASN  ND2[ N] 3.91
97 ASP  OD1[ O] Peptide 7 ASN  ND2[ N] 3.26
97 ASP  OD2[ O] Peptide 7 ASN  ND2[ N] 3.74
Peptide 7 ASN  OD1[ O] 3.43
98 LYS  CE [ C] DR1-α 55 GLU  OE2[ O] 3.60
98 LYS  NZ [ N] DR1-α 55 GLU  OE2[ O] 3.91
F11 TCR
TCR CDR3α Peptide/HLA Contact
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6.4.4 Conserved Interactions with the TCR β-chains and DR1-PKY 
Although clonotypic data are not currently available for TCR β-chain deployment 
against DR1-PKY, structural analysis of the HA1.7 and F11 revealed a number of 
conserved interactions between β-chain residues and DR1-PKY, despite unique TRBV 
genes and distinct CDR3 loops (Table. 6.1).  
Both TCRs contacted HLA residues DR1αAla64 and DR1αVal65 using 
negatively charged amino acids in their CDR1β loops (CDR1βGlu30 for HA1.7, Fig. 6.9A 
or CDR1βAsp29 for F11, Fig. 6.9B). HA1.7 contacted the peptide P7Lys through multiple 
salt bridge interactions (CDR1βAsp28, CDR1βHis29 and CDR1βGlu30, Fig. 6.9A), while 
F11 instead formed a polar contact with P5Asn and CDR1βArg29 (Fig. 6.9B). 
Similarly, both TCRs maintained a network of HLA interactions with residues 
DR1αGln57, DR1αAla61, DR1αAla64, DR1αLys67 and DR1αLys39 through their 
CDR2β loops (Fig. 6.10). Either forming salt bridges/hydrogen bonds through polar 
amino acids (CDR2βAsp51, CDR2βLys55 and CDR2βGlu56 for HA1.7, or CDR2βAsp50 
and CDR2βAsn55 for F11) or vdWs contacts through aromatic amino acids 
(CDR2βTyr50 for HA1.7, or CDR2βPhe48 for F11).  
The CDR3 loops did not share the same degree of binding mode similarity, with 
the CDR3β loop in HA1.7 making three polar contacts between CDR3βSer96, 
CDR3βThr97 and CDR3βGly98 and peptide P8Lys, P5Asn and P6Thr residues 
respectively (Fig. 6.11A). In comparison, the CDR3 loop in F11 made a number of 
contacts with peptide residues P7Asn, P6Thr and P8Lys mainly through a single residue 
CDR3βGlu94 (Fig. 6.11B). It will be interesting to see if the majority of TCRs in response 
to DR1-PKY have similar CDRβ residues, as was observed in the α-chain analysis. This 
will be investigated in future work by generating clonotyping data for the β-chain usage. 
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Figure 6.9. & Table 6.5. CDR1β contacts with peptide and HLA. Format is identical 
to previous figures, CDR1α sequence below each image. (A) HA1.7 and (B) F11. 
HA1.7 CDR1β Contacts F11 CDR1β Contacts
A B
NO. AA ATOM Contact NO. AA ATOM DIST
28 ASP  OD1[ O]:  Peptide 315 LYS  CE [ C] 3.98
28 ASP  O  [ O]:  Peptide 315 LYS  NZ [ N] 2.90
28 ASP  OD1[ O]:  Peptide 315 LYS  NZ [ N] 3.07
30 GLU  CG [ C]:  DR1-α 64 ALA  O  [ O] 3.93
DR1-α 64 ALA  CB [ C] 3.87
30 GLU  OE1[ O]:  DR1-α 65 VAL  CG2[ C] 3.84
30 GLU  OE2[ O]:  DR1-α 68 ALA  CB [ C] 3.72
30 GLU  CD [ C]:  Peptide 315 LYS  CE [ C] 3.71
30 GLU  OE1[ O]:  Peptide 315 LYS  CE [ C] 3.66
30 GLU  OE2[ O]:  Peptide 315 LYS  CE [ C] 2.97
30 GLU  CD [ C]:  Peptide 315 LYS  NZ [ N] 3.24
30 GLU  OE1[ O]:  Peptide 315 LYS  NZ [ N] 3.12
30 GLU  OE2[ O]:  Peptide 315 LYS  NZ [ N] 2.66
HA1.7 TCR Contacts
TCR CDR1β Peptide/HLA Contact
NO. AA ATOM Contact NO. AA ATOM DIST
28 ASP  OD2[ O] DR1-α 64 ALA  C  [ C] 3.88
28 ASP  OD2[ O] DR1-α 64 ALA  O  [ O] 3.91
28 ASP  CB [ C] DR1-α 64 ALA  CB [ C] 3.79
28 ASP  CG [ C] DR1-α 64 ALA  CB [ C] 3.65
28 ASP  OD1[ O] DR1-α 64 ALA  CB [ C] 3.85
28 ASP  OD2[ O] DR1-α 65 VAL  N  [ N] 3.92
28 ASP  OD2[ O] DR1-α 65 VAL  CA [ C] 3.98
28 ASP  OD2[ O] DR1-β 69 GLU  CB [ C] 3.93
28 ASP  OD2[ O] DR1-β 69 GLU  CG [ C] 3.78
29 ARG  CZ [ C] DR1-α 61 ALA  CB [ C] 3.86
29 ARG  NH2[ N] DR1-α 61 ALA  CB [ C] 3.73
29 ARG  NH2[ N] Peptide 7 ASN  CG [ C] 3.58
Peptide 7 ASN  ND2[ N] 3.35
Peptide 7 ASN  OD1[ O] 3.77
F11 TCR
TCR CDR1β Peptide/HLA Contact
Asp28
Arg29
Glu30
Asp28
TRBV 28 – M D H E N  TRBV 24 – K G H D R
His27
His29
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Figure 6.10. CDR2β contacts with the HLA. (A) HA1.7 (B) F11. CDR2 loop sequence 
is shown below each image. Contact table is located in the appendix due to size.  
HA1.7 CDR2β-HLA Contacts
F11 CDR2β-HLA Contacts
TRBV28 – F S Y D V K M K E
TRBV24 – Y S F D V K D I N K
A
B
Tyr50
Phe48
Asp51
Glu56
Lys55
Phe48
Ile53
Asp49
Tyr46
Asp52
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Figure 6.11. CDR3β contacts with the peptide. (A) HA1.7 contacts with the sequences 
shown to the right. Amino acids involved in contact are shown underlined. Acidic residues 
in red and basic in blue. (B) F11 contacts, format as previous.  
HA1.7 CDR3β Contacts
F11 CDR3β Contacts
TRBV 24
CATSDESYGYTF
TRBV 28
CASSSTGLPYGYTF
Thr97
Ser96
Glu94
Gly98
Tyr96
PKYVKQNTLKLAT
PKYVKQNTLKL T
A
B
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Table 6.6. CDR3β contacts with peptide and HLA within 4.00 Å.  
NO. AA ATOM Contact NO. AA ATOM DIST
96 SER  OG [ O]:  Peptide 315 LYS  NZ [ N] 3.95
97 THR  OG1[ O]:  DR1-α 61 ALA  CB [ C] 3.42
97 THR  CG2[ C]:  DR1-α 62 ASN  OD1[ O] 3.69
97 THR  CG2[ C]:  Peptide 310 LYS  NZ [ N] 3.79
97 THR  O  [ O]:  Peptide 312 ASN  CB [ C] 3.54
97 THR  CG2[ C]:  Peptide 312 ASN  CB [ C] 3.49
97 THR  O  [ O]:  Peptide 312 ASN  CG [ C] 3.64
Peptide 312 ASN  ND2[ N] 2.89
Peptide 313 THR  O  [ O] 3.24
97 THR  C  [ C]:  Peptide 313 THR  O  [ O] 3.72
98 GLY  N  [ N]:  DR1-α 65 VAL  CG2[ C] 3.78
98 GLY  N  [ N]:  Peptide 313 THR  O  [ O] 3.71
98 GLY  CA [ C]:  Peptide 313 THR  O  [ O] 3.13
Peptide 314 LEU  CA [ C] 3.96
98 GLY  O  [ O]:  Peptide 314 LEU  CA [ C] 3.93
Peptide 314 LEU  C  [ C] 3.98
98 GLY  CA [ C]:  Peptide 315 LYS  N  [ N] 3.62
98 GLY  C  [ C]:  Peptide 315 LYS  N  [ N] 3.77
98 GLY  O  [ O]:  Peptide 315 LYS  N  [ N] 3.08
Peptide 315 LYS  CA [ C] 3.93
Peptide 315 LYS  CB [ C] 3.60
100 PRO  CG [ C]:  DR1-β 64 GLN  CD [ C] 3.83
100 PRO  CB [ C]:  DR1-β 64 GLN  OE1[ O] 3.93
100 PRO  CG [ C]:  DR1-β 64 GLN  OE1[ O] 3.35
100 PRO  CD [ C]:  DR1-β 64 GLN  OE1[ O] 3.92
TCR CDR3β Peptide/HLA Contact
HA1.7 TCR Contacts
NO. AA ATOM Contact NO. AA ATOM DIST
94 GLU  O  [ O] Peptide 7 ASN  CB [ C] 3.18
Peptide 7 ASN  CG [ C] 3.37
94 GLU  C  [ C] Peptide 7 ASN  ND2[ N] 3.59
94 GLU  O  [ O] Peptide 7 ASN  ND2[ N] 2.65
94 GLU  CG [ C] Peptide 8 THR  O  [ O] 3.37
94 GLU  CB [ C] Peptide 8 THR  O  [ O] 3.31
94 GLU  CG [ C] Peptide 10 LYS  N  [ N] 3.95
94 GLU  OE1[ O] Peptide 10 LYS  N  [ N] 3.98
94 GLU  CD [ C] Peptide 10 LYS  CB [ C] 3.91
94 GLU  OE1[ O] Peptide 10 LYS  CB [ C] 3.78
96 TYR  CE1[ C] Peptide 7 ASN  ND2[ N] 3.52
TC  CDR3β Peptide/HLA Contact
F1  TCR
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6.4.5 Summary  
The responses to PKY were the second most diverse at the clonotypic level, but 
the least TRAV gene usage biased of the six epitopes studied. By comparing repertoire 
data with crystallographic information, we can identify the amino acid interactions that 
govern recognition and offer an explanation for TRAV and TRBV gene usage. If 
representative complex structures can be obtained for the other epitopes such as GMF, 
SGP and QAR, which did not display the same diversity and gene usage, then structural 
breakdown of their repertoire information can take place.  
Further investigation will lead to a greater understanding of CD4+ T-cell 
responses in general, but will specifically shed light on the mechanistic basis by which 
these important T-cell repertoires can meditate protection from highly relevant acute 
infections like Influenza. This understanding can inform new research and become the 
basis for novel vaccination strategies that analyse protection at the level of the HLA and 
responding clonotypic T-cell repertoires. 
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6.5 Discussion 
In this chapter, TCR-pHLA complex structures of the HA1.7 and F11 TCRs were 
compared in order to understand how conserved the TCR α-chain interactions were 
between the same TRAV gene in combination with distinct CDR3α sequences and 
paired with different TRBV chains.  
As expected, CDR2α interactions were exclusively with the HLA, while CDR1α 
residues side chains were within 4 Å contact distance of both the peptide and HLA, with 
the potential to form van der Waals and polar contacts. These interactions correlated 
with conserved CDR1α sequence residues seen in the four TRAV genes that dominated 
clonotypes specific to PKY and partially explain the biased usage. 
CDR3α mediated contacts were consistent in nature regardless of loop length or 
overall amino acid composition. The identification of two salt bridges used by both HA1.7 
and F11 TCRs explained the conserved presence of aspartic or glutamic acid residues 
in sequence motifs of the top TRAV genes identified by repertoire analysis. These strong 
interactions would be energetically favourable and contribute significantly to PKY peptide 
recognition. 
The implications on further comparison of structural data and TCR repertoire 
information are positive, suggesting that observed CDR amino acid and gene usage are 
easily identified and extrapolated from TCR-pHLA complex data. Similar analysis of the 
other class-II epitopes identified in this study, especially those which exhibited highly 
biased gene usage (QAR and GMF) may identify the interactions that result in 
overwhelming preference of a single TRAV gene and striking CDR3 motif patterns (Fig. 
6.12). 
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Figure 6.12. Examples of Gene usage and CDR3 motifs from the previous chapter, 
which may be understood by the generation and analysis of relevant TCR-pHLA 
complex structures. This involves acquisition of relevant paired TCRαβ chain 
information and formation of a complex during crystallisation suitable of high resolution 
analysis.  
Could one or two complex structures with relevant 
TRAV genes explain these striking gene usage and 
CDR3 motif patterns?
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6.5.1 Implications Beyond TRAV8-4 and TRAV8-6 
Work in this chapter suggests that one or two complex structures may be 
sufficient to elucidate the mechanistic basis of highly conserved repertoire patterns 
related to dominant genes. The relevance of structural information on one TRAV gene 
when applied to different TRAV genes specific to the same epitope is a more difficult 
challenge. 
In response to PKY, four TRAV genes were favoured in the repertoires of five 
HLA-DR1 donors. Of these, TRAV8-4 and TRAV8-6 are highly similar based on 
sequence comparison, while TRAV13-1 and TRAV14DV4 are relatively different (Table 
6.7). The similarity means that the structural data analysed is most relevant to TRAV8-4 
(F11 and HA1.7) and TRAV8-6 repertoires, as these TCRs are likely to form similar 
germline contacts and orientation.  
Given the flexibility and variability of TCR CDR3 loops, peptide interactions in 
TRAV8-4 structures may be just as relevant to TRAV13-1 and TRAV14DV4 repertoire 
motifs, i.e. hypervariable regions are impossible to fully group by nature, regardless of 
their parent genes. Understanding of epitope-specific gene usage potentially mediated 
by germline encoded CDR1 peptide and HLA contacts requires structural information to 
support predictions. This has been the basis of a number of recent studies in the CD4+ 
T-cell responses to celiac epitopes at the clonal level167,284,295. 
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Germline CDR1 CDR2 CDR3 
TRAV8-4 CNYSSSV......PPY LFW YTSA..ATLV   SDAAEYF CAVS 
TRAV8-6 CNYSSSV......SVY LFW YLSG..STLV   SDTAEYF CAVS 
TRAV13-1 CTYSDSA......SNY FPW IRSN...VGE   EDSAVYF CAAS 
TRAV14/DV4 CTYDTSDP.....SYG LFW QGSY..DQQN   GDSAMYF CAMRE 
 
Table 6.7. Variation of germline sequences from TRAV8-4 (crystal structure) 
around the CDR loops of TRAV genes used to respond to PKY in five donors. 
TRAV8-4 is coloured in red, and conserved residues in other TRAV genes are coloured 
red to display sequence variations from the structural data. 
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6.5.2 Conservation of Salt Bridges over Weaker Contacts 
When looking at extensive repertoire data, particularly CDR3 motifs, the extent 
to which weak interactions are conserved, and thus understood by limited structural 
information is not clear. Highly favoured salt bridge interactions are likely to be conserved 
and exhibit similar orientations when present in epitope-specific repertoires. Yet whether 
weaker non-covalent interactions necessarily exhibit strong positional rigidity relative to 
the peptide, or HLA, is harder to infer. 
If a CDR3α sequence and cognate peptide contain complementary salt bridging 
charged residues (for example in Fig. 6.8C), then the likelihood of an interaction is high 
and very energetically favourable. Hypothesising such complementary interactions from 
repertoire motifs may be valid. Yet as interactions get weaker, from non-polar hydrogen 
bonds, to hydrophobic then weak van der Waals, positional preferences are less defined 
(no clear positive to negative direction) and these may not be driving overall TCR 
recognition. Therefore, hypothesise based on weak interactions are less likely to be valid. 
Certain repertoires motifs and amino acid conservations may require highly 
relevant structural models to be understood, due to the many potential energetic drivers 
behind the TCR-pHLA binding interaction. Where strong complementary forces are 
present, repertoire dynamics may be understood by a general or loosely related 
example. 
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6.5.3 Future Work 
In addition to obtaining the corresponding TCR β-chain repertoire information, 
the next step is obtaining representative TCR-pHLA complex structures for the other 
epitopes identified in this project. Their analysis will enable understanding of 
corresponding TRAV and TRBV repertoire usage and patterns. Progress in such 
investigations is limited by the difficulty in generating complex structural data. 
Structural analysis and understanding TCR repertoires has relevance in many 
areas of T-cell immunology. When key residues, in either the epitope or the TCR, that 
mediate recognition are identified, these can be altered in order to enhance the 
corresponding immune response for T-cell therapy and novel vaccination.  
The ultimate goal is the accumulation of sufficient repertoire and corresponding 
structural information to accurately model the effects of changing TCR or epitope 
residues in immunotherapy. The binding algorithms used in previous chapters relied on 
existing information to attain accurate predictive capacity of a binary system. Modelling 
of ternary interaction systems such as the TCR, peptide and HLA is much more complex. 
If the effects of amino acid or gene substitution on TCR-pHLA binding affinity 
could be accurately predicted, it would be a powerful tool for immunological research 
and therapeutic development. Given that the TCR recognition detailed in this chapter 
showed strong elements of conservation, modelling and predictive tools may be feasible, 
and within reach in coming years. 
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7 Discussion 
In 2012, Wilkinson et al213 found that CD4+ T-cell responses specific to 
conserved influenza proteins correlated with heterosubtypic protection against pandemic 
flu. In this project, several epitopes that mediate these responses in the HLA-DR1 
population were identified and used to uncover the genetic and molecular basis of 
populations that provide protection. 
In chapter 3, transduction of naked APCs with HLA-DR1 and their implementation 
on ELISpot assay was achieved. These DR1-APCs were used to successfully identify 
DR1-restricted responses to the conserved internal proteins in chapter 4. Structures of 
two of these epitopes were obtained and their analysis confirmed predictions from HLA 
binding algorithms and provided information on the likely amino acids that were 
contacted by cognate TCRs. 
In chapter 5, these epitopes enabled further investigation of the CD4 immune 
response to the conserved proteins through HLA-multimer staining and clonotypic 
analysis. Strong epitope-specific responses were mediated by narrow TRAV gene 
usage, and conservation of amino acid properties across CDR3 sequences as well as 
some rare public clonotypes. The underlying nature of these responses implied a 
uniformity in the mechanisms of class-II mediated immunity to specific viral epitopes. 
In chapter 6, Crystallographic analysis of DR1-PKY in complex with two distinct 
TCRs provided an insight into how clonotypic repertoire data could be aligned with 
structural analysis to rationalise gene usage and amino acid motifs. The implications of 
these results on current knowledge of CD4+ T-cell mediated immunity, potential vaccine 
relevance and application to other challenges will be discussed here. 
7.1 The Basis of Heterosubtypic Protection? 
In this study, the importance of CD4+ T-cells specific to conserved epitopes of 
the Influenza virus was exemplified by the detection of robust and reproducible 
responses in five healthy donors. Whether a result of infection or vaccination, these 
populations may have played a critical role in generation of an antibody response, as 
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well as priming of CD8+ populations to eradicate the virus61, in addition to the provision 
of innate and cytotoxic functions that have been documented as protective64,101. 
As the antigenic targets of these cells are highly conserved, it is likely they provide 
this protection regardless of challenge strain and thus may contribute to heterosubtypic 
immunity48,213. Nearly every adult is expected to have encountered influenza at one time 
in their life, most likely during childhood299. Why some individuals are asymptomatic and 
others hospitalised is a mystery300, but it is likely to be related to important characteristics 
of their immune response. 
Heterosubtypic immunity is known to correlate with the absence of an antibody 
response301 and the presence of a CD8+ T-cell response to the conserved internal 
proteins48. The recent observation that CD4+ T-cells also correlate with cross-protective 
immunity has cemented their positive role in our understanding of influenza infection213. 
However, work by Andrea Sant suggests that CD4+ T-cells specific to internal proteins, 
as opposed to external proteins, do not aid seroconversion of the antibody repertoire to 
novel strains302,303 and are instead a barrier to some important aspects of immunity.  
This is because T-cells specific to external proteins were poised toward a “TFH-
like” phenotype which best facilitates the generation of a neutralising antibody response, 
while those specific to NP were not. Instead NP specific cells were associated with a TH1 
(IFN-γ, CXCR3+) phenotype, which does not directly contribute to antibody 
production242. In order to both clear virus and provide an immediate barrier to infection, 
this neutralising antibody response is essential. 
In these papers, the authors state that conserved responses hinder CD4+ T-cell 
help towards the generation of a novel antibody response to shifted or drifted strains, 
and cites the negative impact of memory responses on the expansion of a naïve 
repertoire. Instead, DiPiazza et al propose the administration of vaccines that do not 
contain these internal elements and thus drive seroconversion unassisted by conserved 
responses242. This is the basis of many “split vaccines”304, while live attenuated or 
inactivated vaccines still contain internal proteins (but not in a standard or quantified 
amount). 
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The Sant hypothesis clearly states the goal of a universal vaccine is to facilitate 
seroconversion to novel Influenza-A strains. The CD8+/CD4+ work48,213 and studies on 
S-Flu305,306 demand a different criterion, namely the reduction in symptom severity and 
prevention of host to host transmission respectively. Given that novel strains with the 
potential to cause pandemic may arise from poorly monitored sources, the sequences of 
upcoming HA proteins cannot be predicted with complete certainty.  
Therefore, only the internal proteins offer the chance to provide heterosubtypic 
protection against all possible future strains. Antibody focused vaccine design always 
requires some foresight or predictive capacity. If it were possible to identify the coming 
pandemic and seasonal threats with complete certainty, then the Sant approach would 
be valid.  
7.2 Implications for Vaccine Design 
Downstream clinical applications that build on the work of this project may exploit 
responses to conserved class-II epitopes in order to establish heterosubtypic immunity. 
Whether CD4+ T-cell immunity can be preferentially boosted or induced, relies on the 
success of vaccines that explicitly target T-cells.  
Bona fide T-cell vaccines involving modified peptides307, recombinant protein, or 
MVA222,308 and adenoviral vectors vaccines309,310 are relatively novel technologies, with 
several systems that are yet to complete clinical trials304. These vaccines diverge from 
the traditional aims of inducing strong antibody responses, and instead target CD8+ and 
CD4+ T-cell responses to provide cross-protective immunity. 
In Influenza research, the novel S-Flu vaccine limits expression of the HA protein 
by the removal of its signal sequence and successfully elicits protection in pig and ferret 
models305,306. Although this is not an exclusive T-cell vaccine, it lessens the focus on an 
HA specific antibody response and has been demonstrated to provide robust protection 
through T-cell mediated immunity. 
If CD4+ T-cells can be successfully targeted, there is scope for even more 
advanced vaccination models that can alter the responding repertoire to class-II epitopes 
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and potentially created a better form of immunity285. This involves modifying amino acids 
outside of the core of an epitope, and vaccinating against the modified peptide in order 
to subtly alter the expanded T-cell pool which recognises the original sequence168.  
The preliminary work for such an investigation, i.e. identification of HLA-restricted 
epitopes, understanding of HLA binding and assessment of wild type responses, has 
been described in this project. What is unknown is what kind of repertoire we would want 
to create in order to best provide protective immunity. 
7.3 Broad or Narrow Repertoires, What’s Best for Protection? 
Questions on the kind of T-cell repertoire which provides the best possible 
protective capacity from disease are likely to become increasingly important as the 
prevalence of epitope-specific repertoire data increases. Simply, is a highly focused 
repertoire composed of similar TCRs in terms of gene usage and CDR3 sequence more 
effective at eliminating pathogen than a broader, more genetically/biochemically diverse, 
TCR repertoire? 
 This has been answered, in part, in HIV infection where highly skewed 
repertoires containing public TCR sequences and conserved CDR3 motifs in multiple 
patients are thought to play an important role in controlling chronic infection286. A focused 
CD4+ T-cell repertoire, like that observed in response to some epitopes detailed here, 
appears to be beneficial. 
In this project, skewing of TRAV gene usage in response to three epitopes was 
striking, and in some cases this was linked to highly conserved CDR3 amino acid usage. 
The remaining three epitopes exhibited slightly broader gene usage and still showed 
CDR3 conservation.  
In terms of clonal diversity (pie charts, chapter 5) some responses were 
dominated by one or two TCR sequences, while others had much more diverse 
hierarchies.  Therefore, in response to influenza, we can extrapolate that we have a 
spectrum of breadth and diversity depending on the epitope and donor in question. 
Where, on this spectrum, do we want our TCR repertoires to be? 
213 
 
Is it possible that focused repertoires are more “immunologically efficient,” 
requiring a smaller pool of clones to respond to, and ultimately control infection? A larger 
pool of clones, with a variation in TCR binding affinity and overall efficacy, may show 
some levels of redundancy, ultimately detracting from the responses of more effective 
clones.  
Do we have an exhaustible supply of immune resources, i.e. B-cells, CD8+ T-
cells and APCs, and therefore we want to limit their use to the most effective action only? 
Certainly, this would be the case in the immunocompromised, i.e. HIV with a reduced 
CD4+ compartment, but to the healthy population, would artificial focusing of the 
repertoire hold potentially catastrophic consequences? 
With the wealth of pathogenic diversity, does some pre-existing, albeit less 
efficient, cross-reactive, or antigenically sinful response provide some level of 
protection? Does the initial response, no matter the efficiency, give us time to nullify a 
new threat before the more efficient clones eventually take over? A broad repertoire may 
be capable of tolerating the many potential mutations that leads to viral evolution, and 
thus will not be compromised in response to novel strains. 
If it is possible to significantly alter repertoire breadth by intelligent vaccine 
design, then this will warrant serious consideration of both the coverage and gaps such 
changes may leave.  
 
7.4 Application of Findings to Other Challenges 
This project has dealt with CD4+ T-cell responses that were most likely forged 
during acute viral infection and possibly vaccination. Do the observations on response 
magnitudes and repertoire characteristic detailed here, have relevance in other disease 
settings where CD4+ T-cells may play a protective or pathogenic role? 
What do the responses to self, chronic or allergic antigens look like in terms of 
the cellular magnitude and repertoire architecture? Chronic disease may shape the 
diversity and number of responding clones in a very unique manner. In the presence of 
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persistent and/or self-antigen, factors including T-cell exhaustion, the impact of 
regulatory T-cells and an absence of high-affinity TCRs due to thymic selection will 
complicate the response. 
If the methodology of this project was applied in the cancer, autoimmune or 
chronic viral setting then the resulting cellular and repertoire information would be 
severely limited. This is because expanded epitope-specific cells may not show high 
avidity for self or persistent antigen, they may be exhausted and thus fail to expand or 
produce cytokine, as well as have more complex cytokine profiles than simply TH1 IFN-
γ. Specifically with CD4+ T-cells, the repertoire isolated may contain a mixture of 
inflammatory and regulatory clones, both of which will have very different roles in 
pathology. 
 As a result, any number of potential scenarios can be envisaged and it is unlikely 
that the data will be easily aligned with a true understanding of the disease in question. 
Instead, when dissecting the roles of CD4+ T-cells in cancer or chronic infection 
methods, hypotheses, and questions will have need to carefully considered and will likely 
be much more advanced than those presented in this project. 
7.5 Future Work 
Following the completion of β-chain analysis and isolation of paired αβ-TCR 
sequence information for structural complex analysis, some wider questions could be 
posed of the T-cell repertoires documented in this project.  
To confirm their protective nature, further investigation would involve looking at 
ex vivo responses pre- and post- vaccination, with a vaccine that includes the internal 
proteins (i.e. not a split vaccine). If these responses are significantly raised, it would 
indicate their importance in active immunity to processed virus. 
The use of these epitopes as diagnostic markers of CD4+ T-cell populations in 
ongoing T-cell vaccine trials could be an excellent clinical application, moving away from 
the focus on A2-GIL responses as the surrogate marker of cell mediated immunity. 
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Finally, the next generation of vaccines may involve subtle alteration of epitopes 
in order to induce highly protective changes to induced immunity at the repertoire level168. 
This differs from heteroclitic peptide vaccinations in that the “core” of the epitope remains 
unchanged, while its surroundings, the flanking residues, are altered to produce the 
desired immunological effect.  
Although highly ambitious, such work may be the future of both vaccination 
against infectious disease and cancer. We can hope to tailor our pre-existing T-cell 
populations to induce highly focused protection with minimal off-target or antigenically 
sinful effects. 
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8 Appendix 
8.1 Details of Peptides 
FluA PB1 
1. MDVNPTLLFLKVPAQNAIST 
2. KVPAQNAISTTFPYTGDPPY 
3. TFPYTGDPPYSHGTGTGYTM 
4. SHGTGTGYTMDTVNRTHQYS 
5. DTVNRTHQYSEKGRWTTNTE 
6. EKGRWTTNTETGAPQLNPID 
7. TGAPQLNPIDGPLPEDNEPS 
8. PLPEDNEPSGYAQTDCVLEA 
9. YAQTDCVLEAMAFLEESHPG 
10. MAFLEESHPGIFENSCIETM 
11. IFENSCIETMEVVQQTRVDK 
12. EVVQQTRVDKLTQGRQTYDW 
13. LTQGRQTYDWTLNRNQPAAT 
14. TLNRNQPAATALANTIEVFR 
15. ALANTIEVFRSNGLTANESG 
16. SNGLTANESGRLIDFLKDVM 
17. RLIDFLKDVMESMKKEEMGI 
18. ESMKKEEMGITTHFQRKRRV 
19. TTHFQRKRRVRDNMTKKMIT 
20. RDNMTKKMITQRTIGKKKQR 
21. QRTIGKKKQRLNKRSYLIRA 
22. LNKRSYLIRALTLNTMTKDA 
23. LTLNTMTKDAERGKLKRRAI 
24. ERGKLKRRAIATPGMQIRGF 
25. ATPGMQIRGFVYFVETLARS 
26. VYFVETLARSICEKLEQSGL 
27. ICEKLEQSGLPVGGNEKKAK 
28. VGGNEKKAKLANVVRKMMTN 
29. NVVRKMMTNSQDTELSFTIT 
30. QDTELSFTITGDNTKWNENQ 
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31. GDNTKWNENQNPRMFLAMIT 
32. NPRMFLAMITYMTRNQPEWF 
33. YMTRNQPEWFRNVLSIAPIM 
34. NVLSIAPIMFSNKMARLGKG 
35. SNKMARLGKGYMFESKSMKL 
36. YMFESKSMKLRTQIPAEMLA 
37. RTQIPAEMLASIDLKYFNDS 
38. SIDLKYFNDSTRKKIEKIRP 
39. TRKKIEKIRPLLIEGTASLS 
40. LLIEGTASLSPGMMMGMFNM 
41. PGMMMGMFNMLSTVLGVSIL 
42. LSTVLGVSILNLGQKRYTKT 
43. NLGQKRYTKTTYWWDGLQSS 
44. TYWWDGLQSSDDFALIVNAP 
45. DDFALIVNAPNHEGIQAGVD 
46. NHEGIQAGVDRFYRTCKLLG 
47. RFYRTCKLLGINMSKKKSYI 
48. INMSKKKSYINRTGTFEFTS 
49. NRTGTFEFTSFFYRYGFVAN 
50. FFYRYGFVANFSMELPSFGV 
51. FSMELPSFGVSGINESADMS 
52. SGINESADMSIGVTVIKNNM 
53. IGVTVIKNNMINNDLGPATA 
54. INNDLGPATAQMALQLFIKD 
55. QMALQLFIKDYRYTYRCHRG 
56. YRYTYRCHRGDTQIQTRRSF 
57. DTQIQTRRSFEIKKLWEQTR 
58. EIKKLWEQTRSKAGLLVSDG 
59. SKAGLLVSDGGPNLYNIRNL 
60. GPNLYNIRNLHIPEVCLKWE 
61. HIPEVCLKWELMDEDYQGRL 
62. LMDEDYQGRLCNPLNPFVSH 
63. CNPLNPFVSHKEIESMNNAV 
64. KEIESMNNAVMMPAHGPAKN 
218 
 
65. MMPAHGPAKNMEYDAVATTH 
66. MEYDAVATTHSWIPKRNRSI 
67. SWIPKRNRSILNTSQRGVLE 
68. LNTSQRGVLEDEQMYQRCCN 
69. DEQMYQRCCNLFEKFFPSSS 
70. LFEKFFPSSSYRRPVGISSM 
71. YRRPVGISSMVEAMVSRARI 
72. VEAMVSRARIDARIDFESGR 
73. DARIDFESGRIKKEEFTEIM 
74. EEFTEIMKICSTIEELRRQK 
 
74 peptides 
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FluA Nucleoprotein 
 
1. GRMVGGIGRFYIQMCTELKL 
2. YIQMCTELKLTDYEGRLIQN 
3. TDYEGRLIQNSITIERMVLS 
4. SITIERMVLSAFDERRNRYL 
5. AFDERRNRYLEEHPSAGKDP 
6. EEHPSAGKDPKKTGGPIYRR 
7. KKTGGPIYRRRDGKWVRELI 
8. RDGKWVRELILYDKEEIRRI 
9. LYDKEEIRRIWRQANNGEDA 
10. WRQANNGEDATAGLTHLMIW 
11. TAGLTHLMIWHSNLNDATYQ 
12. HSNLNDATYQRTRALVRTGM 
13. RTRALVRTGMDPRMCSLMQG 
14. DPRMCSLMQGSTLPRRSGAA 
15. STLPRRSGAAGAAVKGVGTM 
16. GAAVKGVGTMVMELIRMIKR 
17. VMELIRMIKRGINDRNFWRG 
18. GINDRNFWRGENGRRTRVAY 
19. ENGRRTRVAYERMCNILKGK 
20. ERMCNILKGKFQTAAQRAMM 
21. FQTAAQRAMMDQVRESRNPG 
22. DQVRESRNPGNAEIEDLIFL 
23. NAEIEDLIFLARSALILRGS 
24. ARSALILRGSVAHKSCLPAC 
25. VAHKSCLPACVYGLAVASGY 
26. VYGLAVASGYDFEREGYSLV 
27. DFEREGYSLVGIDPFRLLQN 
28. GIDPFRLLQNSQVFSLIRPN 
29. SQVFSLIRPNENPAHKSQLV 
30. ENPAHKSQLVWMACHSAAFE 
31. WMACHSAAFEDLRVSSFIRG 
32. DLRVSSFIRGTRVVPRGQLS 
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33. TRVVPRGQLSTRGVQIASNE 
34. TRGVQIASNENMEAMDSNTL 
35. NMEAMDSNTLELRSRYWAIR 
36. ELRSRYWAIRTRSGGNTNQQ 
37. TRSGGNTNQQRASAGQISVQ 
38. RASAGQISVQPTFSVQRNLPFER 
39. QPTFSVQRNLPFERATIMAAFTG 
 
39 peptides 
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FluA Matirx1 
 
1. MSLLTEVETYVLSIVPSGPL 
2. VLSIVPSGPLKAEIAQRLED 
3. KAEIAQRLEDVFAGKNTDLE 
4. VFAGKNTDLEVLMEWLKTRP 
5. VLMEWLKTRPILSPLTKGIL 
6. ILSPLTKGILGFVFTLTVPS 
7. GFVFTLTVPSERGLQRRRFV 
8. ERGLQRRRFVQNALNGNGDP 
9. QNALNGNGDPNNMDKAVKLY 
10. NNMDKAVKLYRKLKREITFH 
11. RKLKREITFHGAKEIALSYS 
12. GAKEIALSYSAGALASCMGL 
13. AGALASCMGLIYNRMGAVTT 
14. IYNRMGAVTTEVAFGLVCAT 
15. EVAFGLVCATCEQIADSQHR 
16. CEQIADSQHRSHRQMVTTTN 
17. SHRQMVTTTNPLIRHENRMV 
18. PLIRHENRMVLASTTAKAME 
19. LASTTAKAMEQMAGSSEQAA 
20. QMAGSSEQAAEAMDIASQAR 
21. EAMDIASQARQMVQAMRTIG 
22. QMVQAMRTIGTHPSSSAGLK 
23. THPSSSAGLKDDLLENLQAY 
24. DDLLENLQAYQKRMGVQMQRFK 
 
24 peptides 
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8.2 Flow Cytometry & Sorting Data 
 
 
Gating strategy used for analysis of flow cytometry data in chapter 5.   
Live/Dead
CD3+ CD4+
HLA-
Multimer+
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Example 1 of HLA-multimer staining and corresponding irrelevant and FMO controls  
Test- Cognate HLA-
Multimer
Irrelevant class-II 
HLA-multimer
FMO
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 Example 2 of HLA-multimer staining and corresponding irrelevant and FMO controls 
  
Test- Cognate HLA-
Multimer
Irrelevant class-II 
HLA-multimer
FMO
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Example 3 of HLA-multimer staining and corresponding irrelevant and FMO controls   
Test- Cognate HLA-
Multimer
Irrelevant class-II 
HLA-multimer
FMO
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Number of cells isolated from cell sorting and taken forward for clonotypic analysis Boxes in green were analysed, yellow ere not. 
 
Donor Bleed (Date) SGPLK GLIYN QARQMV DPF GMF PKY
3 1 (June-2016) 594 1,400 1,570 236 870 589
2 (July-2016) 2,132 9,515 9,436 1,291 1,584 3,433
1 1 (June-2016) 22,245 37,404 6,355 8,567 0 (n=2) 24,804
2 1 (March-2016) 1,900 15,000 10,758 2,078 1,000 16,859
2 (Dec-2015) 352 364 10 27
4 1 (June-2016) 58 1645 68 19 82 2,600
5 1 (March-2016) 40,309 78,000 40,000 47,324 56,249 39,039
2 (June-2016) 47,441 76,053 18,403 12,782 18,228 28,396
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8.3 Application of the 50 read threshold cut off 
 
Example of Donor-2 clonotypic sequences in the absence of any read cut off value. 
Where a sequence is highlighted in blue or grey, this means that it is present multiple 
times in the across the sequences in the spreadsheet. As each column represents an 
epitope-specific population, there should not be overlap between populations. Yet due 
to the inclusion of low frequency samples below 50 reads, many sequences are present 
that overlap multiple samples. 
See next page. 
 
DONOR-2
SGP GLIYN QAR DPF GMF PKY
CAENMKDTGRRALTF CALQGGSEKLVF CAYLTGTASKLTF CAYRSTGNQFYF CAVEDGSDGQKLLF CALSNDYKLSF
CAVDMKGVWYNFNKFYF CAVEDTNSGYALNF CAYLTGTASKLTF CAESMEAAGNKLTF CVVSAGEGRDDKIIF CLVGDMNSGYSTLTF
CAASMRHSTLTF CALFTGGGNKLTF CAYRRALFGNEKLTF CAMREGPGTGGFKTIF CAVPLGAAGNKLTF CAMSATDSWGKLQF
CATDAGSWGKLQF CALSEVNNNAGNMLTF CAYRSSMAGGADGLTF CAVRDPDYGNNRLAF CAVEKSQKLLF CAMSPTDSWGKLQF
CAESMHGQKLLF CALSEANAGNMLTF CASLTGTASKLTF CAVQNYGGATNKLIF CAVLLGSSASKIIF CAASFSDGQKLLF
CVVSGFGNVLHC CVVSEANSGYALNF CAHFTGTASKLTF CALTNTGNQFYF CAVEGDNAGNKLTF CAASGYSTLTF
CILRDVRRNTGTASKLTF CALSARNSGNTPLVF CAYRSAISDDMRF CAYRSVRNQFYF CAGGGSNYQLIW CAVSGQGSQGNLIF
CAASWRPGYALNF CAVSDLLTSYDKVIF CAGAAAAGNNRKLIW CAARVFGNEKLTF CAVPLGAAGNMLTF CAVSDNDYKLSF
CATDARRYGGATNKLIF CAVYNTNAGKSTF CAVGGYSTLTF CALSDPHGNQGGKLIF CAVTTSYGNNRLAF CILLFGNEKLTF
CAASSRIYNQGGKLIF CAVIGTGRRALTF CAAISQGGSEKLVF CAYRSARSQGNLIF CAVRRWSNTGKLIF CAVSGNGANNLFF
CAASVRGNYQLIW CILLFGNEKLTF CAVHYNNNDMRF CAVYTGANSKLTF CAMREGPGTGGFKTIF CAVSESTDKLIF
CAAIYNFNKFYF CALSPANSGNTPLVF CATTNSGYALNF CATDGEGGGADGLTF CALVASGGSYIPTF
CAAKSNAGGTSYGKLTF CIVRVGLQGAQKLVF CAVSDNYGQNFVF CILRDWNYGGSQGNLIF CAVFSLAGTALIF
CATDEGSWGKLQF CILKSAGGTSYGKLTF CAYLTGTASKLTF CAVEQNTGFQKLVF CALSEGTSYDKVIF
CAASMRDSSYKLIF CAVPNFGNEKLTF CVVNSNTGGFKTIF CAMRERNTDKLIF CAVSEPGANNLFF
CAVEGGATNKLIF CAVPLGGTSYGKLTF CAYLTGTASKLTF CIVRAKGSYNQGGKLIF CAMSGTDSWGKLQF
CAAHLRNTPLVF CAFMRYNAGNMLTF CILRATSDYKLSF CATDKNTGKLIF CALEVSNFGNEKLTF
CAASSRVTGGGNKLTF CAYRSVSGGGADGLTF CAYRSAMAGNQFYF CAVDMRGGADGLTF CAVERQGAQKLVF
CAAMFRGSRLTF CAFMKPPWGTDKLIF CAYRSAMAYGQNFVF CAVNEVSDGQKLLF CAVTRFSDGQKLLF
CAGEVSRGNQFYF CAVRPLTSGSRLTF CALTANTDKLIF CYEASHSVNTGTASKLTF CAATGYSTLTF
CAASKGGTSYGKLTF CALSGSGNQFYF CAYRRIQGAQKLVF CAVSDSGNSGYALNF
CALSFDRGSTLGRLYF CAVEAGGGNKLTF CILKSAGGTSYGKLTF CAETSGSRLTF
CAASPPYGNNRLAF CALWVGTNKLIF CAWTPTVGSQGNLIF CAVVNSGGSNYKLTF
CAPPGNNDMRF CALRDGYNKLIF CARLTGTASKLTF CAMSSSGYSSASKIIF
CAASWRHSTLTF CAARGQGSQGNLIF CAYRSALNSYKLIF CAAYSGGYNKLIF
CLVGSADYGSSNTGKLIF CAVLPGTYKYIF CAYRSALGTDKLIF CAVSETGANNLFF
CASNSGNTPLVF CAVEGITQGGSEKLVF CAGARDSSYKLIF CATERAWVTGGGNKLTF
CIVRVGGNKLVF CYEASHSVNTGTASKLTF CAAVNDYKLSF CATRRDSWGKLQF
CAMRERGGGGADGLTF CAVKSYGQNFVF CAYRSGFATGNQFYF CILKSAGGTSYGKLTF
CAVERSTGGFKTIF CIVRVGLQGAQKLVF CAYIAIQGAQKLVF CAFSYSSASKIIF
CAVERSTGGFKTIF CAYRSAFTGNQFYF CAVSVFDSWGKLQF
CIVRVSYSGGGADGLTF CAYRSALGGQLTF CAYHMEYGNKLVF
CAVSGRDGGATNKLIF CAYRKIMGGGADGLTF CAVKDSGTYKYIF
CAASRNSGGSNYKLTF CAVRPLTSGSRLTF CAVNIVPPGNQFYF
CAVQADSWGKLQF CAASMRGGNKLTF CAMSIYNQGGKLIF
CAVGMNSGYSTLTF CALGTLQGAQKLVF CAVFSGGYNKLIF
CALQGGGNKLTF CAGHPDYKLSF CAVYSGGYQKVTF
CAVNARGTGGFKTIF CAYRRALF CILSDLISNFGNEKLTF
CAEGGNNRLAF CVVSDSVSGGYNKLIF
CAYRSAMAGGADGLTF CAFMNRQTGANNLFF
CAVSGRDGGATNKLIF CALSEAMDSNYQLIW
CAASRNSGGSNYKLTF CAVIVTGGGNKLTF
CIVRVGLQGAQKLVF CAVPGGVNTDKLIF
CVVSDNYGQNFVF CLVGDWNNNARLMF
CTISNFGNEKLTF CAVSDGGNEKLTF
CAVEVITGKLIF CLVKGSASKIIF
CALDPMDSNYQLIW
CAASGGGSNYKLTF
CAVKGSGGSYIPTF
CAVSGTSYGKLTF
CAVSRGSWGKLQF
CAASYNTDKLIF
CALSQGGKLIF
CAVSGRDGGATNKLIF
CAASRNSGGSNYKLTF
CALSPQGYNTDKLIF
CALERDSGYSTLTF
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All low frequency sequences below 50 reads were removed. Only two sequences 
are present that overlap between epitope-specific populations. This justifies the use of 
a 50 read cut off to clean up data and remove the presence of promiscuous 
sequences, the biological explanation of which is yet to be determined.  
 
  
DONOR-2
SGP GLIYN QAR DPF GMF PKY
CAENMKDTGRRALTF CALQGGSEKLVF CAYLTGTASKLTF CAYRSTGNQFYF CAVEDGSDGQKLLF CALSNDYKLSF
CAVDMKGVWYNFNKFYF CAVEDTNSGYALNF CAYLTGTASKLTF CAESMEAAGNKLTF CVVSAGEGRDDKIIF CLVGDMNSGYSTLTF
CAASMRHSTLTF CALFTGGGNKLTF CAYRRALFGNEKLTF CAMREGPGTGGFKTIF CAVPLGAAGNKLTF CAMSATDSWGKLQF
CATDAGSWGKLQF CALSEVNNNAGNMLTF CAYRSSMAGGADGLTF CAVRDPDYGNNRLAF CAVEKSQKLLF CAMSPTDSWGKLQF
CAESMHGQKLLF CALSEANAGNMLTF CASLTGTASKLTF CAVQNYGGATNKLIF CAASFSDGQKLLF
CVVSGFGNVLHC CVVSEANSGYALNF CAHFTGTASKLTF CALTNTGNQFYF CAASGYSTLTF
CILRDVRRNTGTASKLTF CALSARNSGNTPLVF CAYRSAISDDMRF CAYRSVRNQFYF CAVSGQGSQGNLIF
CAASWRPGYALNF CAVSDLLTSYDKVIF CAGAAAAGNNRKLIW CAARVFGNEKLTF CAVSDNDYKLSF
CATDARRYGGATNKLIF CAVYNTNAGKSTF CAVGGYSTLTF CILLFGNEKLTF
CAASSRIYNQGGKLIF CAVIGTGRRALTF CAAISQGGSEKLVF CAVSGNGANNLFF
CAASVRGNYQLIW CILLFGNEKLTF CAVHYNNNDMRF CAVSESTDKLIF
CAAIYNFNKFYF CALSPANSGNTPLVF CATTNSGYALNF CALVASGGSYIPTF
CAAKSNAGGTSYGKLTF CIVRVGLQGAQKLVF CAVSDNYGQNFVF CAVFSLAGTALIF
CATDEGSWGKLQF CILKSAGGTSYGKLTF CAYLTGTASKLTF
CAASMRDSSYKLIF CAVPNFGNEKLTF CVVNSNTGGFKTIF
CAVEGGATNKLIF CAVPLGGTSYGKLTF CAYLTGTASKLTF
CAAHLRNTPLVF CAFMRYNAGNMLTF CILRATSDYKLSF
CAASSRVTGGGNKLTF CAYRSVSGGGADGLTF CAYRSAMAGNQFYF
CAYRSAMAYGQNFVF
CALTANTDKLIF
CAYRRIQGAQKLVF
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8.4 CDR2β Contact Tables 
  
NO. AA ATOM Contact NO. AA ATOM DIST
48 PHE  CZ [ C]:  DR1-α 57 GLN  CD [ C] 3.82
DR1-α 57 GLN  OE1[ O] 3.62
DR1-α 57 GLN  NE2[ N] 3.75
50 TYR  CE1[ C]:  DR1-α 57 GLN  O  [ O] 3.92
50 TYR  CD1[ C]:  DR1-α 57 GLN  O  [ O] 3.45
50 TYR  CE1[ C]:  DR1-α 57 GLN  CB [ C] 3.95
50 TYR  CG [ C]:  DR1-α 61 ALA  CB [ C] 3.91
50 TYR  CD1[ C]:  DR1-α 61 ALA  CB [ C] 3.72
50 TYR  O  [ O]:  DR1-α 64 ALA  CB [ C] 3.36
51 ASP  OD1[ O]:  DR1-α 64 ALA  CA [ C] 3.81
51 ASP  OD2[ O]:  DR1-α 64 ALA  CB [ C] 3.78
51 ASP  CB [ C]:  DR1-α 64 ALA  CB [ C] 3.59
51 ASP  CG [ C]:  DR1-α 64 ALA  CB [ C] 3.40
51 ASP  OD1[ O]:  DR1-α 64 ALA  CB [ C] 3.57
DR1-α 67 LYS  CD [ C] 3.44
DR1-α 67 LYS  CE [ C] 3.33
51 ASP  CG [ C]:  DR1-α 67 LYS  NZ [ N] 3.82
51 ASP  OD1[ O]:  DR1-α 67 LYS  NZ [ N] 2.67
54 MET  CG [ C]:  DR1-α 39 LYS  NZ [ N] 3.75
55 LYS  O  [ O]:  DR1-α 39 LYS  CE [ C] 3.97
55 LYS  C  [ C]:  DR1-α 39 LYS  NZ [ N] 3.63
55 LYS  O  [ O]:  DR1-α 39 LYS  NZ [ N] 2.61
55 LYS  N  [ N]:  DR1-α 39 LYS  NZ [ N] 3.74
56 GLU  OE2[ O]: DR1-α 39 LYS  CG [ C] 3.99
56 GLU  CD [ C]:  DR1-α 39 LYS  CD [ C] 3.99
56 GLU  OE2[ O]:  DR1-α 39 LYS  CD [ C] 2.84
DR1-α 39 LYS  CE [ C] 3.63
56 GLU  CG [ C]:  DR1-α 39 LYS  NZ [ N] 3.79
56 GLU  CD [ C]:  DR1-α 39 LYS  NZ [ N] 3.76
56 GLU  OE2[ O]:  DR1-α 39 LYS  NZ [ N] 3.22
56 GLU  CD [ C]:  DR1-α 57 GLN  CG [ C] 3.97
56 GLU  CG [ C]:  DR1-α 57 GLN  NE2[ N] 3.98
56 GLU  CD [ C]:  DR1-α 57 GLN  NE2[ N] 3.52
56 GLU  OE1[ O]:  DR1-α 57 GLN  NE2[ N] 3.09
TCR CDR2β Peptide/HLA Contact
HA1.7 TCR Contacts
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NO. AA ATOM Contact NO. AA ATOM DIST
46 TYR  OH [ O] DR1-α 57 GLN  CD [ C] 3.95
DR1-α 57 GLN  NE2[ N] 2.98
48 PHE  CD2[ C] DR1-α 57 GLN  O  [ O] 3.36
48 PHE  CE2[ C] DR1-α 57 GLN  O  [ O] 3.57
48 PHE  O  [ O] DR1-α 60 LEU  O  [ O] 4.00
48 PHE  CB [ C] DR1-α 61 ALA  N  [ N] 3.81
48 PHE  CD2[ C] DR1-α 61 ALA  N  [ N] 3.99
48 PHE  CB [ C] DR1-α 61 ALA  CA [ C] 3.71
DR1-α 61 ALA  CB [ C] 3.83
48 PHE  CG [ C] DR1-α 61 ALA  CB [ C] 3.68
48 PHE  CD2[ C] DR1-α 61 ALA  CB [ C] 3.80
48 PHE  O  [ O] DR1-α 64 ALA  CB [ C] 3.13
49 ASP  OD2[ O] DR1-α 64 ALA  CA [ C] 3.87
49 ASP  CG [ C] DR1-α 64 ALA  CB [ C] 3.61
49 ASP  OD1[ O] DR1-α 64 ALA  CB [ C] 3.93
49 ASP  OD2[ O] DR1-α 64 ALA  CB [ C] 3.67
49 ASP  CG [ C] DR1-α 67 LYS  CE [ C] 3.99
49 ASP  OD1[ O] DR1-α 67 LYS  CE [ C] 3.90
49 ASP  OD2[ O] DR1-α 67 LYS  CE [ C] 3.25
49 ASP  CG [ C] DR1-α 67 LYS  NZ [ N] 3.53
49 ASP  OD1[ O] DR1-α 67 LYS  NZ [ N] 3.77
49 ASP  OD2[ O] DR1-α 67 LYS  NZ [ N] 2.61
52 ASP  CG [ C] DR1-α 39 LYS  CE [ C] 3.98
52 ASP  OD1[ O] DR1-α 39 LYS  CE [ C] 2.76
DR1-α 39 LYS  NZ [ N] 3.04
DR1-α 60 LEU  CD2[ C] 3.57
53 ILE  O  [ O] DR1-α 39 LYS  CE [ C] 3.99
53 ILE  N  [ N] DR1-α 39 LYS  NZ [ N] 3.78
53 ILE  C  [ C] DR1-α 39 LYS  NZ [ N] 3.63
53 ILE  O  [ O] DR1-α 39 LYS  NZ [ N] 2.66
54 ASN  OD1[ O] DR1-α 39 LYS  CD [ C] 3.61
DR1-α 39 LYS  CE [ C] 3.25
54 ASN  CG [ C] DR1-α 39 LYS  NZ [ N] 3.90
54 ASN  OD1[ O] DR1-α 39 LYS  NZ [ N] 3.24
DR1-α 57 GLN  CG [ C] 3.50
TCR CDR2β Peptide/HLA Contact
F11 TCR
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